<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">78469</article-id><article-id pub-id-type="doi">10.7554/eLife.78469</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Trio-based whole exome sequencing in patients with suspected sporadic inborn errors of immunity: A retrospective cohort study</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-273079"><name><surname>Hebert</surname><given-names>Anne</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8945-015X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273080"><name><surname>Simons</surname><given-names>Annet</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273081"><name><surname>Schuurs-Hoeijmakers</surname><given-names>Janneke HM</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-253778"><name><surname>Koenen</surname><given-names>Hans JPM</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273082"><name><surname>Zonneveld-Huijssoon</surname><given-names>Evelien</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273083"><name><surname>Henriet</surname><given-names>Stefanie SV</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273084"><name><surname>Schatorjé</surname><given-names>Ellen JH</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273085"><name><surname>Hoppenreijs</surname><given-names>Esther PAH</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273086"><name><surname>Leenders</surname><given-names>Erika KSM</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273087"><name><surname>Janssen</surname><given-names>Etienne JM</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-81321"><name><surname>Santen</surname><given-names>Gijs WE</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273088"><name><surname>de Munnik</surname><given-names>Sonja A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273093"><name><surname>van Reijmersdal</surname><given-names>Simon V</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273089"><name><surname>van Rijssen</surname><given-names>Esther</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-273473"><name><surname>Kersten</surname><given-names>Simone</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0251-5564</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200873"><name><surname>Netea</surname><given-names>Mihai G</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2421-6052</contrib-id><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-273091"><name><surname>Smeets</surname><given-names>Ruben L</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-56354"><name><surname>van de Veerdonk</surname><given-names>Frank L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1121-4894</contrib-id><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-98697"><name><surname>Hoischen</surname><given-names>Alexander</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8072-4476</contrib-id><email>alexander.hoischen@radboudumc.nl</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-272626"><name><surname>van der Made</surname><given-names>Caspar I</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0763-4017</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01yb10j39</institution-id><institution>Department of Human Genetics, Radboud Institute of Molecular Life Sciences (RIMLS), Radboud University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Nijmegen</named-content></addr-line><country>Netherlands</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01yb10j39</institution-id><institution>Department of Laboratory Medicine, Laboratory for Medical Immunology, Radboud University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Nijmegen</named-content></addr-line><country>Netherlands</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/012p63287</institution-id><institution>Department of Genetics, University of Groningen, University Medical Center Groningen</institution></institution-wrap><addr-line><named-content content-type="city">Groningen</named-content></addr-line><country>Netherlands</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/024pk8k39</institution-id><institution>Department of Pediatric Infectious Diseases and Immunology, Amalia Children’s Hospital, Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Nijmegen</named-content></addr-line><country>Netherlands</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05wg1m734</institution-id><institution>Department of Pediatric Rheumatology and Immunology, Amalia Children’s Hospital, Radboud University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Nijmegen</named-content></addr-line><country>Netherlands</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jz4aj89</institution-id><institution>Department of Clinical Genetics, Maastricht University Medical Center+</institution></institution-wrap><addr-line><named-content content-type="city">Maastricht</named-content></addr-line><country>Netherlands</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05xvt9f17</institution-id><institution>Center for Human and Clinical Genetics, Leiden University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Leiden</named-content></addr-line><country>Netherlands</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05wg1m734</institution-id><institution>Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Nijmegen</named-content></addr-line><country>Netherlands</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01xnwqx93</institution-id><institution>Department for Immunology and Metabolism, Life and Medical Sciences Institute (LIMES), University of Bonn</institution></institution-wrap><addr-line><named-content content-type="city">Bonn</named-content></addr-line><country>Germany</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05wg1m734</institution-id><institution>Department of Laboratory Medicine, Laboratory for Diagnostics, Radboud University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Nijmegen</named-content></addr-line><country>Netherlands</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Yuen</surname><given-names>Tony</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>17</day><month>10</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e78469</elocation-id><history><date date-type="received" iso-8601-date="2022-03-08"><day>08</day><month>03</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-10-05"><day>05</day><month>10</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-04-18"><day>18</day><month>04</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.03.30.22272929"/></event></pub-history><permissions><copyright-statement>© 2022, Hebert et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Hebert et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-78469-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-78469-figures-v2.pdf"/><abstract><sec id="abs1"><title>Background:</title><p><italic>De novo</italic> variants (DNVs) are currently not routinely evaluated as part of diagnostic whole exome sequencing (WES) analysis in patients with suspected inborn errors of immunity (IEI).</p></sec><sec id="abs2"><title>Methods:</title><p>This study explored the potential added value of systematic assessment of DNVs in a retrospective cohort of 123 patients with a suspected sporadic IEI that underwent patient-parent trio-based WES.</p></sec><sec id="abs3"><title>Results:</title><p>A (likely) molecular diagnosis for (part) of the immunological phenotype was achieved in 12 patients with the diagnostic <italic>in silico</italic> IEI WES gene panel. Systematic evaluation of rare, non-synonymous DNVs in coding or splice site regions led to the identification of 14 candidate DNVs in genes with an annotated immune function. DNVs were found in IEI genes (<italic>NLRP3</italic> and <italic>RELA</italic>) and in potentially novel candidate genes, including <italic>PSMB10</italic>, <italic>DDX1</italic>, <italic>KMT2C,</italic> and <italic>FBXW11</italic>. The <italic>FBXW11</italic> canonical splice site DNV was shown to lead to defective RNA splicing, increased NF-κB p65 signalling, and elevated IL-1β production in primary immune cells extracted from the patient with autoinflammatory disease.</p></sec><sec id="abs4"><title>Conclusions:</title><p>Our findings in this retrospective cohort study advocate the implementation of trio-based sequencing in routine diagnostics of patients with sporadic IEI. Furthermore, we provide functional evidence supporting a causal role for <italic>FBXW11</italic> loss-of-function mutations in autoinflammatory disease.</p></sec><sec id="abs5"><title>Funding:</title><p>This research was supported by grants from the European Union, ZonMW and the Radboud Institute for Molecular Life Sciences.</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>trio-based whole exome sequencing</kwd><kwd>de novo variants</kwd><kwd>inborn errors of immunity</kwd><kwd>primary immunodeficiencies</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id>No. 833247</award-id><principal-award-recipient><name><surname>Netea</surname><given-names>Mihai G</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001826</institution-id><institution>ZonMw</institution></institution-wrap></funding-source><award-id>Spinoza Grant</award-id><principal-award-recipient><name><surname>Netea</surname><given-names>Mihai G</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Radboud Institute for Molecular Life Sciences</institution></institution-wrap></funding-source><award-id>Internal grant</award-id><principal-award-recipient><name><surname>Netea</surname><given-names>Mihai G</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001826</institution-id><institution>ZonMw</institution></institution-wrap></funding-source><award-id>Vidi</award-id><principal-award-recipient><name><surname>van de Veerdonk</surname><given-names>Frank L</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010663</institution-id><institution>H2020 European Research Council</institution></institution-wrap></funding-source><award-id>HDM-FUN</award-id><principal-award-recipient><name><surname>van de Veerdonk</surname><given-names>Frank L</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010663</institution-id><institution>H2020 European Research Council</institution></institution-wrap></funding-source><award-id>Solve-RD (No. 779257)</award-id><principal-award-recipient><name><surname>Hoischen</surname><given-names>Alexander</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Systematic assessment of <italic>de novo</italic> variants in patients with sporadic inborn errors of immunity led to the identification of promising candidate variants in known and novel immune genes, supporting its implementation in the routine diagnostic evaluation of these patients.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Although we inherit the vast majority of genomic variants from our parents, a small fraction of variants arises <italic>de novo</italic> during parental gametogenesis or after zygosis (<xref ref-type="bibr" rid="bib1">Acuna-Hidalgo et al., 2016</xref>). The biological rate at which these variants develop in humans translates to an average of 50-100 <italic>de novo</italic> single nucleotide variants (SNVs) per genome per generation, only one or two of which affect coding regions (<xref ref-type="bibr" rid="bib1">Acuna-Hidalgo et al., 2016</xref>; <xref ref-type="bibr" rid="bib53">Lynch, 2010</xref>). <italic>De novo</italic> variants (DNVs) are often very rare or unique (absent from population databases) and have a higher <italic>a priori</italic> chance to be pathogenic than inherited variants (<xref ref-type="bibr" rid="bib57">Meyts et al., 2016</xref>; <xref ref-type="bibr" rid="bib79">Veltman and Brunner, 2012</xref>). In contrast to inherited variants, DNVs emerge between two generations and are subjected to minimal evolutionary selection pressure that would normally purify damaging mutations (<xref ref-type="bibr" rid="bib1">Acuna-Hidalgo et al., 2016</xref>). DNVs affecting nucleotides or genes that have been targeted by strong purifying selection can therefore be highly damaging to their respective non-redundant biological functions, as has for example been shown for genes involved in innate immunity, an ancient host defence mechanism that developed under constant environmental selection pressure by microorganisms (<xref ref-type="bibr" rid="bib79">Veltman and Brunner, 2012</xref>; <xref ref-type="bibr" rid="bib62">Quintana-Murci and Clark, 2013</xref>).</p><p>Therefore, DNVs are important candidates to pursue as a cause for disease, particularly in rare, sporadic phenotypes (<xref ref-type="bibr" rid="bib53">Lynch, 2010</xref>; <xref ref-type="bibr" rid="bib79">Veltman and Brunner, 2012</xref>; <xref ref-type="bibr" rid="bib80">Vissers et al., 2010</xref>). The presence of such candidate DNVs can be assessed by trio-based sequencing, in which the patient is sequenced together with the (healthy) parents (<xref ref-type="bibr" rid="bib1">Acuna-Hidalgo et al., 2016</xref>). Most experience with the systematic diagnostic assessment of DNVs has been gained in the field of developmental disorders, in which DNVs have been shown to constitute up to 50% of disease-causing mutations (<xref ref-type="bibr" rid="bib80">Vissers et al., 2010</xref>; <xref ref-type="bibr" rid="bib54">Martin et al., 2018</xref>; <xref ref-type="bibr" rid="bib38">Kaplanis et al., 2020</xref>). However, the contribution of DNVs in the pathogenesis of other disorders such as inborn errors of immunity (IEI) is less clear.</p><p>DNVs as the underlying cause in IEI patients have been widely reported in literature, but most of these mutations were determined to be <italic>de novo</italic> through subsequent segregation analysis and not by trio-based sequencing (<xref ref-type="bibr" rid="bib73">Stray-Pedersen et al., 2017</xref>; <xref ref-type="bibr" rid="bib5">Arts et al., 2019</xref>; <xref ref-type="bibr" rid="bib66">Rudilla et al., 2019</xref>; <xref ref-type="bibr" rid="bib12">Bradshaw et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">Liu et al., 2011</xref>). IEI can present at different stages of life with a variable phenotype ranging from recurrent, life-threatening infections to immune dysregulation and cancer (<xref ref-type="bibr" rid="bib5">Arts et al., 2019</xref>; <xref ref-type="bibr" rid="bib11">Bousfiha et al., 2020</xref>). Particularly in IEI patients with early-onset and severe complex phenotypes, there is an increased chance for an underlying causative DNV (<xref ref-type="bibr" rid="bib79">Veltman and Brunner, 2012</xref>; <xref ref-type="bibr" rid="bib81">Vorsteveld et al., 2021</xref>). Moreover, DNVs that arise post-zygotically or somatically are recognized as an important underlying cause for IEI patients with autoinflammatory disease (<xref ref-type="bibr" rid="bib48">Labrousse et al., 2018</xref>; <xref ref-type="bibr" rid="bib20">de Inocencio et al., 2015</xref>; <xref ref-type="bibr" rid="bib56">Mensa-Vilaro et al., 2016</xref>; <xref ref-type="bibr" rid="bib41">Kawasaki et al., 2017</xref>; <xref ref-type="bibr" rid="bib31">Holzelova et al., 2004</xref>; <xref ref-type="bibr" rid="bib4">Aluri et al., 2021</xref>; <xref ref-type="bibr" rid="bib9">Beck et al., 2020</xref>; <xref ref-type="bibr" rid="bib78">van der Made et al., 2022</xref>; <xref ref-type="bibr" rid="bib90">Zhou et al., 2012</xref>). The potentially added value of systematic DNV assessment in IEI patients is supported by the findings of an international cohort study, which reported a diagnosis in 44% of cases after patient-parent trio sequencing, compared to 36% by single whole exome sequencing (WES) (<xref ref-type="bibr" rid="bib73">Stray-Pedersen et al., 2017</xref>). However, trio-based sequencing has not yet been implemented as part of the routine diagnostic procedure of IEI patients.</p><p>The current study has aimed to explore the potential added value of systematic assessment of DNVs in a retrospective cohort of 123 patients with a suspected, sporadic IEI that underwent trio-based WES.</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and methods</title><sec id="s2-1"><title>Patients and samples</title><p>We retrospectively screened patient-parent trios that were submitted to Genome Diagnostics at the Department of Human Genetics in the Radboud University Medical Center (RUMC) between May 2013 and November 2021. Patient-parent trios were selected for systematic DNV analysis when fulfilling the following inclusion criteria: (1) the patient’s phenotype was sporadic, (2) the clinical description was suspect for an inborn error of immunity (IEI), and (3) the <italic>in silico</italic> IEI whole exome sequencing (WES) panel was requested and analysed. The <italic>in silico</italic> IEI gene panel of the RUMC is periodically updated after literature review and currently encompasses 456 genes (version DG3.1.0 <xref ref-type="bibr" rid="bib64">Radboudumc, 2021</xref>). During the study period, the <italic>in silico</italic> IEI WES panel was analysed in 146 patient-parent trios, of which 123 trios met the inclusion criteria for our retrospective cohort study (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Schematic overview of patient inclusion, <italic>de novo</italic> variant filtering strategy and variant evaluation.</title><p>Of the 146 eligible patient-parent trios, 123 trios met the inclusion criteria for this IEI cohort study. Whole exome sequencing data from these patient-parent trios was filtered to retain rare, non-synonymous candidate <italic>de novo</italic> variants in coding regions. Subsequently, variants were systematically evaluated at variant and gene level for their potential involvement in the patient’s immunological phenotype. Abbreviations: IEI = inborn errors of immunity; dbSNP = Single Nucleotide Polymorphism Database; ExAC = Exome Aggregation Consortium; GnomAD = Genome Aggregation Database; AF = allele frequency; GoNL = Genome of the Netherlands.</p><p><supplementary-material id="fig1scode1"><label>Figure 1—source code 1.</label><caption><title>R script for <italic>de novo</italic> variant filtering.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78469-fig1-code1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>List of 123 patient-parent trios with patient characteristics and whole exome sequencing performance statistics.</title></caption><media mimetype="application" mime-subtype="docx" xlink:href="elife-78469-fig1-data1-v2.docx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>List of all candidate rare, coding <italic>de novo</italic> variants found in the cohort of IEI patients.</title></caption><media mimetype="application" mime-subtype="docx" xlink:href="elife-78469-fig1-data2-v2.docx"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title><italic>De novo</italic> variant rate and distribution of <italic>de novo</italic> variant types across our IEI cohort in comparison to a reference cohort from <xref ref-type="bibr" rid="bib38">Kaplanis et al., 2020</xref>.</title><p>The total amount of candidate <italic>de novo</italic> variants was retrieved from our cohort, consisting of 123 individuals. All identified <italic>de novo</italic> variants with at least 20% variation reads of the <xref ref-type="bibr" rid="bib38">Kaplanis et al., 2020</xref><italic>.</italic> cohort were obtained. The amount of predicted loss-of-function, synonymous and non-synonymous <italic>de novo</italic> single nucleotide variants or small insertion-deletions were extracted from both cohorts. The total amount of all, predicted loss-of-function, synonymous and non-synonymous <italic>de novo</italic> variants were divided by the respective cohort size to obtain the average number of respective variants per individual for each cohort.</p></caption><media mimetype="application" mime-subtype="docx" xlink:href="elife-78469-fig1-data3-v2.docx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Distribution of rare, non-synonymous coding <italic>de novo</italic> variants among cases.</title><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Number of candidate <italic>de novo</italic> variants per case.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-78469-fig1-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-fig1-figsupp1-v2.tif"/></fig></fig-group><p>As described previously (<xref ref-type="bibr" rid="bib5">Arts et al., 2019</xref>), patients and their parents provided written informed consent for <italic>in silico</italic> IEI WES gene panel analysis with or without exome-wide variant analysis that is in line with the diagnostic clinical question, as approved by the Medical Ethics Review Committee Arnhem-Nijmegen (2011/188 and 2020–7142). This research is in compliance with the principles of the Declaration of Helsinki (<xref ref-type="bibr" rid="bib87">World Medical, 2013</xref>).</p><p>For the systematic DNV analysis in this study, WES data of all subjects was pseudonymised. This entailed the at random enciphering of patient DNA numbers to ascending numbers by a Genome Diagnostics member. In addition, clinical descriptions were condensed and classified according to the International Union of Immunological Societies (IUIS) classification (<xref ref-type="bibr" rid="bib11">Bousfiha et al., 2020</xref>). Some of the included trios were part of previous publications: one was published as a clinical case report by D’hauw <italic>et al.</italic>, 19 were part of the IEI cohort of Arts <italic>et al.</italic>, and one was part of a study by Konrad <italic>et al.</italic> (<xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>; <xref ref-type="bibr" rid="bib5">Arts et al., 2019</xref>; <xref ref-type="bibr" rid="bib45">Konrad et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">D’hauw et al., 2008</xref>).</p></sec><sec id="s2-2"><title>Diagnostic whole exome sequencing</title><p>WES was performed as described earlier with minor modifications (<xref ref-type="bibr" rid="bib50">Lelieveld et al., 2016</xref>). In brief, genomic DNA samples isolated from whole blood were processed at the Beijing Genomics Institute (BGI) Europe (BGI Europe, Copenhagen, Denmark) or the in-house sequencing facility. All samples were enriched for exonic DNA using Agilent (Agilent Technologies, Santa Clara, CA, United States) or Twist (Twist Bioscience, San Francisco, CA, United States) exome kits. DNA samples at BGI were sequenced on Illumina HiSeq4000 (Illumina Sequencing, San Diego, CA, United States) or DNBseq (MGI Tech, Shenzhen, China). In-house DNA samples were sequenced on Illumina NovaSeq6000 (Illumina Sequencing). Sequencing was performed with 2x100 base pair (DNBseq) or 2x150 base pair (HiSeq4000 and NovaSeq6000) paired-end sequencing reads. The average median sequence coverage was 124x with an average of 96% target coverage greater than 20x (<xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>).</p><p>Downstream processing was performed by an automated data analysis pipeline, including mapping of sequencing reads to the GRCh37/hg19 reference genome with the Burrows-Wheeler Aligner algorithm and Genome Analysis Toolkit variant calling and additional custom-made annotation (<xref ref-type="bibr" rid="bib51">Li and Durbin, 2010</xref>; <xref ref-type="bibr" rid="bib55">McKenna et al., 2010</xref>). The DeNovoCheck tool is part of the custom-made annotation and was used to align variants called in each member of the patient-parent trios, providing an indication whether variants were inherited or <italic>de novo</italic>. DNVs were filtered out if the variation reads in either parent exceeded 2% (<xref ref-type="bibr" rid="bib50">Lelieveld et al., 2016</xref>; <xref ref-type="bibr" rid="bib22">de Ligt et al., 2012</xref>). Subsequently, all single nucleotide variants (SNVs) or small insertion-deletions (indels) were annotated by a custom, in-house annotation pipeline. Copy number variants (CNVs) were assessed by the copy number inference from exome reads (CoNIFER) method, as of 2018 (<xref ref-type="bibr" rid="bib46">Krumm et al., 2012</xref>).</p><p>Subsequently, variants in genes included in the <italic>in silico</italic> IEI panel were filtered to retain both inherited and <italic>de novo</italic> coding, non-synonymous variants with population frequencies below 1% in our in-house database or population databases (GnomAD and dbSNP) (<xref ref-type="bibr" rid="bib39">Karczewski et al., 2020</xref>; <xref ref-type="bibr" rid="bib68">Sherry et al., 1999</xref>). Variant prioritisation was performed by clinical laboratory geneticists of the Department of Human Genetics at the RUMC. SNVs, small indels or CNVs that were considered to be (partially) related to the phenotype were classified (five-tier classification) and reported according to guidelines of the Association for Clinical Genetic Science and the American College of Medical Genetics and Genomics (ACMG; <xref ref-type="bibr" rid="bib65">Richards et al., 2015</xref>; <xref ref-type="bibr" rid="bib82">Wallis et al., 2013</xref>). Variants that were denoted or classified as carriership of a variant in a known recessive disease gene, known risk factors or variants of uncertain significance or (likely) pathogenic variants in disease genes other than those associated with IEI and candidate variants in genes without any disease association, were additionally reported and are listed in <xref ref-type="supplementary-material" rid="table1sdata1">Table 1—source data 1</xref>.</p></sec><sec id="s2-3"><title><italic>De novo</italic> variant analysis</title><p>In this study, a research-based re-analysis was performed on 123 patient-parent trio WES datasets to assess the presence of candidate DNVs. For this, a standardised variant filtering strategy was scripted using R Studio version 3.6.2 (<xref ref-type="supplementary-material" rid="fig1scode1">Figure 1—source code 1</xref>). Variants were filtered to retain rare (≤0.1% allele frequency in our in-house database and the population databases from Exome Aggregation Consortium (ExAC), Genome Aggregation Database (GnomAD) genomes and dbSNP as well as ≤0.5% in the Genome of the Netherlands (GoNL) database), coding, non-synonymous, possible DNVs, as annotated by the DeNovoCheck tool (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="bibr" rid="bib50">Lelieveld et al., 2016</xref>; <xref ref-type="bibr" rid="bib22">de Ligt et al., 2012</xref>; <xref ref-type="bibr" rid="bib39">Karczewski et al., 2020</xref>; <xref ref-type="bibr" rid="bib68">Sherry et al., 1999</xref>; <xref ref-type="bibr" rid="bib49">Lek et al., 2016</xref>; <xref ref-type="bibr" rid="bib10">Boomsma et al., 2014</xref>). Variants with ≤10 variation reads, ≤20% variant allele fraction or low coverage DNVs (<xref ref-type="bibr" rid="bib22">de Ligt et al., 2012</xref>) were excluded. Moreover, synonymous SNVs and small indels were removed from the analysis. DNVs excluded by this filtering strategy were investigated for potential pathogenicity in known IEI genes. The remaining candidate DNVs are listed in <xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>. These DNVs were prioritised and systematically evaluated using variant and gene level metrics, encompassing database allele frequencies (including DNV counts in other datasets via denovo-db), nucleotide conservation, pathogenicity prediction scores, functional information and possible involvement in the immune system based on mouse knockout models, pathway-based annotation (i.e. Gene Ontology terms), and literature studies (<xref ref-type="bibr" rid="bib39">Karczewski et al., 2020</xref>; <xref ref-type="bibr" rid="bib85">Wiel et al., 2019</xref>; <xref ref-type="bibr" rid="bib72">Stephenson et al., 2019</xref>; <xref ref-type="bibr" rid="bib76">Turner et al., 2017</xref>). Prioritised candidate DNVs were visually inspected using the Integrative Genomics Viewer (IGV) and/or Alamut Visual Software version 2.13 (SOPHiA GENETICS, Saint Sulpice, Switzerland) to investigate biases that would give rise to false-positive variant calls. In addition, splice site DNVs were analysed using the SpliceAI prediction score (<xref ref-type="bibr" rid="bib34">Jaganathan et al., 2019</xref>) and the Alamut Visual Software, which has incorporated splicing prediction tools such as SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer and ESE tools.</p></sec><sec id="s2-4"><title>FBXW11 functional validation experiments</title><sec id="s2-4-1"><title>Epstein–Barr virus (EBV)-B cell lines</title><p>Venous blood was drawn from patient 53 and collected in lithium heparin tubes. Epstein-Barr virus (EBV)-transformed B cell lines were created following established procedures (<xref ref-type="bibr" rid="bib60">Neitzel, 1986</xref>). EBV-transformed lymphoblastoid cell lines (EBV-LCLs) from the patient and a healthy control were grown at 37 °C and 7.5% CO<sub>2</sub> in RPMI 1640 medium (Dutch Modification, Gibco; Thermo Fisher Scientific, Inc, Waltham, MA, United States) containing 15% foetal calf serum (FCS; Sigma-Aldrich, St Louis, MO, United States), 1% 10,000 U/μl penicillin and 10,000  μg/μl streptomycin (Sigma-Aldrich), and 2% HEPES (Sigma-Aldrich). The EBV-LCLs were cultured at a concentration of 10×10<sup>6</sup> in 150 cm<sup>2</sup> culture flasks (Corning, Corning, NY, United States) and treated with or without cycloheximide at 0.1% (20mL/20 mL medium; Sigma-Aldrich) for four hours. Cell pellets were then spun down, washed with PBS, snap-frozen in liquid nitrogen and stored at -80 °C.</p></sec></sec><sec id="s2-5"><title>RNA splicing effect</title><p>RNA was isolated from the EBV-B cell pellets using the RNeasy Mini isolation kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Subsequently, cDNA was synthesised from RNA with the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, United States). A primer set was designed (Primer3web, version 4.1.0) to span exon 11–13 of <italic>FBXW11</italic>, with the following sequences: Forward <named-content content-type="sequence">5’-GAGAGCCGGAATCAGAGGTG-3’</named-content>; Reverse <named-content content-type="sequence">5’-GAATTGGTCCGATGCATCCG-3’</named-content>. Subsequently, RT-PCR was performed using the AmpliTaq Gold 360 Master Mix (Life Technologies, Carlsbad, CA, United States). The amplified PCR products and Orange G ladder were electrophoresed on a 2% agarose gel with GelRed, and the resulting bands were cut out and analysed with Sanger sequencing.</p></sec><sec id="s2-6"><title><italic>Ex vivo</italic> peripheral mononuclear blood cell (PBMC) experiments</title><p>Venous blood was drawn and collected in EDTA tubes. Immune cell isolation was conducted as described elsewhere (<xref ref-type="bibr" rid="bib61">Oosting et al., 2016</xref>). In brief, PBMCs were obtained from blood by differential density centrifugation, diluted 1:1 in pyrogen-free saline over Cytiva Ficoll-Paque Plus (Sigma-Aldrich). Cells were washed twice in saline and suspended in cell culture medium (Roswell Park Memorial Institute (RPMI) 1640, Gibco) supplemented with gentamicin, 50 mg/mL; L-glutamine, 2 mM; and pyruvate, 1 mM. <italic>Ex vivo</italic> PBMC stimulations were performed with 5×10<sup>5</sup> cells/well in round-bottom 96-well plates (Greiner Bio-One, Kremsmünster, Austria) for 24 hr in the presence of 10% human pool serum at 37 °C and 5% carbon dioxide. For cytokine production measurements, cells were treated with <italic>Candida albicans</italic> yeast (UC820 heat-killed, 1×10<sup>6</sup> /mL), lipopolysaccharide (LPS, 10 ng/mL), <italic>Staphylococcus aureus</italic> (ATCC25923 heat-killed, 1×10<sup>6</sup> /mL) or TLR3 ligand Poly I:C (10 µg/mL) or left untreated in regular RPMI medium. After the incubation period and centrifugation, supernatants were collected and stored at -20 °C until the measurement using enzyme-linked immunosorbent assay (ELISA).</p><p>For flow cytometry experiments, PBMCs were cultured in U-bottom plates at a final concentration of 1×10<sup>6</sup> cells in 200 µL per well containing culture medium supplemented with 5% FCS (Sigma-Aldrich) at 37 °C and 5% carbon dioxide. Subsequently, cells were stimulated with phorbol 12-myristate 13-acetate (PMA, 12.5  ng/mL, Sigma-Aldrich) and ionomycin (500  ng/mL, Sigma-Aldrich) in duplicate for 30 min.</p></sec><sec id="s2-7"><title>Flow cytometry</title><p>PBMC suspensions were transferred to a V-bottom plate while pooling the duplicates. Following centrifugation for 2.5 min, cell surface markers were stained in the dark for 30 min at 4 °C with a monoclonal antibody mix containing anti-CD3-ECD (1:25; Beckman Coulter, Brea, CA, United States), anti-CD4-BV510 (1:50; BD Bioscience, Franklin Lakes, NJ, United States), anti-CD8-APC Alexa Fluor 700 (1:400; Beckman Coulter), and anti-CD14-FITC (1:50; Dako; Agilent Technologies). Subsequently, cells were washed twice with flow cytometry buffer (FCM buffer, 0.2% BSA in PBS) and fixed (BD Biosciences Cytofix, 554655) for 10 min at 37 °C. Next, cells were washed and permeabilised with perm buffer IV (1:10 diluted with PBS, BD Biosciences Phosflow, 560746) for 20 min on ice in the dark. Cells were then stained intracellularly with anti-NF-κB p65 (pS529)-PE antibody (1:50; eBioscience; Thermo Fisher Scientific, Inc, Waltham, MA, United States) for 20 min at 4 °C. After washing the cells twice in FCM-buffer, the suspensions were measured on a Beckman Coulter Navios EX Flow Cytometer using Navios System Software. Cell immunophenotypes were analysed using Kaluza Analysis Software version 2.1 (Beckman Coulter). The mean fluorescent intensities (MFIs) were calculated using the median pNF-κB p65 expression levels within the gated immune cell populations of interest.</p></sec><sec id="s2-8"><title>Cytokine measurements</title><p>Levels of cytokines IL-1β, IL-6 and TNFα were determined in supernatants of stimulated PBMC cultures according to the instructions of the manufacturer (Duoset ELISA; R&amp;D Systems, Minneapolis, MN, United States).</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Cohort characteristics</title><p>This retrospective cohort study systematically re-analysed patient-parent trio whole exome sequencing (WES) data of 123 patients with suspected, sporadic inborn errors of immunity (IEI) with the aim to identify candidate <italic>de novo</italic> single-nucleotide variants (SNVs) or small insertion-deletions (indels) (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The selected IEI patients had a median age of 9 years (IQR 2–17), and two-thirds of the cases were below 18 years of age (<xref ref-type="table" rid="table1">Table 1</xref>). The sex distribution among patients was roughly equal. Classification of IEI phenotypes according to the International Union of Immunological Societies (IUIS) indicated that most cases presented with autoinflammatory syndromes, followed by immune dysregulation and combined, predominantly syndromal immunodeficiencies (<xref ref-type="bibr" rid="bib11">Bousfiha et al., 2020</xref>). Eight patients remained unclassified due to limited clinical data.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Patient cohort characteristics.</title><p><supplementary-material id="table1sdata1"><label>Table 1—source data 1.</label><caption><title>List of patient-parent trios with variants identified in genes outside the diagnostic IEI gene panel, or classified as risk factors, carriership or variants of uncertain significance.</title><p>The table displays information on inherited single nucleotide variants and small insertion-deletions or copy number variants that were identified after diagnostic <italic>in silico</italic> gene panel and/or exome-wide analysis prior to the systematic DNV analysis in this study.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78469-table1-data1-v2.zip"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Characteristic</th><th align="left" valign="top">Total N=123</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="2">Demographics</td></tr><tr><td align="left" valign="top">Age<xref ref-type="table-fn" rid="table1fn2">*</xref>, median (IQR) y</td><td align="char" char="." valign="top">9 (2-17)</td></tr><tr><td align="char" char="." valign="top"> &lt;18 y, %</td><td align="char" char="." valign="top">67.4</td></tr><tr><td align="char" char="." valign="top"> &gt;18 y, %</td><td align="char" char="." valign="top">33.6</td></tr><tr><td align="left" valign="top">Sex ratio, M:F</td><td align="char" char="." valign="top">50.4:49.6</td></tr><tr><td align="left" valign="top" colspan="2">Distribution of clinical phenotypes <xref ref-type="table-fn" rid="table1fn3">†</xref></td></tr><tr><td align="left" valign="top"> Severe combined immunodeficiency, n (%)</td><td align="char" char="." valign="top">9 (7.3)</td></tr><tr><td align="left" valign="top"> Suspected SCID (low TRECs), n</td><td align="char" char="." valign="top">5</td></tr><tr><td align="left" valign="top"> Other, n</td><td align="char" char="." valign="top">4</td></tr><tr><td align="left" valign="top">Combined immunodeficiency, n (%)</td><td align="char" char="." valign="top">22 (17.9)</td></tr><tr><td align="left" valign="top"> Syndromal, n</td><td align="char" char="." valign="top">20</td></tr><tr><td align="left" valign="top"> Non-syndromal, n</td><td align="char" char="." valign="top">2</td></tr><tr><td align="left" valign="top">Primary antibody deficiency, n (%)</td><td align="char" char="." valign="top">14 (11.4)</td></tr><tr><td align="left" valign="top"> CVID, n</td><td align="char" char="." valign="top">14</td></tr><tr><td align="left" valign="top"> Agammaglobulinemia, n</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top"> Other, n</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top">Immune dysregulation, n (%)</td><td align="char" char="." valign="top">20 (16.3)</td></tr><tr><td align="left" valign="top"> HLH/EBV, n</td><td align="char" char="." valign="top">5</td></tr><tr><td align="left" valign="top"> Autoimmunity, n</td><td align="char" char="." valign="top">15</td></tr><tr><td align="left" valign="top">Autoinflammatory syndrome, n (%)</td><td align="char" char="." valign="top">22 (17.9)</td></tr><tr><td align="left" valign="top"> Periodic fever syndrome, n</td><td align="char" char="." valign="top">19</td></tr><tr><td align="left" valign="top"> Interferonopathy, n</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top"> Other, n</td><td align="char" char="." valign="top">3</td></tr><tr><td align="left" valign="top">Phagocyte defect, n (%)</td><td align="char" char="." valign="top">5 (4.1)</td></tr><tr><td align="left" valign="top"> Functional defect, n</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top"> Neutropenia/other, n</td><td align="char" char="." valign="top">4</td></tr><tr><td align="left" valign="top">Innate/intrinsic immune defect, n (%)</td><td align="char" char="." valign="top">16 (13.0)</td></tr><tr><td align="left" valign="top"> Bacterial/parasitic, n</td><td align="char" char="." valign="top">2</td></tr><tr><td align="left" valign="top"> MSMD/Viral, n</td><td align="char" char="." valign="top">7</td></tr><tr><td align="left" valign="top"> Other, n</td><td align="char" char="." valign="top">7</td></tr><tr><td align="left" valign="top">Complement deficiencies, n (%)</td><td align="char" char="." valign="top">0 (0.0)</td></tr><tr><td align="left" valign="top">Bone marrow failure, n (%)</td><td align="char" char="." valign="top">10 (8.1)</td></tr><tr><td align="left" valign="top">Phenocopies of PIDs, n (%)</td><td align="char" char="." valign="top">0 (0.0)</td></tr><tr><td align="left" valign="top">Unclassified, n (%)</td><td align="char" char="." valign="top">5 (4.1)</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: IQR = interquartile range; SCID = severe combined immunodeficiency; TREC = T cell receptor excision circle; CVID = common variable immunodeficiency; HLH = haemophagocytic lymphohistiocytosis; EBV = Epstein-Barr virus; MSMD = Mendelian susceptibility to mycobacterial disease; PID = primary immunodeficiency.</p></fn><fn id="table1fn2"><label>*</label><p>The age at the time of genetic testing is indicated, since the age of onset has not been documented for all cases.</p></fn><fn id="table1fn3"><label>†</label><p>Categorization of phenotypes is based on the IUIS classification of 2019 (14).</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-2"><title>Reported genetic variants after diagnostic whole exome sequencing</title><p>Potential disease-causing SNVs and/or copy number variants (CNVs) were reported in 36 index patients after diagnostic WES (<xref ref-type="table" rid="table2">Table 2</xref>). Twenty-four patients were carriers of recessive disease alleles, previously characterised risk factors, variants of uncertain significance (VUS) or (likely) pathogenic variants affecting established disease genes other than those associated with IEI (<xref ref-type="table" rid="table2">Table 2</xref>). Of note, three of these patients carried <italic>de novo</italic> CNVs that met the diagnostic quality criteria. Patient 21 was diagnosed with an autoinflammatory disorder and carried a 17q terminal deletion of uncertain clinical significance. Overlapping CNVs have been previously reported in DECIPHER (<xref ref-type="bibr" rid="bib27">Firth et al., 2009</xref>). A patient with non-syndromal combined immunodeficiency carried a <italic>de novo</italic> CNV involved in the Chromosome 22q11.2 microduplication syndrome (patient 69, OMIM #608363). Another <italic>de novo</italic> CNV was identified in patient 115 who was diagnosed with severe combined immunodeficiency. This young female carried a large duplication in Xq of uncertain clinical significance.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Genetic findings after routine diagnostic panel analysis.</title><p>Genetic variants reported after routine diagnostic whole exome sequencing analysis of the 123 patients included in this cohort of inborn errors of immunity.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Total cases in which a genetic variant was reported, n (%)</th><th align="left" valign="bottom">36 (29.3)</th><th align="left" valign="bottom">Patient nr.</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>(Likely) pathogenic mutation, n (%)</bold></td><td align="char" char="." valign="bottom"><bold>18 (14.6)</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Within IEI gene panel, n (%)</td><td align="char" char="." valign="bottom">12 (9.8)</td><td align="left" valign="bottom">All patients listed in <xref ref-type="table" rid="table3">Table 3</xref></td></tr><tr><td align="left" valign="bottom">Beyond IEI gene panel, n (%)</td><td align="char" char="." valign="bottom">6 (4.9)</td><td align="left" valign="bottom">1, 3, 40, 69, 85, 103 (<xref ref-type="supplementary-material" rid="table1sdata1">Table 1—source data 1</xref>)</td></tr><tr><td align="left" valign="bottom"><bold>Other variants, n (%)</bold></td><td align="char" char="." valign="bottom"><bold>19 (15.4)</bold></td><td align="left" valign="bottom"><xref ref-type="supplementary-material" rid="table1sdata1">Table 1—source data 1</xref></td></tr><tr><td align="left" valign="bottom">Risk factor, n (%)</td><td align="char" char="." valign="bottom">6 (4.9)</td><td align="char" char="." valign="bottom">21, 44, 55, 56, 68, 112</td></tr><tr><td align="left" valign="bottom">Carriership recessive allele, n (%)</td><td align="char" char="." valign="bottom">7 (5.7)</td><td align="char" char="." valign="bottom">3, 7, 16, 23, 32, 44, 76</td></tr><tr><td align="left" valign="bottom">Variant of unknown significance, n (%)</td><td align="char" char="." valign="bottom">9 (7.3)</td><td align="char" char="." valign="bottom">6, 21, 23, 45, 54, 80, 100, 101, 115</td></tr></tbody></table></table-wrap><p>In 12 patients, (likely) pathogenic SNVs were identified in known IEI genes that (partially) explain the patient’s immunological phenotype (<xref ref-type="table" rid="table2">Table 2</xref>, details shown in <xref ref-type="table" rid="table3">Table 3</xref>). While most variants were inherited, one patient with Muckle-Wells syndrome (patient 59) carried a <italic>de novo</italic> missense variant in <italic>NLRP3</italic> (NM_001079821.2:c.1049C&gt;T p.(Thr350Met)). This variant has previously been described in patients with Muckle-Wells syndrome (<xref ref-type="bibr" rid="bib24">Dodé et al., 2002</xref>; <xref ref-type="bibr" rid="bib35">Jiménez-Treviño et al., 2013</xref>). Consequently, the <italic>NLRP3 de novo</italic> variant (DNV) was classified as pathogenic (<xref ref-type="bibr" rid="bib65">Richards et al., 2015</xref>; <xref ref-type="bibr" rid="bib82">Wallis et al., 2013</xref>).</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Patients with previously reported single nucleotide variants, small insertion-deletions, or copy number variants that may (partially) explain the patient’s immunological phenotype.</title><p>Listed variants were identified prior to the research-based systematic re-analysis of the current study following diagnostic gene panel analysis for inborn errors of immunity.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Patient nr.</th><th align="center" valign="bottom">Sex</th><th align="center" valign="bottom">Age range at sampling</th><th align="center" valign="bottom">Phenotype (IUIS classification)</th><th align="center" valign="bottom">Variant</th><th align="center" valign="bottom">Mutational mechanism</th><th align="center" valign="bottom">ACMG classification</th><th align="center" valign="bottom">ClinVar accession</th><th align="center" valign="bottom">Comments</th></tr></thead><tbody><tr><td align="char" char="." valign="bottom" rowspan="2">10</td><td align="center" valign="bottom" rowspan="2">F</td><td align="center" valign="bottom" rowspan="2">0–5</td><td align="center" valign="bottom" rowspan="2">Immune dysregulation, HLH/EBV</td><td align="center" valign="bottom">AP3B1 Chr5(GRCh37):g.77563371del NM_003664.4:c.177del p.(Lys59fs)</td><td align="center" valign="bottom" rowspan="2">AR (ch) LoF</td><td align="center" valign="bottom">Pathogenic</td><td align="center" valign="bottom">VCV000224763</td><td align="center" valign="bottom" rowspan="2">Hermansky-Pudlak syndrome 2 (OMIM #608233)</td></tr><tr><td align="center" valign="bottom">AP3B1 Chr5(GRCh37):g.77423980_77423983del NM_003664.4:c.1839_1842del p.(Asp613fs)</td><td align="center" valign="bottom">Pathogenic</td><td align="center" valign="bottom">VCV000224764</td></tr><tr><td align="char" char="." valign="bottom" rowspan="2">12</td><td align="center" valign="bottom" rowspan="2">F</td><td align="center" valign="bottom" rowspan="2">11–15</td><td align="center" valign="bottom" rowspan="2">CID, syndromal</td><td align="center" valign="bottom">FAS Chr10(GRCh37):g.90774167_90774186dup NM_000043.6:c.968_987dup p.(Glu330fs)</td><td align="center" valign="bottom">AD (htz) LoF</td><td align="center" valign="bottom">Pathogenic</td><td align="center" valign="bottom">VCV000016509</td><td align="center" valign="bottom">Autoimmune lymphoproliferative syndrome, type IA (OMIM #601859)</td></tr><tr><td align="center" valign="bottom">seq[GRCh37] del(16)(p11.2p11.2) NC_000016.9:g.(29469093_29624260)_(30199846_30208282)del</td><td align="center" valign="bottom">AD (htz) LoF</td><td align="center" valign="bottom">Pathogenic</td><td align="center" valign="bottom">-</td><td align="center" valign="bottom">16 p11.2 deletion syndrome (OMIM #611913)</td></tr><tr><td align="char" char="." valign="bottom">26</td><td align="center" valign="bottom">F</td><td align="center" valign="bottom">0–5</td><td align="center" valign="bottom">Bone marrow failure</td><td align="center" valign="bottom">DHFR Chr5(GRCh37):g.79950248C&gt;T NM_000791.3:c.61G&gt;A p.(Gly21Arg)</td><td align="center" valign="bottom">AR (hmz) LoF</td><td align="center" valign="bottom">Likely pathogenic</td><td align="center" valign="bottom">-</td><td align="center" valign="bottom">Megaloblastic anaemia due to dihydrofolate reductase deficiency (OMIM #613839)<break/>Affected sibling carries equal variant</td></tr><tr><td align="char" char="." valign="bottom">59</td><td align="center" valign="bottom">M</td><td align="center" valign="bottom">6–10</td><td align="center" valign="bottom">Autoinflammatory disorder</td><td align="center" valign="bottom">NLRP3 Chr1(GRCh37):g.247587794C&gt;T NM_001079821.2:c.1049C&gt;T p.(Thr350Met)</td><td align="center" valign="bottom">AD (htz) LoF</td><td align="center" valign="bottom">Pathogenic</td><td align="center" valign="bottom">-</td><td align="center" valign="bottom">Muckle-Wells syndrome (OMIM #191900)<break/><italic>De novo</italic> SNV</td></tr><tr><td align="char" char="." valign="bottom">61</td><td align="center" valign="bottom">M</td><td align="center" valign="bottom">0–5</td><td align="center" valign="bottom">CID, syndromal</td><td align="center" valign="bottom">MKL1 Chr22(GRCh37):g.40815086dup NM_020831.4:c.1356dup p.(Val453Argfs)</td><td align="center" valign="bottom">AR (hmz) LoF</td><td align="center" valign="bottom">Likely pathogenic</td><td align="center" valign="bottom">-</td><td align="center" valign="bottom">Immunodeficiency 66 (OMIM #618847)<break/>Affected sibling carries equal variant</td></tr><tr><td align="char" char="." valign="bottom">77</td><td align="center" valign="bottom">F</td><td align="center" valign="bottom">0–5</td><td align="center" valign="bottom">CID, syndromal</td><td align="center" valign="bottom">ALOXE3 Chr17(GRCh37):g.8006708G&gt;A NM_021628.2:c.1889C&gt;T p.(Pro630Leu)</td><td align="center" valign="bottom">AR (hmz) LoF</td><td align="center" valign="bottom">Pathogenic</td><td align="center" valign="bottom">-</td><td align="center" valign="bottom">Congenital ichthyosis 3 (OMIM #606545)</td></tr><tr><td align="char" char="." valign="bottom">91</td><td align="center" valign="bottom">F</td><td align="center" valign="bottom">0–5</td><td align="center" valign="bottom">Suspected SCID (low TRECs)</td><td align="center" valign="bottom">FOXN1 Chr17(GRCh37):g.26857765A&gt;G NM_003593.2:c.831–2A&gt;G p.?</td><td align="center" valign="bottom">AD (htz) LoF</td><td align="center" valign="bottom">Likely pathogenic</td><td align="center" valign="bottom">-</td><td align="center" valign="bottom">T-cell lymphopenia, infantile, with or without nail dystrophy (OMIM #618806)</td></tr><tr><td align="char" char="." valign="bottom" rowspan="2">102</td><td align="center" valign="bottom" rowspan="2">F</td><td align="center" valign="bottom" rowspan="2">11–15</td><td align="center" valign="bottom" rowspan="2">Immune dysregulation, autoimmunity and others</td><td align="center" valign="bottom">CD55 Chr1(GRCh37):g.207497984dup NM_001300902.1:c.367dup p.(Thr123fs)</td><td align="center" valign="bottom">AR (hmz) LoF</td><td align="center" valign="bottom">Pathogenic</td><td align="center" valign="bottom">-</td><td align="center" valign="bottom">Complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy (OMIM #226300)</td></tr><tr><td align="center" valign="bottom">PET117 Chr20(GRCh37):g.18122927C&gt;T NM_001164811.1:c.172C&gt;T p.(Gln58*)</td><td align="center" valign="bottom">AR (hmz) LoF</td><td align="center" valign="bottom">Likely pathogenic</td><td align="center" valign="bottom">VCV000981504</td><td align="center" valign="bottom">Mitochondrial complex IV deficiency, nuclear type 19 (OMIM #619063)</td></tr><tr><td align="char" char="." valign="bottom">105</td><td align="center" valign="bottom">M</td><td align="center" valign="bottom">31–35</td><td align="center" valign="bottom">Defects in intrinsic and innate immunity, MSMD and viral infection</td><td align="center" valign="bottom">TLR7 ChrX(GRCh37):g.12905756_12905759del NM_016562.3:c.2129_2132del p.(Gln710fs)</td><td align="center" valign="bottom">XLR (hemi) LoF</td><td align="center" valign="bottom">Pathogenic</td><td align="center" valign="bottom">VCV000977232</td><td align="center" valign="bottom">Immunodeficiency 74, COVID19-related (OMIM #301051)<break/>Affected sibling carries equal variant</td></tr><tr><td align="char" char="." valign="bottom">114</td><td align="center" valign="bottom">M</td><td align="center" valign="bottom">6–10</td><td align="center" valign="bottom">Immune dysregulation, autoimmunity and others</td><td align="center" valign="bottom">LRBA Chr4(GRCh37):g.151835415del NM_006726.4:c.1093del p.(Tyr365fs)</td><td align="center" valign="bottom">AR (hmz) LoF</td><td align="center" valign="bottom">Pathogenic</td><td align="center" valign="bottom">-</td><td align="center" valign="bottom">Common variable immunodeficiency 8 (OMIM #614700)</td></tr><tr><td align="char" char="." valign="bottom">120</td><td align="center" valign="bottom">M</td><td align="center" valign="bottom">11–15</td><td align="center" valign="bottom">Congenital defect of phagocyte, functional defects</td><td align="center" valign="bottom">NCF1 Chr7(GRCh37):g.74191615_74191616del NM_000265.5:c.75_76del p.(Tyr26fs)</td><td align="center" valign="bottom">AR (hmz) LoF</td><td align="center" valign="bottom">Pathogenic</td><td align="center" valign="bottom">VCV000002249</td><td align="center" valign="bottom">Chronic granulomatous disease 1 (OMIM #233700)</td></tr><tr><td align="char" char="." valign="bottom">122</td><td align="center" valign="bottom">M</td><td align="center" valign="bottom">0–5</td><td align="center" valign="bottom">Suspected SCID (low TRECs)</td><td align="center" valign="bottom">FOXN1 Chr17(GRCh37):g.26851540del NM_003593.2.1:c.143del p.(Cys48fs)</td><td align="center" valign="bottom">AD (htz) LoF</td><td align="center" valign="bottom">Pathogenic</td><td align="center" valign="bottom">-</td><td align="center" valign="bottom">T-cell lymphopenia, infantile, with or without nail dystrophy (OMIM #618806)</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: IUIS = International Union of Immunological societies; ACMG = American College of Medical Genetics and Genomics; HLH = haemophagocytic lymphohistiocytosis; EBV = Epstein-Barr virus; OMIM = Online Mendelian Inheritance in Man; (S)CID = (severe) combined immunodeficiency; TREC = T cell receptor excision circle; MSMD = Mendelian susceptibility to mycobacterial disease; AR = autosomal recessive; AD = autosomal dominant; XLR = X-linked recessive; ch = compound heterozygous; htz = heterozygous; hmz = homozygous; hemi = hemizygous; LoF = loss-of-function; SNV = single nucleotide variant.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Identification of 13 heterozygous, rare and non-synonymous candidate <italic>de novo</italic> variants.</title><p>The 124 non-synonymous candidate <italic>de novo</italic> variants were systematically evaluated based on the potential to be damaging to gene and protein function and the possible involvement in the patient’s immunological phenotype.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Patient nr.</th><th align="left" valign="bottom">Sex</th><th align="left" valign="bottom">Age range at sampling</th><th align="left" valign="bottom">Phenotype (IUIS classification)</th><th align="left" valign="bottom"><italic>De novo</italic> variant</th><th align="left" valign="bottom">GnomAD AF in %</th><th align="left" valign="bottom">in-house AF in %</th><th align="left" valign="bottom">PhyloP</th><th align="left" valign="bottom">CADD</th><th align="left" valign="bottom">VarMap</th><th align="left" valign="bottom">MetaDome</th><th align="left" valign="bottom">Coding DNV in denovo-db (protein effect)</th><th align="left" valign="bottom">LOEUF</th><th align="left" valign="bottom">Function</th><th align="left" valign="bottom">Literature</th><th align="left" valign="bottom">Comments</th></tr></thead><tbody><tr><td align="left" valign="bottom" colspan="16"><bold>Missense SNVs</bold></td></tr><tr><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">M</td><td align="char" char="ndash" valign="bottom">11–15</td><td align="left" valign="bottom">SCID</td><td align="left" valign="bottom">PSMB10 Chr16(GRCh37):<break/>g.67968809C&gt;T NM_002801.3:<break/>c.601G&gt;A p.(Gly201Arg)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">5</td><td align="char" char="." valign="bottom">32</td><td align="left" valign="bottom">Likely deleterious</td><td align="left" valign="bottom">Neutral</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">1.37</td><td align="left" valign="bottom">Immuno- and thymoproteasome subunit</td><td align="left" valign="bottom">Homozygous <italic>Psmb10</italic> variant in mice causes SCID and systemic autoinflammation (<xref ref-type="bibr" rid="bib75">Treise et al., 2018</xref>). Homozygous <italic>PSMB10</italic> variant in humans cause PRAAS, no immunodeficiency (<xref ref-type="bibr" rid="bib67">Sarrabay et al., 2020</xref>).</td><td align="left" valign="bottom">Revertant somatic mosaicism (VAF: 39.7%). Additional inherited SNV and partial somatic UPD16 (<xref ref-type="supplementary-material" rid="table1sdata1">Table 1—source data 1</xref>).</td></tr><tr><td align="char" char="." valign="bottom">9</td><td align="left" valign="bottom">M</td><td align="char" char="ndash" valign="bottom">6–10</td><td align="left" valign="bottom">Predominantly antibody deficiency, hypogamma-globulinemia</td><td align="left" valign="bottom">RPL27A Chr11(GRCh37):<break/>g.8707228T&gt;C NM_000990.4:<break/>c.322T&gt;C p.(Tyr108His)</td><td align="char" char="." valign="bottom">0.0032</td><td align="char" char="." valign="bottom">0.0041</td><td align="char" char="." valign="bottom">7.4</td><td align="char" char="." valign="bottom">27.4</td><td align="left" valign="bottom">Likely deleterious</td><td align="left" valign="bottom">Intolerant</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">0.39</td><td align="left" valign="bottom">Ribosomal subunit</td><td align="left" valign="bottom">Ribosomopathies may include immunological defects (<xref ref-type="bibr" rid="bib42">Khan et al., 2011</xref>).</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">27</td><td align="left" valign="bottom">M</td><td align="char" char="ndash" valign="bottom">11–15</td><td align="left" valign="bottom">Autoinflammatory disorder</td><td align="left" valign="bottom">TAOK2 Chr16(GRCh37):<break/>g.29997683C&gt;T NM_016151.3:<break/>c.2090C&gt;T p.(Ala697Val)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">4.8</td><td align="char" char="." valign="bottom">22.5</td><td align="left" valign="bottom">Possibly deleterious</td><td align="left" valign="bottom">Slightly intolerant</td><td align="char" char="." valign="bottom">6 (4 mis)</td><td align="char" char="." valign="bottom">0.24</td><td align="left" valign="bottom">Serine/threonine-protein kinase (p38 MAPK pathway)</td><td align="left" valign="bottom">Homozygous <italic>TAOK2</italic> variant causes abnormal T cell activation in two patients with inflammatory bowel disease (<xref ref-type="bibr" rid="bib58">Molho-Pessach et al., 2017</xref>).</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">28</td><td align="left" valign="bottom">F</td><td align="char" char="ndash" valign="bottom">16–20</td><td align="left" valign="bottom">Predominantly antibody deficiency, hypogamma-globulinemia</td><td align="left" valign="bottom">KCTD9 Chr8(GRCh37):<break/>g.25292997C&gt;T NM_017634.3:<break/>c.695G&gt;A p.(Arg232His)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0.0082</td><td align="char" char="." valign="bottom">5.8</td><td align="char" char="." valign="bottom">32</td><td align="left" valign="bottom">Likely deleterious</td><td align="left" valign="bottom">Intolerant</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">0.52</td><td align="left" valign="bottom">Substrate-specific adapter</td><td align="left" valign="bottom">Involved in NK cell activation (<xref ref-type="bibr" rid="bib16">Chen et al., 2013</xref>).</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">52</td><td align="left" valign="bottom">M</td><td align="char" char="ndash" valign="bottom">11–15</td><td align="left" valign="bottom">Predominantly antibody deficiency, hypogamma-globulinemia</td><td align="left" valign="bottom">SCRIB Chr8(GRCh37):<break/>g.144874432C&gt;T NM_182706.4:<break/>c.4472G&gt;A p.(Arg1491Gln)</td><td align="char" char="." valign="bottom">0.0032</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">4.2</td><td align="char" char="." valign="bottom">29.9</td><td align="left" valign="bottom">Possibly deleterious</td><td align="left" valign="bottom">Intolerant</td><td align="char" char="." valign="bottom">5 (4 mis)</td><td align="char" char="." valign="bottom">0.31</td><td align="left" valign="bottom">Scaffold protein</td><td align="left" valign="bottom">Involved in uropod and immunological synapse formation, and ROS production by antigen-presenting cells (<xref ref-type="bibr" rid="bib7">Barreda et al., 2020</xref>).</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">58</td><td align="left" valign="bottom">F</td><td align="char" char="ndash" valign="bottom">21–25</td><td align="left" valign="bottom">Unclassified</td><td align="left" valign="bottom">CTCF Chr16(GRCh37):<break/>g.67645905G&gt;T NM_006565.4:<break/>c.833G&gt;T p.(Arg278Leu)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">9.7</td><td align="char" char="." valign="bottom">24.7</td><td align="left" valign="bottom">Possibly deleterious</td><td align="left" valign="bottom">Highly intolerant</td><td align="char" char="." valign="bottom">12 (11 mis)</td><td align="char" char="." valign="bottom">0.15</td><td align="left" valign="bottom">Transcriptional insulator</td><td align="left" valign="bottom"><italic>CTCF</italic> variants cause neurodevelopmental disorders, sometimes associated with recurrent infections and minor facial dysmorphisms (<xref ref-type="bibr" rid="bib45">Konrad et al., 2019</xref>).</td><td align="left" valign="bottom">Published (<xref ref-type="bibr" rid="bib45">Konrad et al., 2019</xref>).</td></tr><tr><td align="char" char="." valign="bottom">75</td><td align="left" valign="bottom">F</td><td align="char" char="ndash" valign="bottom">6–10</td><td align="left" valign="bottom">Bone marrow failure</td><td align="left" valign="bottom">FUBP1 Chr1(GRCh37):<break/>g.78435621A&gt;C NM_001303433.1:<break/>c.199T&gt;G p.(Leu67Val)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">2.6</td><td align="char" char="." valign="bottom">24.8</td><td align="left" valign="bottom">Possibly deleterious</td><td align="left" valign="bottom">Intolerant</td><td align="char" char="." valign="bottom">1 (0 mis)</td><td align="char" char="." valign="bottom">0.12</td><td align="left" valign="bottom">Transcriptional regulator that binds FUSE upstream of the c-myc promoter</td><td align="left" valign="bottom">Essential for long-term repopulating hematopoietic stem cell renewal (<xref ref-type="bibr" rid="bib63">Rabenhorst et al., 2015</xref>). <italic>Fubp1</italic> KO mice show cerebral hyperplasia, pulmonary hypoplasia, pale livers, hypoplastic spleen, thymus, and bone marrow, cardiac hypertrophy, placental distress, and small size (<xref ref-type="bibr" rid="bib91">Zhou et al., 2016</xref>).</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">118</td><td align="left" valign="bottom">F</td><td align="char" char="ndash" valign="bottom">0–5</td><td align="left" valign="bottom">Immune dysregulation, autoimmunity and others</td><td align="left" valign="bottom">RUNX3 Chr1(GRCh37):<break/>g.25256227C&gt;T NM_004350.2:<break/>c.133G&gt;A p.(Gly45Arg)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">2.4</td><td align="char" char="." valign="bottom">18</td><td align="left" valign="bottom">Possibly deleterious</td><td align="left" valign="bottom">Slightly tolerant</td><td align="char" char="." valign="bottom">1 (1 mis)</td><td align="char" char="." valign="bottom">0.42</td><td align="left" valign="bottom">Transcriptional regulator</td><td align="left" valign="bottom">RUNX3 regulates CD8+T cell thymocyte development, maturation of cytotoxic CD8+T cells and the function of innate lymphoid cells 3 via stimulation of RORγt (<xref ref-type="bibr" rid="bib25">Ebihara et al., 2015</xref>). <italic>Runx3</italic> KO mice spontaneously develop inflammatory bowel disease and gastric lesions (<xref ref-type="bibr" rid="bib14">Brenner et al., 2004</xref>).</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom" colspan="16"><bold>Frameshift SNVs</bold></td></tr><tr><td align="char" char="." valign="bottom">49</td><td align="left" valign="bottom">M</td><td align="char" char="ndash" valign="bottom">26–30</td><td align="left" valign="bottom">Predominantly antibody deficiency, hypogamma-globulinemia</td><td align="left" valign="bottom">DDX1 Chr2(GRCh37):<break/>g.15769802dup NM_004939.2:<break/>c.1952dup p.(Trp652fs)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">4 (0 fs)</td><td align="char" char="." valign="bottom">0.28</td><td align="left" valign="bottom">RNA helicase</td><td align="left" valign="bottom">Part of a dsRNA sensor that activates the NF-κB pathway and type I interferon responses (<xref ref-type="bibr" rid="bib89">Zhang et al., 2011</xref>).</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">78</td><td align="left" valign="bottom">F</td><td align="char" char="ndash" valign="bottom">6–10</td><td align="left" valign="bottom">CID, syndromal</td><td align="left" valign="bottom">KMT2C Chr7(GRCh37):<break/>g.151860074del NM_170606.2:<break/>c.10588del p.(Ser3530Leufs*3)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">19 (4 fs)</td><td align="char" char="." valign="bottom">0.12</td><td align="left" valign="bottom">Histone methyltransferase</td><td align="left" valign="bottom"><italic>KMT2C de novo</italic> variant causes Kleefstra syndrome 2, sometimes associated with recurrent respiratory infections (<xref ref-type="bibr" rid="bib44">Koemans et al., 2017</xref>).</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom" colspan="16"><bold>Small in-frame indel</bold></td></tr><tr><td align="char" char="." valign="bottom">108</td><td align="left" valign="bottom">M</td><td align="char" char="ndash" valign="bottom">21–25</td><td align="left" valign="bottom">Bone marrow failure</td><td align="left" valign="bottom">NSD2 Chr4(GRCh37):<break/>g.1959681_1959687delins<break/>TTTTTCT NM_133330.2:<break/>c.2903_2909delins<break/>TTTTTCT p.<break/>(Arg968_Arg970delinsLeuPheLeu)</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"/><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">0.12</td><td align="left" valign="bottom">Histone methyltransferase</td><td align="left" valign="bottom"><italic>NSD2 de novo</italic> LoF variant causes mild Wolf-Hirschhorn syndrome (<xref ref-type="bibr" rid="bib8">Barrie et al., 2019</xref>). Unclear role in immunity.</td><td align="left" valign="bottom">Postzygotic mosaicism (VAF 29%).</td></tr><tr><td align="left" valign="bottom"><bold>Patient nr.</bold></td><td align="left" valign="bottom"><bold>Sex</bold></td><td align="left" valign="bottom"><bold>Age range at sampling</bold></td><td align="left" valign="bottom"><bold>Phenotype (IUIS classification)</bold></td><td align="left" valign="bottom"><bold><italic>De novo</italic> variant</bold></td><td align="left" valign="bottom"><bold>GnomAD AF in %</bold></td><td align="left" valign="bottom"><bold>in-house AF in %</bold></td><td align="left" valign="bottom"><bold>PhyloP</bold></td><td align="left" valign="bottom"><bold>CADD</bold></td><td align="left" valign="bottom"><bold>SpliceAI Acceptor Gain</bold></td><td align="left" valign="bottom"><bold>SpliceAI Acceptor Loss</bold></td><td align="left" valign="bottom"><bold>Coding DNV in denovo-db (protein effect)</bold></td><td align="left" valign="bottom"><bold>LOEUF</bold></td><td align="left" valign="bottom"><bold>Function</bold></td><td align="left" valign="bottom"><bold>Literature</bold></td><td align="left" valign="bottom"><bold>Comments</bold></td></tr><tr><td align="left" valign="bottom" colspan="16"><bold>Splice site SNVs</bold></td></tr><tr><td align="char" char="." valign="bottom">53</td><td align="left" valign="bottom">F</td><td align="char" char="ndash" valign="bottom">11–15</td><td align="left" valign="bottom">Autoinflammatory disorder</td><td align="left" valign="bottom">FBXW11 Chr5(GRCh37):<break/>g.171295802T&gt;C NM_012300.2:<break/>c.1468–2A&gt;G p.?</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">7.9</td><td align="char" char="." valign="bottom">34</td><td align="char" char="." valign="bottom">0.0134</td><td align="char" char="." valign="bottom">0.9862</td><td align="char" char="." valign="bottom">2 (0 ss)</td><td align="char" char="." valign="bottom">0.31</td><td align="left" valign="bottom">Component of SCF (SKP1-CUL1-F-box) E3 ubiquitin ligase complex</td><td align="left" valign="bottom">Involved in the regulation of NF-κB signalling (<xref ref-type="bibr" rid="bib83">Wang et al., 2018</xref>).</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">119</td><td align="left" valign="bottom">F</td><td align="char" char="ndash" valign="bottom">11–15</td><td align="left" valign="bottom">Autoinflammatory disorder</td><td align="left" valign="bottom">RELA Chr11(GRCh37):<break/>g.65423234C&gt;T NM_021975.3:<break/>c.959–1G&gt;A p.?</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">3.5</td><td align="char" char="." valign="bottom">34</td><td align="char" char="." valign="bottom">0.7968</td><td align="char" char="." valign="bottom">0.9991</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">0.18</td><td align="left" valign="bottom">Transcription factor p65 (NF-κB subunit)</td><td align="left" valign="bottom">Heterozygous <italic>RELA</italic> variant causes chronic mucocutaneous ulceration (<xref ref-type="bibr" rid="bib6">Badran et al., 2017</xref>).</td><td align="left" valign="bottom"/></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: IUIS = International Union of Immunological Societies; GnomAD = Genome Aggregation Database; AF = allele frequency; CADD = Combined Annotation Dependent Depletion; DNV = <italic>de novo</italic> variant; LOEUF = loss-of-function observed/expected upper bound fraction; SNV = single nucleotide variant; indel = insertion-deletion; (S)CID = severe combined immunodeficiency; NA = not applicable; mis = missense; fs = frameshift; ss = splice site; MAPK = mitogen-activated protein kinase; FUSE = far upstream element; PRAAS = proteasome-associated autoinflammatory syndrome; NK = natural killer; ROS = reactive oxygen species; KO = knockout; dsRNA = double-stranded RNA; NF-κB = nuclear factor kappa-light-chain-enhancer of activated B cells; LoF = loss-of-function; VAF = variant allele fraction; UPD16 = uniparental disomy of chromosome 16.</p></fn></table-wrap-foot></table-wrap><p>Overall, routine diagnostic WES analysis provided a likely molecular diagnosis for (part) of the phenotype in 18 patients (14.6%) based on established mutational mechanisms and disease associations (<xref ref-type="table" rid="table2">Table 2</xref>).</p></sec><sec id="s3-3"><title>Rare, non-synonymous <italic>de novo</italic> variants in novel IEI candidate genes</title><p>Next, re-analysis was performed on WES data of all 123 sporadic IEI cases and their parents to systematically identify and interpret DNVs in novel IEI genes. Automated DNV filtering retained a total of 172 candidate DNVs that were rare (148 DNVs were absent from GnomAD genomes) and located in either exonic or splice site regions (the complete list can be found in <xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>). The total number of candidate DNVs among patients ranged between zero and six (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Moreover, the average number of candidate DNVs was comparable to recent literature (<xref ref-type="supplementary-material" rid="fig1sdata3">Figure 1—source data 3</xref>). Of these candidate DNVs, 124 were non-synonymous and therefore expected to exert an effect on protein function (<xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>). Two pairs of patients carried candidate DNVs in the same gene, <italic>GIGYF1</italic> (patients 49 and 83) and <italic>MAP3K10</italic> (patients 98 and 118). However, these patients did not share phenotypic features and the function of the proteins encoded by these genes could not be linked to the respective patient phenotype.</p><p>Subsequently, all non-synonymous candidate DNVs were systematically evaluated based on information on variant and gene level metrics, leading to the selection of 14 candidate DNVs potentially causing IEI (<xref ref-type="table" rid="table3 table4">Tables 3 and 4</xref>), including the above-mentioned variant in the known IEI gene <italic>NLRP3</italic>. The 13 novel IEI candidate DNVs were found in patients with different IEI phenotypes, although three subtypes reoccurred: predominantly antibody deficiency (hypogammaglobulinemia), autoinflammatory disorder and bone marrow failure. Candidate DNVs that were considered most promising based on variant and gene level metrics are presented in more detail in the following paragraphs.</p><p>A patient with an autoinflammatory phenotype characterised by mucocutaneous ulceration of mouth and genital area carried a DNV in <italic>RELA</italic> that was located in the canonical splice acceptor site preceding exon 10 (patient 119, <xref ref-type="table" rid="table4">Table 4</xref>). The guanine to adenine change was predicted to compromise the splice acceptor site by transferring it to the first guanine of exon 10, leading to an out-of-frame exon. The resulting frameshift was therefore assumed to cause a reduction in functional RelA protein by nonsense-mediated decay. RelA is also known as p65 and is critically involved in nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) heterodimer formation and consequent activation of NF-κB-mediated proinflammatory signalling. Although <italic>RELA</italic> has already been reported as an IEI gene in a previous IUIS classification (<xref ref-type="bibr" rid="bib74">Tangye et al., 2020</xref>), it was not yet listed in the IEI <italic>in silico</italic> gene panel of our Department of Human Genetics (<xref ref-type="bibr" rid="bib64">Radboudumc, 2021</xref>), because evidence was considered insufficient at the time.</p><p>In addition, a private <italic>de novo</italic> missense variant in <italic>PSMB10</italic> was found in a patient with Omenn syndrome with severe combined immunodeficiency (SCID), ectodermal dysplasia, alopecia, hypodontia and anonychia (patient 1, <xref ref-type="table" rid="table4">Table 4</xref>). The clinical phenotype of this patient has been previously reported (<xref ref-type="bibr" rid="bib23">D’hauw et al., 2008</xref>). The DNV was predicted to be pathogenic based on the majority of variant and gene level metrics. In additional data that was available from a single-nucleotide polymorphism (SNP) micro-array, it was shown that the genomic location of <italic>PSMB10</italic> was spanned by a partial somatic uniparental disomy of chromosome 16 (UPD16) (manuscript in preparation). <italic>PSMB10</italic> encodes the β2i-subunit of the immuno- and thymoproteasome and mutations leading to a loss of PSMB10 protein function have been associated with severe immunological defects (<xref ref-type="bibr" rid="bib75">Treise et al., 2018</xref>; <xref ref-type="bibr" rid="bib67">Sarrabay et al., 2020</xref>). Furthermore, another candidate DNV was identified in a patient with common variable immunodeficiency (CVID) due to a B cell maturation defect, auto-immune cytopenia, polyclonal T cell large granular lymphocytes in the bone marrow, recurrent viral infections, psoriasis and alopecia areata, (patient 49, <xref ref-type="table" rid="table4">Table 4</xref>). This frameshift variant in <italic>DDX1</italic> was predicted to cause loss of protein function. <italic>DDX1</italic> encodes a RNA helicase, which is part of a double-stranded RNA sensor that activates the NF-κB pathway and type I interferon responses (<xref ref-type="bibr" rid="bib89">Zhang et al., 2011</xref>). Moreover, DDX1 is involved in the regulation of hematopoietic stem and progenitor cell homeostasis (<xref ref-type="bibr" rid="bib89">Zhang et al., 2011</xref>; <xref ref-type="bibr" rid="bib84">Wang et al., 2021</xref>).</p><p>Another frameshift DNV in <italic>KMT2C</italic> was carried by a patient with a syndromal combined immunodeficiency characterised by recurrent ear infections, developmental delay, low-average intelligence level and facial dysmorphism (patient 78, <xref ref-type="table" rid="table4">Table 4</xref>). The variant was predicted to lead to a loss-of-function (LoF) of the KMT2C protein, which acts as a histone methyltransferase in the regulation of chromatin organisation.</p><p>Lastly, a DNV affecting <italic>FBXW11</italic> was identified in a patient with an autoinflammatory disorder characterised by recurrent periodic fever and severe headaches (patient 53, <xref ref-type="table" rid="table4">Table 4</xref>). <italic>FBXW11</italic> encodes a component of SCF (SKP1-CUL1-F-box) E3 ubiquitin ligase complex, TrCP2, that is involved in the regulation of NF-κB signalling through the ubiquitination of several of its components (<xref ref-type="bibr" rid="bib83">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="bib36">Kanarek and Ben-Neriah, 2012</xref>). An important function of both the TrCP1 and TrCP2 isoforms is the regulation of IκBα degradation, leading to subsequent activation of NF-κB and release of pro-inflammatory cytokines (<xref ref-type="bibr" rid="bib43">Kim et al., 2015</xref>; <xref ref-type="bibr" rid="bib88">Yaron et al., 1998</xref>). The identified DNV affected the canonical splice acceptor site preceding exon 12 (NM_012300.2:c.1468-2A&gt;G) and was predicted to lead to skipping of exon 12 based on splicing prediction by the Alamut Visual Software and to be deleterious by all utilised <italic>in silico</italic> prediction tools. The predicted RNA splicing defect leading to an in-frame, shortened RNA transcript was confirmed in Epstein-Barr virus (EBV) transformed B cells from the patient (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p><p>The other candidate DNVs will not be described in detail here, as there is insufficient evidence to suggest pathogenicity or a genotype-phenotype relationship. Future discovery of cases with DNVs in the presented genes and overlapping clinical phenotypes could encourage further in-depth research into the possible mutational mechanisms.</p></sec><sec id="s3-4"><title>Functional validation of <italic>FBXW11 de novo</italic> variant</title><p>In addition to systematic DNV analysis, we have selected the candidate DNV in <italic>FBXW11</italic> for functional validation as part of this study to provide further evidence for a causal genotype-phenotype relationship (patient 53, <xref ref-type="table" rid="table4">Table 4</xref>). As such, the putative effects on NF-κB signalling and the downstream production of pro-inflammatory cytokines were investigated in peripheral blood mononuclear cells (PBMC) extracted from the patient and a healthy control. In unstimulated PBMC of the patient showed higher levels of phosphorylated NF-kB p65 compared to the control. <italic>Ex vivo</italic> stimulation of these PBMC with phorbol 12-myristate 13-acetate (PMA) and ionomycin for 30 min led to higher NF-κB activation, reflected by p65 phosphorylation fluorescence intensity measured by flow cytometry, as compared to the healthy control (<xref ref-type="fig" rid="fig2">Figure 2</xref>, panel A). The greatest difference was observed in the lymphocyte subset, particularly in CD8 +T cells (<xref ref-type="fig" rid="fig2">Figure 2</xref>, panel A). Subsequently, the downstream production of the cytokines IL-1β, IL-6, and TNFα was investigated. The patient-derived PBMC produced more IL-1β upon <italic>in vitro</italic> stimulation with the heat-killed pathogens <italic>Candida albicans</italic> and <italic>Staphylococcus aureus</italic>, the TLR4 agonist lipopolysaccharides (LPS) and the TLR3 ligand Poly I:C after 24 hr, as compared to the healthy control (<xref ref-type="fig" rid="fig2">Figure 2</xref>, panel B). This trend was not observed for the production of IL-6 and TNFα (<xref ref-type="fig" rid="fig2">Figure 2</xref>, panels C and D). These results indicate that the <italic>FBXW11</italic> DNV leads to a splicing defect with skipping of exon 12, resulting in a shorter transcript and increased NF-κB signalling and downstream IL-1β production.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>NF-κB signalling and production of innate cytokines upon <italic>ex vivo</italic> PBMC stimulation.</title><p>Panel A shows the median fluorescence intensity expression levels of pNF-κB p65 (S529) in peripheral blood CD14 +monocytes and CD8 +T cells from a healthy control (blue) and patient 53 (red), in the absence (baseline) or presence of phorbol 12-myristate 13-acetate and ionomycin stimulation, with the absolute values indicated in the lower right corner. Panels B, C, and D display the production of IL-1β, IL-6, and TNFα, respectively, after <italic>ex vivo</italic> stimulation for 24 hr.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Original vector file of <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="x-eps" xlink:href="elife-78469-fig2-data1-v2.eps"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Uncropped gel with labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-78469-fig2-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Raw data of cytokine measurements.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-78469-fig2-data3-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>RNA splicing effect of the FBXW11 <italic>de novo</italic> splice site variant (c.1468-2A&gt;G).</title><p>Panel A shows the agarose gel on cDNA PCR products of patient and control Epstein–Barr virus (EBV)-transformed lymphoblastoid cell lines (EBV-LCLs) treated with or without cycloheximide (CHX). Three distinct bands were identified and are indicated by arrows next to a 100bp ladder (L). Both the wildtype allele of the patient and the control show a smear, possibly indicating the presence of multiple FBXW11 isoforms. Panel B shows traces of the three bands from the agarose gel that were cut out and sent for Sanger sequencing. As the splice site variant in the patient was expected to lead to skipping of exon 12, the boundaries between exons 11, 12 and 13 were shown. The second band confirms skipping of exon 12 that results in a shorter transcript of the mutated <italic>FBXW11</italic> allele. After CHX treatment, this band increased in size, indicating that the mutated allele undergoes nonsense mediated decay, but incomplete. Furthermore, a smaller transcript is formed in the patient, which is shown to contain part of exon 12, but not exon 13.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-fig2-figsupp1-v2.tif"/></fig></fig-group></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>We investigated the potential benefit of trio-based whole exome sequencing (WES) over routine single WES analysis in a retrospective cohort of 123 patients with suspected, sporadic inborn errors of immunity (IEI). Systematic analysis of <italic>de novo</italic> SNVs and small insertion-deletions (indels) led to the identification of 14 candidate <italic>de novo</italic> variants (DNVs), of which two were in known IEI genes and classified as pathogenic (<italic>NLRP3, RELA</italic>). Of the 12 variants in potentially novel candidate genes for IEI, four were considered to be most likely pathogenic (<italic>PSMB10, DDX1, KMT2C, FBXW11</italic>) based on gene and variant level metrics. Additionally, we have provided functional evidence that the <italic>FBXW11</italic> splice site DNV led to skipping of exon 12 resulting in the transcription of an altered protein product and subsequent downstream activation of NF-κB signalling with higher IL-1β production capacity.</p><p>We have performed a systematic DNV analysis in patients with a suspected, sporadic IEI. On average, these patients carried 1.4 DNVs in coding regions, a rate comparable to other, larger studies, indicating that DNV enrichment or depletion in IEI patients is unlikely (<xref ref-type="bibr" rid="bib38">Kaplanis et al., 2020</xref>). Based on gene and variant level information, 14 DNVs (11.4%) were considered potential disease-causing candidates. Six of the candidate DNVs (4.9%) were considered likely or possibly pathogenic variants, while the consequence of the other eight DNVs (6.5%) was uncertain.</p><p>Two DNVs were in IEI genes (<italic>NLRP3, RELA</italic>) listed in the most recent IUIS classification and were classified as pathogenic (<xref ref-type="bibr" rid="bib65">Richards et al., 2015</xref>; <xref ref-type="bibr" rid="bib82">Wallis et al., 2013</xref>; <xref ref-type="bibr" rid="bib74">Tangye et al., 2020</xref>). The heterozygous <italic>NLRP3</italic> variant in patient 59 (p.Thr350Met) with Muckle-Wells syndrome had been reported in patients with a similar phenotype (<xref ref-type="bibr" rid="bib24">Dodé et al., 2002</xref>; <xref ref-type="bibr" rid="bib35">Jiménez-Treviño et al., 2013</xref>). Moreover, the canonical splice site DNV affecting <italic>RELA</italic> in patient 119 with mucocutaneous ulceration was predicted to lead to a loss of the splice acceptor site and a subsequent frameshift. Heterozygous loss-of-function (LoF) mutations causing RelA haploinsufficiency have been reported as a cause of chronic mucocutaneous ulceration and familial Behçet’s disease (<xref ref-type="bibr" rid="bib6">Badran et al., 2017</xref>; <xref ref-type="bibr" rid="bib2">Adeeb et al., 2021</xref>). Badran <italic>et al.</italic> reported a family of four affected family members with mucocutaneous ulceration harbouring a mutation in the canonical donor splice site of exon 6 (NM_021975:c.559+1 G&gt;A), likely leading to a premature stop codon and haploinsufficiency (<xref ref-type="bibr" rid="bib6">Badran et al., 2017</xref>). The DNV in <italic>RELA</italic> was not picked up in our diagnostic <italic>in silico</italic> IEI gene panel (<xref ref-type="bibr" rid="bib64">Radboudumc, 2021</xref>), because evidence was considered insufficient at the time. Based on the matching phenotype and similar mutational mechanism this DNV has now been classified as pathogenic, which could potentially carry implications for therapy with anti-tumour necrosis factor alpha (TNFα) inhibitors (<xref ref-type="bibr" rid="bib2">Adeeb et al., 2021</xref>).</p><p>Moreover, DNVs in the potentially novel IEI genes <italic>PSMB10</italic>, <italic>DDX1</italic>, <italic>KMT2C,</italic> and <italic>FBXW11</italic> were considered the most promising candidate DNVs based on the predicted variant effect and immunological function of the respective gene. The private missense DNV in <italic>PSMB10</italic> was found in a patient with clinically diagnosed Omenn syndrome and showed high scores for pathogenicity. The presumed deleterious effect was further supported by the extremely rare occurrence of revertant mosaicism in this patient (unpublished data), that is<italic>,</italic> somatic and recurrent uniparental disomy 16q overlapping the <italic>PSMB10</italic> locus, suggesting a strong (cellular) effect of this variant. A homozygous missense variant in <italic>PSMB10</italic> has been shown previously in a 3-year-old Algerian female with autoinflammatory signs suggestive of proteasome-associated autoinflammatory syndrome (PRAAS), leading to disturbed formation of the 20S proteasome (<xref ref-type="bibr" rid="bib67">Sarrabay et al., 2020</xref>). In addition, it has been shown in mice that another homozygous <italic>PSMB10</italic> variant (p.Gly170Trp) could induce severe combined immunodeficiency (SCID) and systemic autoinflammation, while heterozygous mice only had a T cell defect (<xref ref-type="bibr" rid="bib75">Treise et al., 2018</xref>). PRAAS is predominantly caused by autosomal recessive or digenic heterozygous mutations in proteasome subunit genes or their chaperone proteins, although heterozygous (<italic>de novo</italic>) mutations have also been shown to underlie PRAAS (<xref ref-type="bibr" rid="bib67">Sarrabay et al., 2020</xref>; <xref ref-type="bibr" rid="bib3">Agarwal et al., 2010</xref>; <xref ref-type="bibr" rid="bib13">Brehm et al., 2015</xref>). A <italic>de novo</italic> missense variant in the b1i-subunit <italic>PSMB9</italic> (NM_002800; c.467 G&gt;A; p.G156D) was found in three unrelated infants with a type I interferonopathy with immunodeficiency (PRAAS-ID). This variant resulted in impaired maturation and activity of the immunoproteasome in patient-derived B lymphoblastoid cell lines (<xref ref-type="bibr" rid="bib37">Kanazawa et al., 2021</xref>; <xref ref-type="bibr" rid="bib40">Kataoka et al., 2021</xref>), a phenotype that was mirrored in mice (<xref ref-type="bibr" rid="bib37">Kanazawa et al., 2021</xref>). It is interesting to consider that the <italic>PSMB10</italic> DNV could act through a similar autosomal dominant mutational mechanism by affecting the formation of the immunoproteasome, as has been shown in mice harbouring a mutation affecting an amino acid in close proximity to the identified DNV in the patient (<xref ref-type="bibr" rid="bib75">Treise et al., 2018</xref>). However, the functional consequence and pathogenic relevance of the candidate DNV in <italic>PSMB10</italic> remain to be confirmed.</p><p>In addition, a <italic>de novo</italic> frameshift variant in the highly intolerant <italic>DDX1</italic> (pLI 0.994) was identified in a patient with hypogammaglobulinemia, hematopoietic cell lineage abnormalities and recurrent infections. Although DDX1 plays a role in NF-κB signalling, type I interferon responses and the regulation of hematopoietic stem and progenitor cell homeostasis (<xref ref-type="bibr" rid="bib89">Zhang et al., 2011</xref>; <xref ref-type="bibr" rid="bib84">Wang et al., 2021</xref>), a causal genotype-phenotype relationship remains unclear. Furthermore, the <italic>de novo</italic> frameshift variant in <italic>KMT2C</italic> was detected in a patient with combined immunodeficiency and a neurodevelopmental phenotype, displaying partial phenotypic overlap with Kleefstra syndrome type 2 that has already been associated with <italic>de novo</italic> LoF mutations in <italic>KMT2C</italic> (<xref ref-type="bibr" rid="bib44">Koemans et al., 2017</xref>). Two of the six individuals described by Koemans <italic>et al.</italic> were reported to have recurrent respiratory infections (<xref ref-type="bibr" rid="bib44">Koemans et al., 2017</xref>). The occurrence of immunological symptoms in patients with mutations in chromatin-regulating genes is increasingly being recognised in the field of intellectual disability (ID) (<xref ref-type="bibr" rid="bib26">Ehrlich et al., 2008</xref>; <xref ref-type="bibr" rid="bib28">Hoffman et al., 2005</xref>). Therefore, more in-depth characterisation of patients with <italic>KMT2C</italic> mutations and predominant ID phenotypes might indicate (mild) immunological phenotypes that overlap with the phenotype of our patient, in support of pathogenicity of the observed DNV.</p><p>Another candidate DNV in a potentially novel IEI gene was identified in the highly conserved <italic>FBXW11</italic> (pLI 0.976). This DNV affected the canonical splice acceptor site preceding exon 12 and was shown to create a splice defect leading to exon skipping with a shortened transcript that retained expression at the RNA level. Exon 12 encodes component 7 of the WD40 repeat domain (WD7), which is involved in substrate recognition (<xref ref-type="bibr" rid="bib70">Skaar et al., 2013</xref>). <italic>De novo</italic> missense and nonsense variants in <italic>FBXW11</italic> have been previously described in patients with a neurodevelopmental syndrome with abnormalities of the digits, jaw and eyes (<xref ref-type="bibr" rid="bib30">Holt et al., 2019</xref>). These variants were located in WD1, WD4, and WD6 and have been shown to compromise substrate recognition or binding of the Wnt and Hedgehog signalling developmental pathways. We hypothesised a specific functional effect on NF-κB signalling in our patient with a distinct autoinflammatory phenotype. In peripheral blood mononuclear cells (PBMC) extracted from the patient, we demonstrated that the phosphorylation of the NF-κB subunit p65 was constitutively higher in monocytes and CD8+ T cells as compared to a healthy control, which suggests a functional effect of the <italic>FBXW11</italic> variant. This effect is further substantiated by the observation of increased p65 phosphorylation and downstream production of IL-1β after stimulation with pathogens and a TLR3 ligand in the patient. However, a note of caution should be made regarding n=1 studies, as we cannot exclude that the difference is due to normal inter-individual biological variability. These results suggest that NF-κB signalling was aberrantly increased in the patient, a mechanism that has been shown to be involved in the pathogenesis of other monogenic autoinflammatory disorders known as relopathies (<xref ref-type="bibr" rid="bib77">van der Made et al., 2020</xref>). However, the exact mutational mechanism that explains the different phenotype compared to the previous cases with neurodevelopmental disease remains unclear. The most likely explanation would be a differential effect on the specific functions of the SCF complex that could be cell-type dependent rather than a difference in tissue-specific isoform expression, since the DNV affects all three high quality protein-coding transcripts that produce the most abundant isoforms (<xref ref-type="bibr" rid="bib18">Consortium, 2020</xref>). Further experiments addressing the effect of this DNV on IκBα degradation, substrate recognition and TrCP protein abundance should be undertaken to provide conclusive evidence.</p><p>To our knowledge, two other cohort studies have systematically performed trio-based sequencing in IEI patients as part of their study design, although patients were not pre-selected based on sporadic phenotypes (<xref ref-type="bibr" rid="bib73">Stray-Pedersen et al., 2017</xref>; <xref ref-type="bibr" rid="bib69">Simon et al., 2020</xref>). Stray-Pedersen <italic>et al.</italic> conducted a large international cohort study to investigate the benefit of WES in IEI patients from 278 families, which included 39 patient-parent trios (<xref ref-type="bibr" rid="bib73">Stray-Pedersen et al., 2017</xref>). The authors reported a molecular diagnosis in 40% of the patients, including 15 (13.6%) <italic>de novo</italic> mutations, of which 4 were identified by trio-based analysis and 11 after segregation analysis. The additional value of trio-based sequencing is indicated by the higher detection rate compared to that of the single cases followed by segregation analysis of candidate variants (44 vs 36%), as well as the discovery of potentially novel IEI genes or expansion of the immunological phenotype. Furthermore, Simon <italic>et al.</italic> performed WES in a cohort of 106 IEI patients with a consanguineous background, including 26 patient-parent trios (<xref ref-type="bibr" rid="bib69">Simon et al., 2020</xref>). A molecular diagnosis was established in 70% of the patients, including 13 (17.6%) <italic>de novo</italic> mutations, although it is unclear whether these variants were identified through trio-based sequencing or the segregation analysis that was performed for each variant. The authors conclude that trio-based sequencing does not lead to additional diagnostic benefit, although it should be argued that this is also not expected in a cohort of predominantly consanguineous patients (62.2%) with a higher <italic>a priori</italic> chance of autosomal recessive (AR) disease.</p><p>Multiple studies have highlighted the potential benefits of routine trio-based sequencing in IEI patients over single WES (<xref ref-type="bibr" rid="bib57">Meyts et al., 2016</xref>; <xref ref-type="bibr" rid="bib5">Arts et al., 2019</xref>; <xref ref-type="bibr" rid="bib81">Vorsteveld et al., 2021</xref>; <xref ref-type="bibr" rid="bib17">Chinn et al., 2020</xref>). These advantages apply mostly to patients with sporadic, severe phenotypes in particular, as has been shown for other rare diseases such as neurodevelopmental disorders (<xref ref-type="bibr" rid="bib38">Kaplanis et al., 2020</xref>). Trio-based sequencing constitutes an unbiased way to identify rare, coding DNVs that are by definition strong candidate variants. It could therefore improve candidate variant prioritisation both during <italic>in silico</italic> gene panel analysis as part of routine diagnostics, as well as for research-based exome-wide analysis. Furthermore, targeted DNV analysis could improve the detection of somatic variants, which is especially relevant in the field of monogenic autoinflammatory disorders (<xref ref-type="bibr" rid="bib78">van der Made et al., 2022</xref>). Somatic variants can be successfully identified by trio-based WES (<xref ref-type="bibr" rid="bib21">de Koning et al., 2015</xref>). However, this specific DNV subtype can be missed during routine analysis especially if the variant allele fraction (VAF) is below the set threshold during standard variant filtering, which is not required to filter out false-positive variants for a condensed set of potential DNVs. In this study, no candidate DNVs with a VAF below the set threshold of 20% were found in established IEI genes. Another advantage of trio-based sequencing is that it provides direct segregation of inherited variants and enables determination of autosomal recessive compound heterozygosity or X-linked recessive disease as the causative disease mechanism.</p><p>Based on the results of this study as well as evidence from other studies including those from other rare disease fields, we suggest that trio-based sequencing should be part of the routine evaluation of patients with a sporadic IEI phenotype (<xref ref-type="box" rid="box1">Box 1</xref>). An exome-wide analysis should be conducted to identify potentially novel disease genes in cases with a negative diagnostic WES result in whom a strong clinical suspicion for an underlying monogenic cause remains. Thus far, the relative proportion of DNVs among IEI patients with a genetic diagnosis, estimated to be around 6–14%, seems modest compared to other rare disease fields (i.e. &gt;80% in neurodevelopmental disorders (NDDs)) (<xref ref-type="bibr" rid="bib15">Brunet et al., 2021</xref>). There are several explanations for this difference that suggest that the true contribution of DNVs is higher than currently appreciated. Most importantly, much more experience has been gained with DNV assessment in the field of NDDs. Despite a steep increase in the total diagnostic rate (<xref ref-type="bibr" rid="bib80">Vissers et al., 2010</xref>; <xref ref-type="bibr" rid="bib22">de Ligt et al., 2012</xref>; <xref ref-type="bibr" rid="bib19">Deciphering Developmental Disorders Study, 2017</xref>) and the identification of 285 developmental disorder (DD)-associated DNVs, modelling suggests that more than 1000 DD-associated genes still remain to be discovered (<xref ref-type="bibr" rid="bib38">Kaplanis et al., 2020</xref>). As more trio-based sequencing data will be generated from suspected IEI patients, the field should undertake larger-scale analyses that leverage existing statistical models from the field of NDDs/DDs, including models for gene/exon level enrichment and the identification of gain-of-function nucleotide clusters (<xref ref-type="bibr" rid="bib38">Kaplanis et al., 2020</xref>). Moreover, there is still a bias towards AR disease genes in the IEI field, while this imbalance is shifting with the discovery of an increasing number of autosomal dominant (AD) disease genes (<xref ref-type="bibr" rid="bib77">van der Made et al., 2020</xref>). Trio-based sequencing could accelerate the discovery of mutations in novel AD IEI genes.</p><boxed-text id="box1"><label>Box 1.</label><p>Proposed indications for trio-based sequencing in patients with inborn errors of immunity.</p><list list-type="order"><list-item><p>Clinical features with a high <italic>a priori</italic> chance for a causative pre- or post-zygotic <italic>de novo</italic> variant (DNV)</p><list list-type="alpha-lower"><list-item><p>Sporadic and ultra-rare</p></list-item><list-item><p>Early-onset (infancy/childhood)</p></list-item><list-item><p>Severe symptoms, often involving organs other than the immune system</p></list-item></list></list-item><list-item><p>Clinical features with a high <italic>a priori</italic> chance for a causative somatic DNV acquired during life</p><list list-type="alpha-lower"><list-item><p>Late-onset (adolescence/adulthood)</p></list-item><list-item><p>Severe symptoms, often involving signs of autoinflammation, immune dysregulation and/or bone marrow abnormalities</p></list-item><list-item><p>Evidence for immune cell- or bone marrow lineage-specific dysfunction (i.e. myeloid cells [<xref ref-type="bibr" rid="bib9">Beck et al., 2020</xref>], lymphoid cells [<xref ref-type="bibr" rid="bib86">Wolach et al., 2005</xref>])</p></list-item></list></list-item></list></boxed-text><p>Inborn errors of immunity constitute a large group of heterogeneous disorders with differences in the expected contribution of DNVs. The <italic>a priori</italic> probability for the identification of a DNV will be highest in patients with early-onset, severe phenotypes, such as the combined immunodeficiencies (CID), especially CIDs with syndromic features, and patients with autoinflammatory syndromes and/or immune dysregulation with autoimmunity (<xref ref-type="box" rid="box1">Box 1</xref>). Although most of the reported genes underlying CIDs follow AR inheritance patterns, many genes following AD and X-linked (dominant) inheritance patterns have been described in recent years (<xref ref-type="bibr" rid="bib74">Tangye et al., 2020</xref>). The genes affected in these disorders possess high intolerance for loss-of-function mutations and essential biological functions. As expected, the DNVs in this category reported to date act through mechanisms of haploinsufficiency (i.e<italic>. RELA</italic>, pLI 0.999), dominant-negative interference (i.e<italic>. IKZF1</italic>, pLI 0.999 <xref ref-type="bibr" rid="bib47">Kuehn et al., 2016</xref>; <italic>STAT3</italic>, pLI 1.000 <xref ref-type="bibr" rid="bib29">Holland et al., 2007</xref>) or complete deficiency in hemizygotic males (i.e<italic>. WAS</italic>, pLI 0.999 <xref ref-type="bibr" rid="bib32">Howard et al., 2016</xref>; <italic>IL2RG</italic>, pLI 0.992 <xref ref-type="bibr" rid="bib59">Moya-Quiles et al., 2014</xref>). Some heterozygous DNVs can also cause CID through hypermorphic effects at protein level (i.e<italic>. RAC2</italic>, pLI 0.966 <xref ref-type="bibr" rid="bib33">Hsu et al., 2019</xref>). Trio-based sequencing should also be considered in patients with sporadic autoinflammatory syndromes and/or autoimmunity, even when presenting at an adult age that could suggest somatic <italic>de novo</italic> mutations. In these patients, various pathogenic DNVs in different genes have already been described, originating both from the germline (<italic>PLCG2, STAT1</italic>) and soma (i.e. <italic>NLRP3, UBA1, TLR8</italic>) (<xref ref-type="bibr" rid="bib52">Liu et al., 2011</xref>; <xref ref-type="bibr" rid="bib56">Mensa-Vilaro et al., 2016</xref>; <xref ref-type="bibr" rid="bib4">Aluri et al., 2021</xref>; <xref ref-type="bibr" rid="bib9">Beck et al., 2020</xref>; <xref ref-type="bibr" rid="bib78">van der Made et al., 2022</xref>; <xref ref-type="bibr" rid="bib90">Zhou et al., 2012</xref>). These genes do not necessarily have high constraint for LoF mutations, but they possess nucleotide clusters that are highly conserved and intolerant to variation, encoding protein domains with important regulatory functions.</p><p>This explorative study has a number of limitations. First, the sample size precludes a reliable estimation of the prevalence of DNVs among patients with sporadic IEIs. Furthermore, the strict diagnostic rate of both inherited variants and (likely) pathogenic DNVs in our cohort is limited compared to other studies. It has been previously reported that the diagnostic yield of WES for IEI patients varies widely from 10 to 79% (<xref ref-type="bibr" rid="bib81">Vorsteveld et al., 2021</xref>). This study reports (likely) pathogenic variants in 22 cases (17.9%), of which 10 (8.1%) received a definitive molecular diagnosis for their immunological phenotype. In addition to inherent technical shortcomings of WES, including uneven coverage of coding regions and GC bias and also the inability to explore the non-coding space (<xref ref-type="bibr" rid="bib57">Meyts et al., 2016</xref>), the most likely explanation for a relatively low diagnostic yield in our study is the patient selection and the primary focus on DNVs, which constitute only a fraction of disease-causing variants. We excluded patients with suspected inherited disease but chose not to apply any other selection criteria in order to study a representative cross-section of suspected IEI patients in our centre in whom WES was performed. As a result, patients were included even if the <italic>a priori</italic> chance of an IEI was limited but to be ruled out in the differential diagnosis (i.e. new-born screening shows low T cell receptor excision circles (TRECs)). Moreover, compared to other cohorts, the percentage of patients with syndromal CIDs, autoinflammatory syndromes and immune dysregulation was relatively high and could influence the generalisability of our results. Lastly, the functional effect of most candidate DNVs were not evaluated. As DNVs have a high chance of being deleterious, functional experiments should always be attempted to validate the predicted effect. The candidate DNVs in potentially novel IEI genes were shared on GeneMatcher in order to find similar cases that could motivate further investigation into the underlying mechanisms (<xref ref-type="bibr" rid="bib1">Acuna-Hidalgo et al., 2016</xref>; <xref ref-type="bibr" rid="bib71">Sobreira et al., 2015</xref>).</p><p>In conclusion, we applied trio-based WES in a retrospective cohort of 123 patients with suspected, sporadic IEI, leading to the identification of 14 DNVs with a possible or likely chance of pathogenicity. Amongst the candidate DNVs in potentially novel IEI genes, additional functional evidence was provided in support of a pathogenic role for the DNV in <italic>FBXW11</italic> in a patient with an autoinflammatory phenotype. We advocate the structural implementation of trio-based sequencing in the diagnostic evaluation of patients with sporadic IEI. With decreasing costs of exome sequencing, this approach could improve the diagnostic rate of IEI and advance IEI gene discovery.</p></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>Reviewing editor, <italic>eLife</italic></p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Resources, Formal analysis, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Resources, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Resources, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Supervision, Funding acquisition, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Resources, Formal analysis, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Supervision, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con20"><p>Conceptualization, Data curation, Formal analysis, Supervision, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Patients and their parents provided written informed consent for <italic>in silico</italic> inborn errors of immunity whole exome sequencing gene panel analysis with or without exome-wide variant analysis in line with the diagnostic procedure and clinical question, as approved by the Medical Ethics Review Committee Arnhem-Nijmegen (2011/188 and 2020-7142). This research is in compliance with the principles of the Declaration of Helsinki.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media xlink:href="elife-78469-transrepform1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The code used to filter DNA sequencing data for candidate <italic>de novo</italic> mutations (DNMs) and to generate output files is provided in Figure 1—source code 1. Source data linked to Figure 1—figure supplement 1 is provided as an additional, numerical data file. Source data for candidate DNM evaluation is provided in Figure 1—source data 2. Source data linked to Figure 2—figure supplement 1A is an uncropped, raw gel image used to create this figure. Source data linked to Figure 2B–D is provided as an additional, numerical data file. Raw DNA sequencing data of patients are not publicly available as it is confidential human subject data that would compromise anonymity. Researchers that are interested to access the sequencing data of our cohort are advised to contact the corresponding author, A Hoischen (alexander.hoischen@radboudumc.nl). Anonymized subject data will be shared on request from qualified investigators for the purposes of replicating procedures and results, and for other non-commercial research purposes within the limits of participants' consent. Any data sharing will also require evaluation of the request by the regional Arnhem and Nijmegen Ethics Committee and the signature of a data transfer agreement (DTA).</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank the Bioinformatics group of the Genome Diagnostics division of the department of Human Genetics and the Radboud Genomics Technology Center of the Radboud University Medical Center for the sharing, annotation and pseudonymisation of whole exome sequencing datasets of patients and their parents included in this study. Furthermore, we acknowledge all members of the multidisciplinary immunogenetics sign-out meeting of the University Medical Centers from Nijmegen and Maastricht. The authors also acknowledge support from several funding parties. MG Netea was supported by an ERC Advanced Grant (No. 833247) and a Spinoza Grant of the Netherlands Organization for Scientific Support. This research was also part of a Radboud Institute for Molecular Life Sciences PhD grant (to M G Netea). F L van de Veerdonk was supported by a ZonMW Vidi grant and HDM-FUN EU H2020. A Hoischen was supported by the Solve-RD project of the European Union’s Horizon 2020 research and innovation programme (No. 779257). Funding This research was supported by grants from the European Union, ZonMW and the Radboud Institute for Molecular Life Sciences.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acuna-Hidalgo</surname><given-names>R</given-names></name><name><surname>Veltman</surname><given-names>JA</given-names></name><name><surname>Hoischen</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>New insights into the generation and role of <italic>de novo</italic> mutations in health and disease</article-title><source>Genome Biology</source><volume>17</volume><elocation-id>241</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-016-1110-1</pub-id><pub-id pub-id-type="pmid">27894357</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adeeb</surname><given-names>F</given-names></name><name><surname>Dorris</surname><given-names>ER</given-names></name><name><surname>Morgan</surname><given-names>NE</given-names></name><name><surname>Lawless</surname><given-names>D</given-names></name><name><surname>Maqsood</surname><given-names>A</given-names></name><name><surname>Ng</surname><given-names>WL</given-names></name><name><surname>Killeen</surname><given-names>O</given-names></name><name><surname>Cummins</surname><given-names>EP</given-names></name><name><surname>Taylor</surname><given-names>CT</given-names></name><name><surname>Savic</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>AG</given-names></name><name><surname>Fraser</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A novel rela truncating mutation in A familial behçet’s disease-like mucocutaneous ulcerative condition</article-title><source>Arthritis &amp; Rheumatology</source><volume>73</volume><fpage>490</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1002/art.41531</pub-id><pub-id pub-id-type="pmid">32969189</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>AK</given-names></name><name><surname>Xing</surname><given-names>C</given-names></name><name><surname>DeMartino</surname><given-names>GN</given-names></name><name><surname>Mizrachi</surname><given-names>D</given-names></name><name><surname>Hernandez</surname><given-names>MD</given-names></name><name><surname>Sousa</surname><given-names>AB</given-names></name><name><surname>Martínez de Villarreal</surname><given-names>L</given-names></name><name><surname>dos Santos</surname><given-names>HG</given-names></name><name><surname>Garg</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PSMB8 encoding the β5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome</article-title><source>American Journal of Human Genetics</source><volume>87</volume><fpage>866</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2010.10.031</pub-id><pub-id pub-id-type="pmid">21129723</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aluri</surname><given-names>J</given-names></name><name><surname>Bach</surname><given-names>A</given-names></name><name><surname>Kaviany</surname><given-names>S</given-names></name><name><surname>Chiquetto Paracatu</surname><given-names>L</given-names></name><name><surname>Kitcharoensakkul</surname><given-names>M</given-names></name><name><surname>Walkiewicz</surname><given-names>MA</given-names></name><name><surname>Putnam</surname><given-names>CD</given-names></name><name><surname>Shinawi</surname><given-names>M</given-names></name><name><surname>Saucier</surname><given-names>N</given-names></name><name><surname>Rizzi</surname><given-names>EM</given-names></name><name><surname>Harmon</surname><given-names>MT</given-names></name><name><surname>Keppel</surname><given-names>MP</given-names></name><name><surname>Ritter</surname><given-names>M</given-names></name><name><surname>Similuk</surname><given-names>M</given-names></name><name><surname>Kulm</surname><given-names>E</given-names></name><name><surname>Joyce</surname><given-names>M</given-names></name><name><surname>de Jesus</surname><given-names>AA</given-names></name><name><surname>Goldbach-Mansky</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Cella</surname><given-names>M</given-names></name><name><surname>Kendall</surname><given-names>PL</given-names></name><name><surname>Dinauer</surname><given-names>MC</given-names></name><name><surname>Bednarski</surname><given-names>JJ</given-names></name><name><surname>Bemrich-Stolz</surname><given-names>C</given-names></name><name><surname>Canna</surname><given-names>SW</given-names></name><name><surname>Abraham</surname><given-names>SM</given-names></name><name><surname>Demczko</surname><given-names>MM</given-names></name><name><surname>Powell</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>SM</given-names></name><name><surname>Scurlock</surname><given-names>AM</given-names></name><name><surname>De Ravin</surname><given-names>SS</given-names></name><name><surname>Bleesing</surname><given-names>JJ</given-names></name><name><surname>Connelly</surname><given-names>JA</given-names></name><name><surname>Rao</surname><given-names>VK</given-names></name><name><surname>Schuettpelz</surname><given-names>LG</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain of function</article-title><source>Blood</source><volume>137</volume><fpage>2450</fpage><lpage>2462</lpage><pub-id pub-id-type="doi">10.1182/blood.2020009620</pub-id><pub-id pub-id-type="pmid">33512449</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arts</surname><given-names>P</given-names></name><name><surname>Simons</surname><given-names>A</given-names></name><name><surname>AlZahrani</surname><given-names>MS</given-names></name><name><surname>Yilmaz</surname><given-names>E</given-names></name><name><surname>AlIdrissi</surname><given-names>E</given-names></name><name><surname>van Aerde</surname><given-names>KJ</given-names></name><name><surname>Alenezi</surname><given-names>N</given-names></name><name><surname>AlGhamdi</surname><given-names>HA</given-names></name><name><surname>AlJubab</surname><given-names>HA</given-names></name><name><surname>Al-Hussaini</surname><given-names>AA</given-names></name><name><surname>AlManjomi</surname><given-names>F</given-names></name><name><surname>Alsaad</surname><given-names>AB</given-names></name><name><surname>Alsaleem</surname><given-names>B</given-names></name><name><surname>Andijani</surname><given-names>AA</given-names></name><name><surname>Asery</surname><given-names>A</given-names></name><name><surname>Ballourah</surname><given-names>W</given-names></name><name><surname>Bleeker-Rovers</surname><given-names>CP</given-names></name><name><surname>van Deuren</surname><given-names>M</given-names></name><name><surname>van der Flier</surname><given-names>M</given-names></name><name><surname>Gerkes</surname><given-names>EH</given-names></name><name><surname>Gilissen</surname><given-names>C</given-names></name><name><surname>Habazi</surname><given-names>MK</given-names></name><name><surname>Hehir-Kwa</surname><given-names>JY</given-names></name><name><surname>Henriet</surname><given-names>SS</given-names></name><name><surname>Hoppenreijs</surname><given-names>EP</given-names></name><name><surname>Hortillosa</surname><given-names>S</given-names></name><name><surname>Kerkhofs</surname><given-names>CH</given-names></name><name><surname>Keski-Filppula</surname><given-names>R</given-names></name><name><surname>Lelieveld</surname><given-names>SH</given-names></name><name><surname>Lone</surname><given-names>K</given-names></name><name><surname>MacKenzie</surname><given-names>MA</given-names></name><name><surname>Mensenkamp</surname><given-names>AR</given-names></name><name><surname>Moilanen</surname><given-names>J</given-names></name><name><surname>Nelen</surname><given-names>M</given-names></name><name><surname>Ten Oever</surname><given-names>J</given-names></name><name><surname>Potjewijd</surname><given-names>J</given-names></name><name><surname>van Paassen</surname><given-names>P</given-names></name><name><surname>Schuurs-Hoeijmakers</surname><given-names>JHM</given-names></name><name><surname>Simon</surname><given-names>A</given-names></name><name><surname>Stokowy</surname><given-names>T</given-names></name><name><surname>van de Vorst</surname><given-names>M</given-names></name><name><surname>Vreeburg</surname><given-names>M</given-names></name><name><surname>Wagner</surname><given-names>A</given-names></name><name><surname>van Well</surname><given-names>GTJ</given-names></name><name><surname>Zafeiropoulou</surname><given-names>D</given-names></name><name><surname>Zonneveld-Huijssoon</surname><given-names>E</given-names></name><name><surname>Veltman</surname><given-names>JA</given-names></name><name><surname>van Zelst-Stams</surname><given-names>WAG</given-names></name><name><surname>Faqeih</surname><given-names>EA</given-names></name><name><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Hoischen</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Exome sequencing in routine diagnostics: a generic test for 254 patients with primary immunodeficiencies</article-title><source>Genome Medicine</source><volume>11</volume><elocation-id>38</elocation-id><pub-id pub-id-type="doi">10.1186/s13073-019-0649-3</pub-id><pub-id pub-id-type="pmid">31203817</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badran</surname><given-names>YR</given-names></name><name><surname>Dedeoglu</surname><given-names>F</given-names></name><name><surname>Leyva Castillo</surname><given-names>JM</given-names></name><name><surname>Bainter</surname><given-names>W</given-names></name><name><surname>Ohsumi</surname><given-names>TK</given-names></name><name><surname>Bousvaros</surname><given-names>A</given-names></name><name><surname>Goldsmith</surname><given-names>JD</given-names></name><name><surname>Geha</surname><given-names>RS</given-names></name><name><surname>Chou</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Human rela haploinsufficiency results in autosomal-dominant chronic mucocutaneous ulceration</article-title><source>The Journal of Experimental Medicine</source><volume>214</volume><fpage>1937</fpage><lpage>1947</lpage><pub-id pub-id-type="doi">10.1084/jem.20160724</pub-id><pub-id pub-id-type="pmid">28600438</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barreda</surname><given-names>D</given-names></name><name><surname>Gutiérrez-González</surname><given-names>LH</given-names></name><name><surname>Martínez-Cordero</surname><given-names>E</given-names></name><name><surname>Cabello-Gutiérrez</surname><given-names>C</given-names></name><name><surname>Chacón-Salinas</surname><given-names>R</given-names></name><name><surname>Santos-Mendoza</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The scribble complex PDZ proteins in immune cell polarities</article-title><source>Journal of Immunology Research</source><volume>2020</volume><elocation-id>5649790</elocation-id><pub-id pub-id-type="doi">10.1155/2020/5649790</pub-id><pub-id pub-id-type="pmid">32411799</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrie</surname><given-names>ES</given-names></name><name><surname>Alfaro</surname><given-names>MP</given-names></name><name><surname>Pfau</surname><given-names>RB</given-names></name><name><surname>Goff</surname><given-names>MJ</given-names></name><name><surname>McBride</surname><given-names>KL</given-names></name><name><surname>Manickam</surname><given-names>K</given-names></name><name><surname>Zmuda</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title><italic>De novo</italic> loss-of-function variants in NSD2 (WHSC1) associate with a subset of wolf-hirschhorn syndrome</article-title><source>Cold Spring Harbor Molecular Case Studies</source><volume>5</volume><elocation-id>a004044</elocation-id><pub-id pub-id-type="doi">10.1101/mcs.a004044</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>DB</given-names></name><name><surname>Ferrada</surname><given-names>MA</given-names></name><name><surname>Sikora</surname><given-names>KA</given-names></name><name><surname>Ombrello</surname><given-names>AK</given-names></name><name><surname>Collins</surname><given-names>JC</given-names></name><name><surname>Pei</surname><given-names>W</given-names></name><name><surname>Balanda</surname><given-names>N</given-names></name><name><surname>Ross</surname><given-names>DL</given-names></name><name><surname>Ospina Cardona</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Patel</surname><given-names>B</given-names></name><name><surname>Manthiram</surname><given-names>K</given-names></name><name><surname>Groarke</surname><given-names>EM</given-names></name><name><surname>Gutierrez-Rodrigues</surname><given-names>F</given-names></name><name><surname>Hoffmann</surname><given-names>P</given-names></name><name><surname>Rosenzweig</surname><given-names>S</given-names></name><name><surname>Nakabo</surname><given-names>S</given-names></name><name><surname>Dillon</surname><given-names>LW</given-names></name><name><surname>Hourigan</surname><given-names>CS</given-names></name><name><surname>Tsai</surname><given-names>WL</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Carmona-Rivera</surname><given-names>C</given-names></name><name><surname>Asmar</surname><given-names>AJ</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Oda</surname><given-names>H</given-names></name><name><surname>Goodspeed</surname><given-names>W</given-names></name><name><surname>Barron</surname><given-names>KS</given-names></name><name><surname>Nehrebecky</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>A</given-names></name><name><surname>Laird</surname><given-names>RS</given-names></name><name><surname>Deuitch</surname><given-names>N</given-names></name><name><surname>Rowczenio</surname><given-names>D</given-names></name><name><surname>Rominger</surname><given-names>E</given-names></name><name><surname>Wells</surname><given-names>KV</given-names></name><name><surname>Lee</surname><given-names>C-CR</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Trick</surname><given-names>M</given-names></name><name><surname>Mullikin</surname><given-names>J</given-names></name><name><surname>Wigerblad</surname><given-names>G</given-names></name><name><surname>Brooks</surname><given-names>S</given-names></name><name><surname>Dell’Orso</surname><given-names>S</given-names></name><name><surname>Deng</surname><given-names>Z</given-names></name><name><surname>Chae</surname><given-names>JJ</given-names></name><name><surname>Dulau-Florea</surname><given-names>A</given-names></name><name><surname>Malicdan</surname><given-names>MCV</given-names></name><name><surname>Novacic</surname><given-names>D</given-names></name><name><surname>Colbert</surname><given-names>RA</given-names></name><name><surname>Kaplan</surname><given-names>MJ</given-names></name><name><surname>Gadina</surname><given-names>M</given-names></name><name><surname>Savic</surname><given-names>S</given-names></name><name><surname>Lachmann</surname><given-names>HJ</given-names></name><name><surname>Abu-Asab</surname><given-names>M</given-names></name><name><surname>Solomon</surname><given-names>BD</given-names></name><name><surname>Retterer</surname><given-names>K</given-names></name><name><surname>Gahl</surname><given-names>WA</given-names></name><name><surname>Burgess</surname><given-names>SM</given-names></name><name><surname>Aksentijevich</surname><given-names>I</given-names></name><name><surname>Young</surname><given-names>NS</given-names></name><name><surname>Calvo</surname><given-names>KR</given-names></name><name><surname>Werner</surname><given-names>A</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name><name><surname>Grayson</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Somatic mutations in <italic>uba1</italic> and severe adult-onset autoinflammatory disease</article-title><source>The New England Journal of Medicine</source><volume>383</volume><fpage>2628</fpage><lpage>2638</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2026834</pub-id><pub-id pub-id-type="pmid">33108101</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boomsma</surname><given-names>DI</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Slagboom</surname><given-names>EP</given-names></name><name><surname>Swertz</surname><given-names>MA</given-names></name><name><surname>Karssen</surname><given-names>LC</given-names></name><name><surname>Abdellaoui</surname><given-names>A</given-names></name><name><surname>Ye</surname><given-names>K</given-names></name><name><surname>Guryev</surname><given-names>V</given-names></name><name><surname>Vermaat</surname><given-names>M</given-names></name><name><surname>van Dijk</surname><given-names>F</given-names></name><name><surname>Francioli</surname><given-names>LC</given-names></name><name><surname>Hottenga</surname><given-names>JJ</given-names></name><name><surname>Laros</surname><given-names>JFJ</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>van Setten</surname><given-names>J</given-names></name><name><surname>Menelaou</surname><given-names>A</given-names></name><name><surname>Pulit</surname><given-names>SL</given-names></name><name><surname>Hehir-Kwa</surname><given-names>JY</given-names></name><name><surname>Beekman</surname><given-names>M</given-names></name><name><surname>Elbers</surname><given-names>CC</given-names></name><name><surname>Byelas</surname><given-names>H</given-names></name><name><surname>de Craen</surname><given-names>AJM</given-names></name><name><surname>Deelen</surname><given-names>P</given-names></name><name><surname>Dijkstra</surname><given-names>M</given-names></name><name><surname>den Dunnen</surname><given-names>JT</given-names></name><name><surname>de Knijff</surname><given-names>P</given-names></name><name><surname>Houwing-Duistermaat</surname><given-names>J</given-names></name><name><surname>Koval</surname><given-names>V</given-names></name><name><surname>Estrada</surname><given-names>K</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Kanterakis</surname><given-names>A</given-names></name><name><surname>Enckevort</surname><given-names>DV</given-names></name><name><surname>Mai</surname><given-names>H</given-names></name><name><surname>Kattenberg</surname><given-names>M</given-names></name><name><surname>van Leeuwen</surname><given-names>EM</given-names></name><name><surname>Neerincx</surname><given-names>PBT</given-names></name><name><surname>Oostra</surname><given-names>B</given-names></name><name><surname>Rivadeneira</surname><given-names>F</given-names></name><name><surname>Suchiman</surname><given-names>EHD</given-names></name><name><surname>Uitterlinden</surname><given-names>AG</given-names></name><name><surname>Willemsen</surname><given-names>G</given-names></name><name><surname>Wolffenbuttel</surname><given-names>BH</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>de Bakker</surname><given-names>PIW</given-names></name><name><surname>van Ommen</surname><given-names>GJ</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The genome of the netherlands: design, and project goals</article-title><source>European Journal of Human Genetics</source><volume>22</volume><fpage>221</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2013.118</pub-id><pub-id pub-id-type="pmid">23714750</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousfiha</surname><given-names>A</given-names></name><name><surname>Jeddane</surname><given-names>L</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Al-Herz</surname><given-names>W</given-names></name><name><surname>Ailal</surname><given-names>F</given-names></name><name><surname>Chatila</surname><given-names>T</given-names></name><name><surname>Cunningham-Rundles</surname><given-names>C</given-names></name><name><surname>Etzioni</surname><given-names>A</given-names></name><name><surname>Franco</surname><given-names>JL</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>Morio</surname><given-names>T</given-names></name><name><surname>Ochs</surname><given-names>HD</given-names></name><name><surname>Oksenhendler</surname><given-names>E</given-names></name><name><surname>Puck</surname><given-names>J</given-names></name><name><surname>Torgerson</surname><given-names>TR</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name><name><surname>Sullivan</surname><given-names>KE</given-names></name><name><surname>Tangye</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification</article-title><source>Journal of Clinical Immunology</source><volume>40</volume><fpage>66</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1007/s10875-020-00758-x</pub-id><pub-id pub-id-type="pmid">32048120</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradshaw</surname><given-names>G</given-names></name><name><surname>Lualhati</surname><given-names>RR</given-names></name><name><surname>Albury</surname><given-names>CL</given-names></name><name><surname>Maksemous</surname><given-names>N</given-names></name><name><surname>Roos-Araujo</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>RA</given-names></name><name><surname>Benton</surname><given-names>MC</given-names></name><name><surname>Eccles</surname><given-names>DA</given-names></name><name><surname>Lea</surname><given-names>RA</given-names></name><name><surname>Sutherland</surname><given-names>HG</given-names></name><name><surname>Haupt</surname><given-names>LM</given-names></name><name><surname>Griffiths</surname><given-names>LR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Exome sequencing diagnoses X-linked moesin-associated immunodeficiency in a primary immunodeficiency case</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>420</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.00420</pub-id><pub-id pub-id-type="pmid">29556235</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brehm</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Sheikh</surname><given-names>A</given-names></name><name><surname>Marrero</surname><given-names>B</given-names></name><name><surname>Omoyinmi</surname><given-names>E</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Montealegre</surname><given-names>G</given-names></name><name><surname>Biancotto</surname><given-names>A</given-names></name><name><surname>Reinhardt</surname><given-names>A</given-names></name><name><surname>Almeida de Jesus</surname><given-names>A</given-names></name><name><surname>Pelletier</surname><given-names>M</given-names></name><name><surname>Tsai</surname><given-names>WL</given-names></name><name><surname>Remmers</surname><given-names>EF</given-names></name><name><surname>Kardava</surname><given-names>L</given-names></name><name><surname>Hill</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Lachmann</surname><given-names>HJ</given-names></name><name><surname>Megarbane</surname><given-names>A</given-names></name><name><surname>Chae</surname><given-names>JJ</given-names></name><name><surname>Brady</surname><given-names>J</given-names></name><name><surname>Castillo</surname><given-names>RD</given-names></name><name><surname>Brown</surname><given-names>D</given-names></name><name><surname>Casano</surname><given-names>AV</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Chapelle</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Stone</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Sotzny</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>CCR</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name><name><surname>Torrelo</surname><given-names>A</given-names></name><name><surname>Zlotogorski</surname><given-names>A</given-names></name><name><surname>Moir</surname><given-names>S</given-names></name><name><surname>Gadina</surname><given-names>M</given-names></name><name><surname>McCoy</surname><given-names>P</given-names></name><name><surname>Wesley</surname><given-names>R</given-names></name><name><surname>Rother</surname><given-names>KI</given-names></name><name><surname>Rother</surname><given-names>K</given-names></name><name><surname>Hildebrand</surname><given-names>PW</given-names></name><name><surname>Brogan</surname><given-names>P</given-names></name><name><surname>Krüger</surname><given-names>E</given-names></name><name><surname>Aksentijevich</surname><given-names>I</given-names></name><name><surname>Goldbach-Mansky</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production</article-title><source>The Journal of Clinical Investigation</source><volume>125</volume><fpage>4196</fpage><lpage>4211</lpage><pub-id pub-id-type="doi">10.1172/JCI81260</pub-id><pub-id pub-id-type="pmid">26524591</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>O</given-names></name><name><surname>Levanon</surname><given-names>D</given-names></name><name><surname>Negreanu</surname><given-names>V</given-names></name><name><surname>Golubkov</surname><given-names>O</given-names></name><name><surname>Fainaru</surname><given-names>O</given-names></name><name><surname>Woolf</surname><given-names>E</given-names></name><name><surname>Groner</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Loss of RUNX3 function in leukocytes is associated with spontaneously developed colitis and gastric mucosal hyperplasia</article-title><source>PNAS</source><volume>101</volume><fpage>16016</fpage><lpage>16021</lpage><pub-id pub-id-type="doi">10.1073/pnas.0407180101</pub-id><pub-id pub-id-type="pmid">15514019</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunet</surname><given-names>T</given-names></name><name><surname>Jech</surname><given-names>R</given-names></name><name><surname>Brugger</surname><given-names>M</given-names></name><name><surname>Kovacs</surname><given-names>R</given-names></name><name><surname>Alhaddad</surname><given-names>B</given-names></name><name><surname>Leszinski</surname><given-names>G</given-names></name><name><surname>Riedhammer</surname><given-names>KM</given-names></name><name><surname>Westphal</surname><given-names>DS</given-names></name><name><surname>Mahle</surname><given-names>I</given-names></name><name><surname>Mayerhanser</surname><given-names>K</given-names></name><name><surname>Skorvanek</surname><given-names>M</given-names></name><name><surname>Weber</surname><given-names>S</given-names></name><name><surname>Graf</surname><given-names>E</given-names></name><name><surname>Berutti</surname><given-names>R</given-names></name><name><surname>Necpál</surname><given-names>J</given-names></name><name><surname>Havránková</surname><given-names>P</given-names></name><name><surname>Pavelekova</surname><given-names>P</given-names></name><name><surname>Hempel</surname><given-names>M</given-names></name><name><surname>Kotzaeridou</surname><given-names>U</given-names></name><name><surname>Hoffmann</surname><given-names>GF</given-names></name><name><surname>Leiz</surname><given-names>S</given-names></name><name><surname>Makowski</surname><given-names>C</given-names></name><name><surname>Roser</surname><given-names>T</given-names></name><name><surname>Schroeder</surname><given-names>SA</given-names></name><name><surname>Steinfeld</surname><given-names>R</given-names></name><name><surname>Strobl-Wildemann</surname><given-names>G</given-names></name><name><surname>Hoefele</surname><given-names>J</given-names></name><name><surname>Borggraefe</surname><given-names>I</given-names></name><name><surname>Distelmaier</surname><given-names>F</given-names></name><name><surname>Strom</surname><given-names>TM</given-names></name><name><surname>Winkelmann</surname><given-names>J</given-names></name><name><surname>Meitinger</surname><given-names>T</given-names></name><name><surname>Zech</surname><given-names>M</given-names></name><name><surname>Wagner</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title><italic>De novo</italic> variants in neurodevelopmental disorders-experiences from a tertiary care center</article-title><source>Clinical Genetics</source><volume>100</volume><fpage>14</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1111/cge.13946</pub-id><pub-id pub-id-type="pmid">33619735</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Pi</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Ning</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>KCTD9 contributes to liver injury through NK cell activation during hepatitis B virus-induced acute-on-chronic liver failure</article-title><source>Clinical Immunology</source><volume>146</volume><fpage>207</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2012.12.013</pub-id><pub-id pub-id-type="pmid">23376586</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chinn</surname><given-names>IK</given-names></name><name><surname>Chan</surname><given-names>AY</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Chou</surname><given-names>J</given-names></name><name><surname>Dorsey</surname><given-names>MJ</given-names></name><name><surname>Hajjar</surname><given-names>J</given-names></name><name><surname>Jongco</surname><given-names>AM</given-names></name><name><surname>Keller</surname><given-names>MD</given-names></name><name><surname>Kobrynski</surname><given-names>LJ</given-names></name><name><surname>Kumanovics</surname><given-names>A</given-names></name><name><surname>Lawrence</surname><given-names>MG</given-names></name><name><surname>Leiding</surname><given-names>JW</given-names></name><name><surname>Lugar</surname><given-names>PL</given-names></name><name><surname>Orange</surname><given-names>JS</given-names></name><name><surname>Patel</surname><given-names>K</given-names></name><name><surname>Platt</surname><given-names>CD</given-names></name><name><surname>Puck</surname><given-names>JM</given-names></name><name><surname>Raje</surname><given-names>N</given-names></name><name><surname>Romberg</surname><given-names>N</given-names></name><name><surname>Slack</surname><given-names>MA</given-names></name><name><surname>Sullivan</surname><given-names>KE</given-names></name><name><surname>Tarrant</surname><given-names>TK</given-names></name><name><surname>Torgerson</surname><given-names>TR</given-names></name><name><surname>Walter</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Diagnostic interpretation of genetic studies in patients with primary immunodeficiency diseases: a working group report of the primary immunodeficiency diseases committee of the american academy of allergy, asthma &amp; immunology</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>145</volume><fpage>46</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2019.09.009</pub-id><pub-id pub-id-type="pmid">31568798</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Consortium</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The gtex consortium atlas of genetic regulatory effects across human tissues</article-title><source>Science</source><volume>369</volume><fpage>1318</fpage><lpage>1330</lpage><pub-id pub-id-type="doi">10.1126/science.aaz1776</pub-id><pub-id pub-id-type="pmid">32913098</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Deciphering Developmental Disorders Study</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Prevalence and architecture of <italic>de novo</italic> mutations in developmental disorders</article-title><source>Nature</source><volume>542</volume><fpage>433</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1038/nature21062</pub-id><pub-id pub-id-type="pmid">28135719</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Inocencio</surname><given-names>J</given-names></name><name><surname>Mensa-Vilaro</surname><given-names>A</given-names></name><name><surname>Tejada-Palacios</surname><given-names>P</given-names></name><name><surname>Enriquez-Merayo</surname><given-names>E</given-names></name><name><surname>González-Roca</surname><given-names>E</given-names></name><name><surname>Magri</surname><given-names>G</given-names></name><name><surname>Ruiz-Ortiz</surname><given-names>E</given-names></name><name><surname>Cerutti</surname><given-names>A</given-names></name><name><surname>Yagüe</surname><given-names>J</given-names></name><name><surname>Aróstegui</surname><given-names>JI</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Somatic NOD2 mosaicism in blau syndrome</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>136</volume><fpage>484</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2014.12.1941</pub-id><pub-id pub-id-type="pmid">25724124</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Koning</surname><given-names>HD</given-names></name><name><surname>van Gijn</surname><given-names>ME</given-names></name><name><surname>Stoffels</surname><given-names>M</given-names></name><name><surname>Jongekrijg</surname><given-names>J</given-names></name><name><surname>Zeeuwen</surname><given-names>P</given-names></name><name><surname>Elferink</surname><given-names>MG</given-names></name><name><surname>Nijman</surname><given-names>IJ</given-names></name><name><surname>Jansen</surname><given-names>PAM</given-names></name><name><surname>Neveling</surname><given-names>K</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Schalkwijk</surname><given-names>J</given-names></name><name><surname>Simon</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Myeloid lineage-restricted somatic mosaicism of NLRP3 mutations in patients with variant schnitzler syndrome</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>135</volume><fpage>561</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2014.07.050</pub-id><pub-id pub-id-type="pmid">25239704</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Ligt</surname><given-names>J</given-names></name><name><surname>Willemsen</surname><given-names>MH</given-names></name><name><surname>van Bon</surname><given-names>BWM</given-names></name><name><surname>Kleefstra</surname><given-names>T</given-names></name><name><surname>Yntema</surname><given-names>HG</given-names></name><name><surname>Kroes</surname><given-names>T</given-names></name><name><surname>Vulto-van Silfhout</surname><given-names>AT</given-names></name><name><surname>Koolen</surname><given-names>DA</given-names></name><name><surname>de Vries</surname><given-names>P</given-names></name><name><surname>Gilissen</surname><given-names>C</given-names></name><name><surname>del Rosario</surname><given-names>M</given-names></name><name><surname>Hoischen</surname><given-names>A</given-names></name><name><surname>Scheffer</surname><given-names>H</given-names></name><name><surname>de Vries</surname><given-names>BBA</given-names></name><name><surname>Brunner</surname><given-names>HG</given-names></name><name><surname>Veltman</surname><given-names>JA</given-names></name><name><surname>Vissers</surname><given-names>LELM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Diagnostic exome sequencing in persons with severe intellectual disability</article-title><source>The New England Journal of Medicine</source><volume>367</volume><fpage>1921</fpage><lpage>1929</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1206524</pub-id><pub-id pub-id-type="pmid">23033978</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’hauw</surname><given-names>A</given-names></name><name><surname>Seyger</surname><given-names>MMB</given-names></name><name><surname>Groenen</surname><given-names>P</given-names></name><name><surname>Weemaes</surname><given-names>CMR</given-names></name><name><surname>Warris</surname><given-names>A</given-names></name><name><surname>Blokx</surname><given-names>WAM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Cutaneous graft-versus-host-like histology in childhood importance of clonality analysis in differential diagnosis: A case report</article-title><source>The British Journal of Dermatology</source><volume>158</volume><fpage>1153</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2008.08497.x</pub-id><pub-id pub-id-type="pmid">18341659</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodé</surname><given-names>C</given-names></name><name><surname>Le Dû</surname><given-names>N</given-names></name><name><surname>Cuisset</surname><given-names>L</given-names></name><name><surname>Letourneur</surname><given-names>F</given-names></name><name><surname>Berthelot</surname><given-names>JM</given-names></name><name><surname>Vaudour</surname><given-names>G</given-names></name><name><surname>Meyrier</surname><given-names>A</given-names></name><name><surname>Watts</surname><given-names>RA</given-names></name><name><surname>Scott</surname><given-names>DGI</given-names></name><name><surname>Nicholls</surname><given-names>A</given-names></name><name><surname>Granel</surname><given-names>B</given-names></name><name><surname>Frances</surname><given-names>C</given-names></name><name><surname>Garcier</surname><given-names>F</given-names></name><name><surname>Edery</surname><given-names>P</given-names></name><name><surname>Boulinguez</surname><given-names>S</given-names></name><name><surname>Domergues</surname><given-names>JP</given-names></name><name><surname>Delpech</surname><given-names>M</given-names></name><name><surname>Grateau</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>New mutations of CIAS1 that are responsible for muckle-wells syndrome and familial cold urticaria: a novel mutation underlies both syndromes</article-title><source>American Journal of Human Genetics</source><volume>70</volume><fpage>1498</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.1086/340786</pub-id><pub-id pub-id-type="pmid">11992256</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebihara</surname><given-names>T</given-names></name><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Ryu</surname><given-names>SH</given-names></name><name><surname>Plougastel-Douglas</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Levanon</surname><given-names>D</given-names></name><name><surname>Groner</surname><given-names>Y</given-names></name><name><surname>Bern</surname><given-names>MD</given-names></name><name><surname>Stappenbeck</surname><given-names>TS</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>Egawa</surname><given-names>T</given-names></name><name><surname>Yokoyama</surname><given-names>WM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Runx3 specifies lineage commitment of innate lymphoid cells</article-title><source>Nature Immunology</source><volume>16</volume><fpage>1124</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1038/ni.3272</pub-id><pub-id pub-id-type="pmid">26414766</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrlich</surname><given-names>M</given-names></name><name><surname>Sanchez</surname><given-names>C</given-names></name><name><surname>Shao</surname><given-names>C</given-names></name><name><surname>Nishiyama</surname><given-names>R</given-names></name><name><surname>Kehrl</surname><given-names>J</given-names></name><name><surname>Kuick</surname><given-names>R</given-names></name><name><surname>Kubota</surname><given-names>T</given-names></name><name><surname>Hanash</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Icf, an immunodeficiency syndrome: DNA methyltransferase 3B involvement, chromosome anomalies, and gene dysregulation</article-title><source>Autoimmunity</source><volume>41</volume><fpage>253</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1080/08916930802024202</pub-id><pub-id pub-id-type="pmid">18432406</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Firth</surname><given-names>HV</given-names></name><name><surname>Richards</surname><given-names>SM</given-names></name><name><surname>Bevan</surname><given-names>AP</given-names></name><name><surname>Clayton</surname><given-names>S</given-names></name><name><surname>Corpas</surname><given-names>M</given-names></name><name><surname>Rajan</surname><given-names>D</given-names></name><name><surname>Van Vooren</surname><given-names>S</given-names></name><name><surname>Moreau</surname><given-names>Y</given-names></name><name><surname>Pettett</surname><given-names>RM</given-names></name><name><surname>Carter</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Decipher: database of chromosomal imbalance and phenotype in humans using ensembl resources</article-title><source>American Journal of Human Genetics</source><volume>84</volume><fpage>524</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2009.03.010</pub-id><pub-id pub-id-type="pmid">19344873</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>JD</given-names></name><name><surname>Ciprero</surname><given-names>KL</given-names></name><name><surname>Sullivan</surname><given-names>KE</given-names></name><name><surname>Kaplan</surname><given-names>PB</given-names></name><name><surname>McDonald-McGinn</surname><given-names>DM</given-names></name><name><surname>Zackai</surname><given-names>EH</given-names></name><name><surname>Ming</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Immune abnormalities are a frequent manifestation of kabuki syndrome</article-title><source>American Journal of Medical Genetics. Part A</source><volume>135</volume><fpage>278</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.30722</pub-id><pub-id pub-id-type="pmid">15887282</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holland</surname><given-names>SM</given-names></name><name><surname>DeLeo</surname><given-names>FR</given-names></name><name><surname>Elloumi</surname><given-names>HZ</given-names></name><name><surname>Hsu</surname><given-names>AP</given-names></name><name><surname>Uzel</surname><given-names>G</given-names></name><name><surname>Brodsky</surname><given-names>N</given-names></name><name><surname>Freeman</surname><given-names>AF</given-names></name><name><surname>Demidowich</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>J</given-names></name><name><surname>Turner</surname><given-names>ML</given-names></name><name><surname>Anderson</surname><given-names>VL</given-names></name><name><surname>Darnell</surname><given-names>DN</given-names></name><name><surname>Welch</surname><given-names>PA</given-names></name><name><surname>Kuhns</surname><given-names>DB</given-names></name><name><surname>Frucht</surname><given-names>DM</given-names></name><name><surname>Malech</surname><given-names>HL</given-names></name><name><surname>Gallin</surname><given-names>JI</given-names></name><name><surname>Kobayashi</surname><given-names>SD</given-names></name><name><surname>Whitney</surname><given-names>AR</given-names></name><name><surname>Voyich</surname><given-names>JM</given-names></name><name><surname>Musser</surname><given-names>JM</given-names></name><name><surname>Woellner</surname><given-names>C</given-names></name><name><surname>Schäffer</surname><given-names>AA</given-names></name><name><surname>Puck</surname><given-names>JM</given-names></name><name><surname>Grimbacher</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>STAT3 mutations in the hyper-ige syndrome</article-title><source>The New England Journal of Medicine</source><volume>357</volume><fpage>1608</fpage><lpage>1619</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa073687</pub-id><pub-id pub-id-type="pmid">17881745</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holt</surname><given-names>RJ</given-names></name><name><surname>Young</surname><given-names>RM</given-names></name><name><surname>Crespo</surname><given-names>B</given-names></name><name><surname>Ceroni</surname><given-names>F</given-names></name><name><surname>Curry</surname><given-names>CJ</given-names></name><name><surname>Bellacchio</surname><given-names>E</given-names></name><name><surname>Bax</surname><given-names>DA</given-names></name><name><surname>Ciolfi</surname><given-names>A</given-names></name><name><surname>Simon</surname><given-names>M</given-names></name><name><surname>Fagerberg</surname><given-names>CR</given-names></name><name><surname>van Binsbergen</surname><given-names>E</given-names></name><name><surname>De Luca</surname><given-names>A</given-names></name><name><surname>Memo</surname><given-names>L</given-names></name><name><surname>Dobyns</surname><given-names>WB</given-names></name><name><surname>Mohammed</surname><given-names>AA</given-names></name><name><surname>Clokie</surname><given-names>SJH</given-names></name><name><surname>Zazo Seco</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>Y-H</given-names></name><name><surname>Sørensen</surname><given-names>KP</given-names></name><name><surname>Andersen</surname><given-names>H</given-names></name><name><surname>Sullivan</surname><given-names>J</given-names></name><name><surname>Powis</surname><given-names>Z</given-names></name><name><surname>Chassevent</surname><given-names>A</given-names></name><name><surname>Smith-Hicks</surname><given-names>C</given-names></name><name><surname>Petrovski</surname><given-names>S</given-names></name><name><surname>Antoniadi</surname><given-names>T</given-names></name><name><surname>Shashi</surname><given-names>V</given-names></name><name><surname>Gelb</surname><given-names>BD</given-names></name><name><surname>Wilson</surname><given-names>SW</given-names></name><name><surname>Gerrelli</surname><given-names>D</given-names></name><name><surname>Tartaglia</surname><given-names>M</given-names></name><name><surname>Chassaing</surname><given-names>N</given-names></name><name><surname>Calvas</surname><given-names>P</given-names></name><name><surname>Ragge</surname><given-names>NK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title><italic>De novo</italic> missense variants in FBXW11 cause diverse developmental phenotypes including brain, eye, and digit anomalies</article-title><source>American Journal of Human Genetics</source><volume>105</volume><fpage>640</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2019.07.005</pub-id><pub-id pub-id-type="pmid">31402090</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holzelova</surname><given-names>E</given-names></name><name><surname>Vonarbourg</surname><given-names>C</given-names></name><name><surname>Stolzenberg</surname><given-names>MC</given-names></name><name><surname>Arkwright</surname><given-names>PD</given-names></name><name><surname>Selz</surname><given-names>F</given-names></name><name><surname>Prieur</surname><given-names>AM</given-names></name><name><surname>Blanche</surname><given-names>S</given-names></name><name><surname>Bartunkova</surname><given-names>J</given-names></name><name><surname>Vilmer</surname><given-names>E</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Le Deist</surname><given-names>F</given-names></name><name><surname>Rieux-Laucat</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Autoimmune lymphoproliferative syndrome with somatic fas mutations</article-title><source>The New England Journal of Medicine</source><volume>351</volume><fpage>1409</fpage><lpage>1418</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa040036</pub-id><pub-id pub-id-type="pmid">15459302</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>K</given-names></name><name><surname>Hall</surname><given-names>CP</given-names></name><name><surname>Al-Rahawan</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Wiskott-aldrich syndrome: description of a new gene mutation without immunodeficiency</article-title><source>Journal of Pediatric Hematology/Oncology</source><volume>38</volume><elocation-id>163</elocation-id><pub-id pub-id-type="doi">10.1097/MPH.0000000000000479</pub-id><pub-id pub-id-type="pmid">26583625</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>AP</given-names></name><name><surname>Donkó</surname><given-names>A</given-names></name><name><surname>Arrington</surname><given-names>ME</given-names></name><name><surname>Swamydas</surname><given-names>M</given-names></name><name><surname>Fink</surname><given-names>D</given-names></name><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Escobedo</surname><given-names>O</given-names></name><name><surname>Bonagura</surname><given-names>V</given-names></name><name><surname>Szabolcs</surname><given-names>P</given-names></name><name><surname>Steinberg</surname><given-names>HN</given-names></name><name><surname>Bergerson</surname><given-names>J</given-names></name><name><surname>Skoskiewicz</surname><given-names>A</given-names></name><name><surname>Makhija</surname><given-names>M</given-names></name><name><surname>Davis</surname><given-names>J</given-names></name><name><surname>Foruraghi</surname><given-names>L</given-names></name><name><surname>Palmer</surname><given-names>C</given-names></name><name><surname>Fuleihan</surname><given-names>RL</given-names></name><name><surname>Church</surname><given-names>JA</given-names></name><name><surname>Bhandoola</surname><given-names>A</given-names></name><name><surname>Lionakis</surname><given-names>MS</given-names></name><name><surname>Campbell</surname><given-names>S</given-names></name><name><surname>Leto</surname><given-names>TL</given-names></name><name><surname>Kuhns</surname><given-names>DB</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Dominant activating rac2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects</article-title><source>Blood</source><volume>133</volume><fpage>1977</fpage><lpage>1988</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-11-886028</pub-id><pub-id pub-id-type="pmid">30723080</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaganathan</surname><given-names>K</given-names></name><name><surname>Kyriazopoulou Panagiotopoulou</surname><given-names>S</given-names></name><name><surname>McRae</surname><given-names>JF</given-names></name><name><surname>Darbandi</surname><given-names>SF</given-names></name><name><surname>Knowles</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>YI</given-names></name><name><surname>Kosmicki</surname><given-names>JA</given-names></name><name><surname>Arbelaez</surname><given-names>J</given-names></name><name><surname>Cui</surname><given-names>W</given-names></name><name><surname>Schwartz</surname><given-names>GB</given-names></name><name><surname>Chow</surname><given-names>ED</given-names></name><name><surname>Kanterakis</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Kia</surname><given-names>A</given-names></name><name><surname>Batzoglou</surname><given-names>S</given-names></name><name><surname>Sanders</surname><given-names>SJ</given-names></name><name><surname>Farh</surname><given-names>KKH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Predicting splicing from primary sequence with deep learning</article-title><source>Cell</source><volume>176</volume><fpage>535</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.12.015</pub-id><pub-id pub-id-type="pmid">30661751</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiménez-Treviño</surname><given-names>S</given-names></name><name><surname>González-Roca</surname><given-names>E</given-names></name><name><surname>Ruiz-Ortiz</surname><given-names>E</given-names></name><name><surname>Yagüe</surname><given-names>J</given-names></name><name><surname>Ramos</surname><given-names>E</given-names></name><name><surname>Aróstegui</surname><given-names>JI</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>First report of vertical transmission of a somatic NLRP3 mutation in cryopyrin-associated periodic syndromes</article-title><source>Annals of the Rheumatic Diseases</source><volume>72</volume><fpage>1109</fpage><lpage>1110</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2012-202913</pub-id><pub-id pub-id-type="pmid">23486414</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanarek</surname><given-names>N</given-names></name><name><surname>Ben-Neriah</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Regulation of NF-κB by ubiquitination and degradation of the iκbs</article-title><source>Immunological Reviews</source><volume>246</volume><fpage>77</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2012.01098.x</pub-id><pub-id pub-id-type="pmid">22435548</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanazawa</surname><given-names>N</given-names></name><name><surname>Hemmi</surname><given-names>H</given-names></name><name><surname>Kinjo</surname><given-names>N</given-names></name><name><surname>Ohnishi</surname><given-names>H</given-names></name><name><surname>Hamazaki</surname><given-names>J</given-names></name><name><surname>Mishima</surname><given-names>H</given-names></name><name><surname>Kinoshita</surname><given-names>A</given-names></name><name><surname>Mizushima</surname><given-names>T</given-names></name><name><surname>Hamada</surname><given-names>S</given-names></name><name><surname>Hamada</surname><given-names>K</given-names></name><name><surname>Kawamoto</surname><given-names>N</given-names></name><name><surname>Kadowaki</surname><given-names>S</given-names></name><name><surname>Honda</surname><given-names>Y</given-names></name><name><surname>Izawa</surname><given-names>K</given-names></name><name><surname>Nishikomori</surname><given-names>R</given-names></name><name><surname>Tsumura</surname><given-names>M</given-names></name><name><surname>Yamashita</surname><given-names>Y</given-names></name><name><surname>Tamura</surname><given-names>S</given-names></name><name><surname>Orimo</surname><given-names>T</given-names></name><name><surname>Ozasa</surname><given-names>T</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>I</given-names></name><name><surname>Fukuda-Ohta</surname><given-names>Y</given-names></name><name><surname>Wakaki-Nishiyama</surname><given-names>N</given-names></name><name><surname>Inaba</surname><given-names>Y</given-names></name><name><surname>Kunimoto</surname><given-names>K</given-names></name><name><surname>Okada</surname><given-names>S</given-names></name><name><surname>Taketani</surname><given-names>T</given-names></name><name><surname>Nakanishi</surname><given-names>K</given-names></name><name><surname>Murata</surname><given-names>S</given-names></name><name><surname>Yoshiura</surname><given-names>K</given-names></name><name><surname>Kaisho</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Heterozygous missense variant of the proteasome subunit β-type 9 causes neonatal-onset autoinflammation and immunodeficiency</article-title><source>Nature Communications</source><volume>12</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/s41467-021-27085-y</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplanis</surname><given-names>J</given-names></name><name><surname>Samocha</surname><given-names>KE</given-names></name><name><surname>Wiel</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Arvai</surname><given-names>KJ</given-names></name><name><surname>Eberhardt</surname><given-names>RY</given-names></name><name><surname>Gallone</surname><given-names>G</given-names></name><name><surname>Lelieveld</surname><given-names>SH</given-names></name><name><surname>Martin</surname><given-names>HC</given-names></name><name><surname>McRae</surname><given-names>JF</given-names></name><name><surname>Short</surname><given-names>PJ</given-names></name><name><surname>Torene</surname><given-names>RI</given-names></name><name><surname>de Boer</surname><given-names>E</given-names></name><name><surname>Danecek</surname><given-names>P</given-names></name><name><surname>Gardner</surname><given-names>EJ</given-names></name><name><surname>Huang</surname><given-names>N</given-names></name><name><surname>Lord</surname><given-names>J</given-names></name><name><surname>Martincorena</surname><given-names>I</given-names></name><name><surname>Pfundt</surname><given-names>R</given-names></name><name><surname>Reijnders</surname><given-names>MRF</given-names></name><name><surname>Yeung</surname><given-names>A</given-names></name><name><surname>Yntema</surname><given-names>HG</given-names></name><name><surname>Vissers</surname><given-names>L</given-names></name><name><surname>Juusola</surname><given-names>J</given-names></name><name><surname>Wright</surname><given-names>CF</given-names></name><name><surname>Brunner</surname><given-names>HG</given-names></name><name><surname>Firth</surname><given-names>HV</given-names></name><name><surname>FitzPatrick</surname><given-names>DR</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Hurles</surname><given-names>ME</given-names></name><name><surname>Gilissen</surname><given-names>C</given-names></name><name><surname>Retterer</surname><given-names>K</given-names></name><collab>Deciphering Developmental Disorders Study</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Evidence for 28 genetic disorders discovered by combining healthcare and research data</article-title><source>Nature</source><volume>586</volume><fpage>757</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2832-5</pub-id><pub-id pub-id-type="pmid">33057194</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karczewski</surname><given-names>KJ</given-names></name><name><surname>Francioli</surname><given-names>LC</given-names></name><name><surname>Tiao</surname><given-names>G</given-names></name><name><surname>Cummings</surname><given-names>BB</given-names></name><name><surname>Alföldi</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Collins</surname><given-names>RL</given-names></name><name><surname>Laricchia</surname><given-names>KM</given-names></name><name><surname>Ganna</surname><given-names>A</given-names></name><name><surname>Birnbaum</surname><given-names>DP</given-names></name><name><surname>Gauthier</surname><given-names>LD</given-names></name><name><surname>Brand</surname><given-names>H</given-names></name><name><surname>Solomonson</surname><given-names>M</given-names></name><name><surname>Watts</surname><given-names>NA</given-names></name><name><surname>Rhodes</surname><given-names>D</given-names></name><name><surname>Singer-Berk</surname><given-names>M</given-names></name><name><surname>England</surname><given-names>EM</given-names></name><name><surname>Seaby</surname><given-names>EG</given-names></name><name><surname>Kosmicki</surname><given-names>JA</given-names></name><name><surname>Walters</surname><given-names>RK</given-names></name><name><surname>Tashman</surname><given-names>K</given-names></name><name><surname>Farjoun</surname><given-names>Y</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Poterba</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Seed</surname><given-names>C</given-names></name><name><surname>Whiffin</surname><given-names>N</given-names></name><name><surname>Chong</surname><given-names>JX</given-names></name><name><surname>Samocha</surname><given-names>KE</given-names></name><name><surname>Pierce-Hoffman</surname><given-names>E</given-names></name><name><surname>Zappala</surname><given-names>Z</given-names></name><name><surname>O’Donnell-Luria</surname><given-names>AH</given-names></name><name><surname>Minikel</surname><given-names>EV</given-names></name><name><surname>Weisburd</surname><given-names>B</given-names></name><name><surname>Lek</surname><given-names>M</given-names></name><name><surname>Ware</surname><given-names>JS</given-names></name><name><surname>Vittal</surname><given-names>C</given-names></name><name><surname>Armean</surname><given-names>IM</given-names></name><name><surname>Bergelson</surname><given-names>L</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Connolly</surname><given-names>KM</given-names></name><name><surname>Covarrubias</surname><given-names>M</given-names></name><name><surname>Donnelly</surname><given-names>S</given-names></name><name><surname>Ferriera</surname><given-names>S</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Gentry</surname><given-names>J</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Jeandet</surname><given-names>T</given-names></name><name><surname>Kaplan</surname><given-names>D</given-names></name><name><surname>Llanwarne</surname><given-names>C</given-names></name><name><surname>Munshi</surname><given-names>R</given-names></name><name><surname>Novod</surname><given-names>S</given-names></name><name><surname>Petrillo</surname><given-names>N</given-names></name><name><surname>Roazen</surname><given-names>D</given-names></name><name><surname>Ruano-Rubio</surname><given-names>V</given-names></name><name><surname>Saltzman</surname><given-names>A</given-names></name><name><surname>Schleicher</surname><given-names>M</given-names></name><name><surname>Soto</surname><given-names>J</given-names></name><name><surname>Tibbetts</surname><given-names>K</given-names></name><name><surname>Tolonen</surname><given-names>C</given-names></name><name><surname>Wade</surname><given-names>G</given-names></name><name><surname>Talkowski</surname><given-names>ME</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>MacArthur</surname><given-names>DG</given-names></name><collab>Genome Aggregation Database Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>The mutational constraint spectrum quantified from variation in 141,456 humans</article-title><source>Nature</source><volume>581</volume><fpage>434</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2308-7</pub-id><pub-id pub-id-type="pmid">32461654</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kataoka</surname><given-names>S</given-names></name><name><surname>Kawashima</surname><given-names>N</given-names></name><name><surname>Okuno</surname><given-names>Y</given-names></name><name><surname>Muramatsu</surname><given-names>H</given-names></name><name><surname>Miwata</surname><given-names>S</given-names></name><name><surname>Narita</surname><given-names>K</given-names></name><name><surname>Hamada</surname><given-names>M</given-names></name><name><surname>Murakami</surname><given-names>N</given-names></name><name><surname>Taniguchi</surname><given-names>R</given-names></name><name><surname>Ichikawa</surname><given-names>D</given-names></name><name><surname>Kitazawa</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Nishikawa</surname><given-names>E</given-names></name><name><surname>Narita</surname><given-names>A</given-names></name><name><surname>Nishio</surname><given-names>N</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Fukasawa</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Natsume</surname><given-names>J</given-names></name><name><surname>Kojima</surname><given-names>S</given-names></name><name><surname>Nishino</surname><given-names>I</given-names></name><name><surname>Taketani</surname><given-names>T</given-names></name><name><surname>Ohnishi</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Successful treatment of a novel type I interferonopathy due to a <italic>de novo</italic> PSMB9 gene mutation with a janus kinase inhibitor</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>148</volume><fpage>639</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2021.03.010</pub-id><pub-id pub-id-type="pmid">33727065</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>Y</given-names></name><name><surname>Oda</surname><given-names>H</given-names></name><name><surname>Ito</surname><given-names>J</given-names></name><name><surname>Niwa</surname><given-names>A</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Hijikata</surname><given-names>A</given-names></name><name><surname>Seki</surname><given-names>R</given-names></name><name><surname>Nagahashi</surname><given-names>A</given-names></name><name><surname>Osawa</surname><given-names>M</given-names></name><name><surname>Asaka</surname><given-names>I</given-names></name><name><surname>Watanabe</surname><given-names>A</given-names></name><name><surname>Nishimata</surname><given-names>S</given-names></name><name><surname>Shirai</surname><given-names>T</given-names></name><name><surname>Kawashima</surname><given-names>H</given-names></name><name><surname>Ohara</surname><given-names>O</given-names></name><name><surname>Nakahata</surname><given-names>T</given-names></name><name><surname>Nishikomori</surname><given-names>R</given-names></name><name><surname>Heike</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Identification of a high-frequency somatic NLRC4 mutation as a cause of autoinflammation by pluripotent cell-based phenotype dissection</article-title><source>Arthritis &amp; Rheumatology</source><volume>69</volume><fpage>447</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1002/art.39960</pub-id><pub-id pub-id-type="pmid">27788288</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Pereira</surname><given-names>J</given-names></name><name><surname>Darbyshire</surname><given-names>PJ</given-names></name><name><surname>Holding</surname><given-names>S</given-names></name><name><surname>Doré</surname><given-names>PC</given-names></name><name><surname>Sewell</surname><given-names>WAC</given-names></name><name><surname>Huissoon</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Do ribosomopathies explain some cases of common variable immunodeficiency?</article-title><source>Clinical and Experimental Immunology</source><volume>163</volume><fpage>96</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2010.04280.x</pub-id><pub-id pub-id-type="pmid">21062271</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>TY</given-names></name><name><surname>Siesser</surname><given-names>PF</given-names></name><name><surname>Rossman</surname><given-names>KL</given-names></name><name><surname>Goldfarb</surname><given-names>D</given-names></name><name><surname>Mackinnon</surname><given-names>K</given-names></name><name><surname>Yan</surname><given-names>F</given-names></name><name><surname>Yi</surname><given-names>X</given-names></name><name><surname>MacCoss</surname><given-names>MJ</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name><name><surname>Der</surname><given-names>CJ</given-names></name><name><surname>Major</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Substrate trapping proteomics reveals targets of the βtrcp2/FBXW11 ubiquitin ligase</article-title><source>Molecular and Cellular Biology</source><volume>35</volume><fpage>167</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1128/MCB.00857-14</pub-id><pub-id pub-id-type="pmid">25332235</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koemans</surname><given-names>TS</given-names></name><name><surname>Kleefstra</surname><given-names>T</given-names></name><name><surname>Chubak</surname><given-names>MC</given-names></name><name><surname>Stone</surname><given-names>MH</given-names></name><name><surname>Reijnders</surname><given-names>MRF</given-names></name><name><surname>de Munnik</surname><given-names>S</given-names></name><name><surname>Willemsen</surname><given-names>MH</given-names></name><name><surname>Fenckova</surname><given-names>M</given-names></name><name><surname>Stumpel</surname><given-names>C</given-names></name><name><surname>Bok</surname><given-names>LA</given-names></name><name><surname>Sifuentes Saenz</surname><given-names>M</given-names></name><name><surname>Byerly</surname><given-names>KA</given-names></name><name><surname>Baughn</surname><given-names>LB</given-names></name><name><surname>Stegmann</surname><given-names>APA</given-names></name><name><surname>Pfundt</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>van Bokhoven</surname><given-names>H</given-names></name><name><surname>Schenck</surname><given-names>A</given-names></name><name><surname>Kramer</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Functional convergence of histone methyltransferases EHMT1 and KMT2C involved in intellectual disability and autism spectrum disorder</article-title><source>PLOS Genetics</source><volume>13</volume><elocation-id>e1006864</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1006864</pub-id><pub-id pub-id-type="pmid">29069077</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konrad</surname><given-names>EDH</given-names></name><name><surname>Nardini</surname><given-names>N</given-names></name><name><surname>Caliebe</surname><given-names>A</given-names></name><name><surname>Nagel</surname><given-names>I</given-names></name><name><surname>Young</surname><given-names>D</given-names></name><name><surname>Horvath</surname><given-names>G</given-names></name><name><surname>Santoro</surname><given-names>SL</given-names></name><name><surname>Shuss</surname><given-names>C</given-names></name><name><surname>Ziegler</surname><given-names>A</given-names></name><name><surname>Bonneau</surname><given-names>D</given-names></name><name><surname>Kempers</surname><given-names>M</given-names></name><name><surname>Pfundt</surname><given-names>R</given-names></name><name><surname>Legius</surname><given-names>E</given-names></name><name><surname>Bouman</surname><given-names>A</given-names></name><name><surname>Stuurman</surname><given-names>KE</given-names></name><name><surname>Õunap</surname><given-names>K</given-names></name><name><surname>Pajusalu</surname><given-names>S</given-names></name><name><surname>Wojcik</surname><given-names>MH</given-names></name><name><surname>Vasileiou</surname><given-names>G</given-names></name><name><surname>Le Guyader</surname><given-names>G</given-names></name><name><surname>Schnelle</surname><given-names>HM</given-names></name><name><surname>Berland</surname><given-names>S</given-names></name><name><surname>Zonneveld-Huijssoon</surname><given-names>E</given-names></name><name><surname>Kersten</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Blackburn</surname><given-names>PR</given-names></name><name><surname>Ellingson</surname><given-names>MS</given-names></name><name><surname>Ferber</surname><given-names>MJ</given-names></name><name><surname>Dhamija</surname><given-names>R</given-names></name><name><surname>Klee</surname><given-names>EW</given-names></name><name><surname>McEntagart</surname><given-names>M</given-names></name><name><surname>Lichtenbelt</surname><given-names>KD</given-names></name><name><surname>Kenney</surname><given-names>A</given-names></name><name><surname>Vergano</surname><given-names>SA</given-names></name><name><surname>Abou Jamra</surname><given-names>R</given-names></name><name><surname>Platzer</surname><given-names>K</given-names></name><name><surname>Ella Pierpont</surname><given-names>M</given-names></name><name><surname>Khattar</surname><given-names>D</given-names></name><name><surname>Hopkin</surname><given-names>RJ</given-names></name><name><surname>Martin</surname><given-names>RJ</given-names></name><name><surname>Jongmans</surname><given-names>MCJ</given-names></name><name><surname>Chang</surname><given-names>VY</given-names></name><name><surname>Martinez-Agosto</surname><given-names>JA</given-names></name><name><surname>Kuismin</surname><given-names>O</given-names></name><name><surname>Kurki</surname><given-names>MI</given-names></name><name><surname>Pietiläinen</surname><given-names>O</given-names></name><name><surname>Palotie</surname><given-names>A</given-names></name><name><surname>Maarup</surname><given-names>TJ</given-names></name><name><surname>Johnson</surname><given-names>DS</given-names></name><name><surname>Venborg Pedersen</surname><given-names>K</given-names></name><name><surname>Laulund</surname><given-names>LW</given-names></name><name><surname>Lynch</surname><given-names>SA</given-names></name><name><surname>Blyth</surname><given-names>M</given-names></name><name><surname>Prescott</surname><given-names>K</given-names></name><name><surname>Canham</surname><given-names>N</given-names></name><name><surname>Ibitoye</surname><given-names>R</given-names></name><name><surname>Brilstra</surname><given-names>EH</given-names></name><name><surname>Shinawi</surname><given-names>M</given-names></name><name><surname>Fassi</surname><given-names>E</given-names></name><name><surname>Sticht</surname><given-names>H</given-names></name><name><surname>Gregor</surname><given-names>A</given-names></name><name><surname>Van Esch</surname><given-names>H</given-names></name><name><surname>Zweier</surname><given-names>C</given-names></name><collab>DDD Study</collab></person-group><year iso-8601-date="2019">2019</year><article-title>CTCF variants in 39 individuals with a variable neurodevelopmental disorder broaden the mutational and clinical spectrum</article-title><source>Genetics in Medicine</source><volume>21</volume><fpage>2723</fpage><lpage>2733</lpage><pub-id pub-id-type="doi">10.1038/s41436-019-0585-z</pub-id><pub-id pub-id-type="pmid">31239556</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krumm</surname><given-names>N</given-names></name><name><surname>Sudmant</surname><given-names>PH</given-names></name><name><surname>Ko</surname><given-names>A</given-names></name><name><surname>O’Roak</surname><given-names>BJ</given-names></name><name><surname>Malig</surname><given-names>M</given-names></name><name><surname>Coe</surname><given-names>BP</given-names></name><name><surname>Project</surname><given-names>NES</given-names></name><name><surname>Quinlan</surname><given-names>AR</given-names></name><name><surname>Nickerson</surname><given-names>DA</given-names></name><name><surname>Eichler</surname><given-names>EE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Copy number variation detection and genotyping from exome sequence data</article-title><source>Genome Research</source><volume>22</volume><fpage>1525</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.1101/gr.138115.112</pub-id><pub-id pub-id-type="pmid">22585873</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuehn</surname><given-names>HS</given-names></name><name><surname>Boisson</surname><given-names>B</given-names></name><name><surname>Cunningham-Rundles</surname><given-names>C</given-names></name><name><surname>Reichenbach</surname><given-names>J</given-names></name><name><surname>Stray-Pedersen</surname><given-names>A</given-names></name><name><surname>Gelfand</surname><given-names>EW</given-names></name><name><surname>Maffucci</surname><given-names>P</given-names></name><name><surname>Pierce</surname><given-names>KR</given-names></name><name><surname>Abbott</surname><given-names>JK</given-names></name><name><surname>Voelkerding</surname><given-names>KV</given-names></name><name><surname>South</surname><given-names>ST</given-names></name><name><surname>Augustine</surname><given-names>NH</given-names></name><name><surname>Bush</surname><given-names>JS</given-names></name><name><surname>Dolen</surname><given-names>WK</given-names></name><name><surname>Wray</surname><given-names>BB</given-names></name><name><surname>Itan</surname><given-names>Y</given-names></name><name><surname>Cobat</surname><given-names>A</given-names></name><name><surname>Sorte</surname><given-names>HS</given-names></name><name><surname>Ganesan</surname><given-names>S</given-names></name><name><surname>Prader</surname><given-names>S</given-names></name><name><surname>Martins</surname><given-names>TB</given-names></name><name><surname>Lawrence</surname><given-names>MG</given-names></name><name><surname>Orange</surname><given-names>JS</given-names></name><name><surname>Calvo</surname><given-names>KR</given-names></name><name><surname>Niemela</surname><given-names>JE</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name><name><surname>Fleisher</surname><given-names>TA</given-names></name><name><surname>Hill</surname><given-names>HR</given-names></name><name><surname>Kumánovics</surname><given-names>A</given-names></name><name><surname>Conley</surname><given-names>ME</given-names></name><name><surname>Rosenzweig</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Loss of B cells in patients with heterozygous mutations in ikaros</article-title><source>The New England Journal of Medicine</source><volume>374</volume><fpage>1032</fpage><lpage>1043</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1512234</pub-id><pub-id pub-id-type="pmid">26981933</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labrousse</surname><given-names>M</given-names></name><name><surname>Kevorkian-Verguet</surname><given-names>C</given-names></name><name><surname>Boursier</surname><given-names>G</given-names></name><name><surname>Rowczenio</surname><given-names>D</given-names></name><name><surname>Maurier</surname><given-names>F</given-names></name><name><surname>Lazaro</surname><given-names>E</given-names></name><name><surname>Aggarwal</surname><given-names>M</given-names></name><name><surname>Lemelle</surname><given-names>I</given-names></name><name><surname>Mura</surname><given-names>T</given-names></name><name><surname>Belot</surname><given-names>A</given-names></name><name><surname>Touitou</surname><given-names>I</given-names></name><name><surname>Sarrabay</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mosaicism in autoinflammatory diseases: cryopyrin-associated periodic syndromes (CAPS) and beyond: A systematic review</article-title><source>Critical Reviews in Clinical Laboratory Sciences</source><volume>55</volume><fpage>432</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1080/10408363.2018.1488805</pub-id><pub-id pub-id-type="pmid">30035647</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lek</surname><given-names>M</given-names></name><name><surname>Karczewski</surname><given-names>KJ</given-names></name><name><surname>Minikel</surname><given-names>EV</given-names></name><name><surname>Samocha</surname><given-names>KE</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Fennell</surname><given-names>T</given-names></name><name><surname>O’Donnell-Luria</surname><given-names>AH</given-names></name><name><surname>Ware</surname><given-names>JS</given-names></name><name><surname>Hill</surname><given-names>AJ</given-names></name><name><surname>Cummings</surname><given-names>BB</given-names></name><name><surname>Tukiainen</surname><given-names>T</given-names></name><name><surname>Birnbaum</surname><given-names>DP</given-names></name><name><surname>Kosmicki</surname><given-names>JA</given-names></name><name><surname>Duncan</surname><given-names>LE</given-names></name><name><surname>Estrada</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Pierce-Hoffman</surname><given-names>E</given-names></name><name><surname>Berghout</surname><given-names>J</given-names></name><name><surname>Cooper</surname><given-names>DN</given-names></name><name><surname>Deflaux</surname><given-names>N</given-names></name><name><surname>DePristo</surname><given-names>M</given-names></name><name><surname>Do</surname><given-names>R</given-names></name><name><surname>Flannick</surname><given-names>J</given-names></name><name><surname>Fromer</surname><given-names>M</given-names></name><name><surname>Gauthier</surname><given-names>L</given-names></name><name><surname>Goldstein</surname><given-names>J</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Howrigan</surname><given-names>D</given-names></name><name><surname>Kiezun</surname><given-names>A</given-names></name><name><surname>Kurki</surname><given-names>MI</given-names></name><name><surname>Moonshine</surname><given-names>AL</given-names></name><name><surname>Natarajan</surname><given-names>P</given-names></name><name><surname>Orozco</surname><given-names>L</given-names></name><name><surname>Peloso</surname><given-names>GM</given-names></name><name><surname>Poplin</surname><given-names>R</given-names></name><name><surname>Rivas</surname><given-names>MA</given-names></name><name><surname>Ruano-Rubio</surname><given-names>V</given-names></name><name><surname>Rose</surname><given-names>SA</given-names></name><name><surname>Ruderfer</surname><given-names>DM</given-names></name><name><surname>Shakir</surname><given-names>K</given-names></name><name><surname>Stenson</surname><given-names>PD</given-names></name><name><surname>Stevens</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>BP</given-names></name><name><surname>Tiao</surname><given-names>G</given-names></name><name><surname>Tusie-Luna</surname><given-names>MT</given-names></name><name><surname>Weisburd</surname><given-names>B</given-names></name><name><surname>Won</surname><given-names>HH</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Altshuler</surname><given-names>DM</given-names></name><name><surname>Ardissino</surname><given-names>D</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name><name><surname>Danesh</surname><given-names>J</given-names></name><name><surname>Donnelly</surname><given-names>S</given-names></name><name><surname>Elosua</surname><given-names>R</given-names></name><name><surname>Florez</surname><given-names>JC</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Glatt</surname><given-names>SJ</given-names></name><name><surname>Hultman</surname><given-names>CM</given-names></name><name><surname>Kathiresan</surname><given-names>S</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>McCarroll</surname><given-names>S</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>McGovern</surname><given-names>D</given-names></name><name><surname>McPherson</surname><given-names>R</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Palotie</surname><given-names>A</given-names></name><name><surname>Purcell</surname><given-names>SM</given-names></name><name><surname>Saleheen</surname><given-names>D</given-names></name><name><surname>Scharf</surname><given-names>JM</given-names></name><name><surname>Sklar</surname><given-names>P</given-names></name><name><surname>Sullivan</surname><given-names>PF</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Tsuang</surname><given-names>MT</given-names></name><name><surname>Watkins</surname><given-names>HC</given-names></name><name><surname>Wilson</surname><given-names>JG</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>MacArthur</surname><given-names>DG</given-names></name><collab>Exome Aggregation Consortium</collab></person-group><year iso-8601-date="2016">2016</year><article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title><source>Nature</source><volume>536</volume><fpage>285</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1038/nature19057</pub-id><pub-id pub-id-type="pmid">27535533</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lelieveld</surname><given-names>SH</given-names></name><name><surname>Reijnders</surname><given-names>MRF</given-names></name><name><surname>Pfundt</surname><given-names>R</given-names></name><name><surname>Yntema</surname><given-names>HG</given-names></name><name><surname>Kamsteeg</surname><given-names>EJ</given-names></name><name><surname>de Vries</surname><given-names>P</given-names></name><name><surname>de Vries</surname><given-names>BBA</given-names></name><name><surname>Willemsen</surname><given-names>MH</given-names></name><name><surname>Kleefstra</surname><given-names>T</given-names></name><name><surname>Löhner</surname><given-names>K</given-names></name><name><surname>Vreeburg</surname><given-names>M</given-names></name><name><surname>Stevens</surname><given-names>SJC</given-names></name><name><surname>van der Burgt</surname><given-names>I</given-names></name><name><surname>Bongers</surname><given-names>E</given-names></name><name><surname>Stegmann</surname><given-names>APA</given-names></name><name><surname>Rump</surname><given-names>P</given-names></name><name><surname>Rinne</surname><given-names>T</given-names></name><name><surname>Nelen</surname><given-names>MR</given-names></name><name><surname>Veltman</surname><given-names>JA</given-names></name><name><surname>Vissers</surname><given-names>L</given-names></name><name><surname>Brunner</surname><given-names>HG</given-names></name><name><surname>Gilissen</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability</article-title><source>Nature Neuroscience</source><volume>19</volume><fpage>1194</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1038/nn.4352</pub-id><pub-id pub-id-type="pmid">27479843</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Fast and accurate long-read alignment with burrows-wheeler transform</article-title><source>Bioinformatics</source><volume>26</volume><fpage>589</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp698</pub-id><pub-id pub-id-type="pmid">20080505</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Okada</surname><given-names>S</given-names></name><name><surname>Kong</surname><given-names>XF</given-names></name><name><surname>Kreins</surname><given-names>AY</given-names></name><name><surname>Cypowyj</surname><given-names>S</given-names></name><name><surname>Abhyankar</surname><given-names>A</given-names></name><name><surname>Toubiana</surname><given-names>J</given-names></name><name><surname>Itan</surname><given-names>Y</given-names></name><name><surname>Audry</surname><given-names>M</given-names></name><name><surname>Nitschke</surname><given-names>P</given-names></name><name><surname>Masson</surname><given-names>C</given-names></name><name><surname>Toth</surname><given-names>B</given-names></name><name><surname>Flatot</surname><given-names>J</given-names></name><name><surname>Migaud</surname><given-names>M</given-names></name><name><surname>Chrabieh</surname><given-names>M</given-names></name><name><surname>Kochetkov</surname><given-names>T</given-names></name><name><surname>Bolze</surname><given-names>A</given-names></name><name><surname>Borghesi</surname><given-names>A</given-names></name><name><surname>Toulon</surname><given-names>A</given-names></name><name><surname>Hiller</surname><given-names>J</given-names></name><name><surname>Eyerich</surname><given-names>S</given-names></name><name><surname>Eyerich</surname><given-names>K</given-names></name><name><surname>Gulácsy</surname><given-names>V</given-names></name><name><surname>Chernyshova</surname><given-names>L</given-names></name><name><surname>Chernyshov</surname><given-names>V</given-names></name><name><surname>Bondarenko</surname><given-names>A</given-names></name><name><surname>Grimaldo</surname><given-names>RMC</given-names></name><name><surname>Blancas-Galicia</surname><given-names>L</given-names></name><name><surname>Beas</surname><given-names>IMM</given-names></name><name><surname>Roesler</surname><given-names>J</given-names></name><name><surname>Magdorf</surname><given-names>K</given-names></name><name><surname>Engelhard</surname><given-names>D</given-names></name><name><surname>Thumerelle</surname><given-names>C</given-names></name><name><surname>Burgel</surname><given-names>PR</given-names></name><name><surname>Hoernes</surname><given-names>M</given-names></name><name><surname>Drexel</surname><given-names>B</given-names></name><name><surname>Seger</surname><given-names>R</given-names></name><name><surname>Kusuma</surname><given-names>T</given-names></name><name><surname>Jansson</surname><given-names>AF</given-names></name><name><surname>Sawalle-Belohradsky</surname><given-names>J</given-names></name><name><surname>Belohradsky</surname><given-names>B</given-names></name><name><surname>Jouanguy</surname><given-names>E</given-names></name><name><surname>Bustamante</surname><given-names>J</given-names></name><name><surname>Bué</surname><given-names>M</given-names></name><name><surname>Karin</surname><given-names>N</given-names></name><name><surname>Wildbaum</surname><given-names>G</given-names></name><name><surname>Bodemer</surname><given-names>C</given-names></name><name><surname>Lortholary</surname><given-names>O</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Blanche</surname><given-names>S</given-names></name><name><surname>Al-Muhsen</surname><given-names>S</given-names></name><name><surname>Reichenbach</surname><given-names>J</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Rosales</surname><given-names>FE</given-names></name><name><surname>Lozano</surname><given-names>CT</given-names></name><name><surname>Kilic</surname><given-names>SS</given-names></name><name><surname>Oleastro</surname><given-names>M</given-names></name><name><surname>Etzioni</surname><given-names>A</given-names></name><name><surname>Traidl-Hoffmann</surname><given-names>C</given-names></name><name><surname>Renner</surname><given-names>ED</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Maródi</surname><given-names>L</given-names></name><name><surname>Boisson-Dupuis</surname><given-names>S</given-names></name><name><surname>Puel</surname><given-names>A</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis</article-title><source>The Journal of Experimental Medicine</source><volume>208</volume><fpage>1635</fpage><lpage>1648</lpage><pub-id pub-id-type="doi">10.1084/jem.20110958</pub-id><pub-id pub-id-type="pmid">21727188</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Rate, molecular spectrum, and consequences of human mutation</article-title><source>PNAS</source><volume>107</volume><fpage>961</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1073/pnas.0912629107</pub-id><pub-id pub-id-type="pmid">20080596</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>HC</given-names></name><name><surname>Jones</surname><given-names>WD</given-names></name><name><surname>McIntyre</surname><given-names>R</given-names></name><name><surname>Sanchez-Andrade</surname><given-names>G</given-names></name><name><surname>Sanderson</surname><given-names>M</given-names></name><name><surname>Stephenson</surname><given-names>JD</given-names></name><name><surname>Jones</surname><given-names>CP</given-names></name><name><surname>Handsaker</surname><given-names>J</given-names></name><name><surname>Gallone</surname><given-names>G</given-names></name><name><surname>Bruntraeger</surname><given-names>M</given-names></name><name><surname>McRae</surname><given-names>JF</given-names></name><name><surname>Prigmore</surname><given-names>E</given-names></name><name><surname>Short</surname><given-names>P</given-names></name><name><surname>Niemi</surname><given-names>M</given-names></name><name><surname>Kaplanis</surname><given-names>J</given-names></name><name><surname>Radford</surname><given-names>EJ</given-names></name><name><surname>Akawi</surname><given-names>N</given-names></name><name><surname>Balasubramanian</surname><given-names>M</given-names></name><name><surname>Dean</surname><given-names>J</given-names></name><name><surname>Horton</surname><given-names>R</given-names></name><name><surname>Hulbert</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>DS</given-names></name><name><surname>Johnson</surname><given-names>K</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Lynch</surname><given-names>SA</given-names></name><name><surname>Mehta</surname><given-names>SG</given-names></name><name><surname>Morton</surname><given-names>J</given-names></name><name><surname>Parker</surname><given-names>MJ</given-names></name><name><surname>Splitt</surname><given-names>M</given-names></name><name><surname>Turnpenny</surname><given-names>PD</given-names></name><name><surname>Vasudevan</surname><given-names>PC</given-names></name><name><surname>Wright</surname><given-names>M</given-names></name><name><surname>Bassett</surname><given-names>A</given-names></name><name><surname>Gerety</surname><given-names>SS</given-names></name><name><surname>Wright</surname><given-names>CF</given-names></name><name><surname>FitzPatrick</surname><given-names>DR</given-names></name><name><surname>Firth</surname><given-names>HV</given-names></name><name><surname>Hurles</surname><given-names>ME</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name><collab>Deciphering Developmental Disorders Study</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Quantifying the contribution of recessive coding variation to developmental disorders</article-title><source>Science</source><volume>362</volume><fpage>1161</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.1126/science.aar6731</pub-id><pub-id pub-id-type="pmid">30409806</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname><given-names>A</given-names></name><name><surname>Hanna</surname><given-names>M</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Sivachenko</surname><given-names>A</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Kernytsky</surname><given-names>A</given-names></name><name><surname>Garimella</surname><given-names>K</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Daly</surname><given-names>M</given-names></name><name><surname>DePristo</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The genome analysis toolkit: a mapreduce framework for analyzing next-generation DNA sequencing data</article-title><source>Genome Res</source><volume>20</volume><fpage>1297</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1101/gr.107524.110</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mensa-Vilaro</surname><given-names>A</given-names></name><name><surname>Teresa Bosque</surname><given-names>M</given-names></name><name><surname>Magri</surname><given-names>G</given-names></name><name><surname>Honda</surname><given-names>Y</given-names></name><name><surname>Martínez-Banaclocha</surname><given-names>H</given-names></name><name><surname>Casorran-Berges</surname><given-names>M</given-names></name><name><surname>Sintes</surname><given-names>J</given-names></name><name><surname>González-Roca</surname><given-names>E</given-names></name><name><surname>Ruiz-Ortiz</surname><given-names>E</given-names></name><name><surname>Heike</surname><given-names>T</given-names></name><name><surname>Martínez-Garcia</surname><given-names>JJ</given-names></name><name><surname>Baroja-Mazo</surname><given-names>A</given-names></name><name><surname>Cerutti</surname><given-names>A</given-names></name><name><surname>Nishikomori</surname><given-names>R</given-names></name><name><surname>Yagüe</surname><given-names>J</given-names></name><name><surname>Pelegrín</surname><given-names>P</given-names></name><name><surname>Delgado-Beltran</surname><given-names>C</given-names></name><name><surname>Aróstegui</surname><given-names>JI</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Brief report: late-onset cryopyrin-associated periodic syndrome due to myeloid-restricted somatic NLRP3 mosaicism</article-title><source>Arthritis &amp; Rheumatology</source><volume>68</volume><fpage>3035</fpage><lpage>3041</lpage><pub-id pub-id-type="doi">10.1002/art.39770</pub-id><pub-id pub-id-type="pmid">27273849</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyts</surname><given-names>I</given-names></name><name><surname>Bosch</surname><given-names>B</given-names></name><name><surname>Bolze</surname><given-names>A</given-names></name><name><surname>Boisson</surname><given-names>B</given-names></name><name><surname>Itan</surname><given-names>Y</given-names></name><name><surname>Belkadi</surname><given-names>A</given-names></name><name><surname>Pedergnana</surname><given-names>V</given-names></name><name><surname>Moens</surname><given-names>L</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Cobat</surname><given-names>A</given-names></name><name><surname>Bossuyt</surname><given-names>X</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Exome and genome sequencing for inborn errors of immunity</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>138</volume><fpage>957</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2016.08.003</pub-id><pub-id pub-id-type="pmid">27720020</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molho-Pessach</surname><given-names>V</given-names></name><name><surname>Ramot</surname><given-names>Y</given-names></name><name><surname>Mogilevsky</surname><given-names>M</given-names></name><name><surname>Cohen-Daniel</surname><given-names>L</given-names></name><name><surname>Eisenstein</surname><given-names>EM</given-names></name><name><surname>Abu-Libdeh</surname><given-names>A</given-names></name><name><surname>Siam</surname><given-names>I</given-names></name><name><surname>Berger</surname><given-names>M</given-names></name><name><surname>Karni</surname><given-names>R</given-names></name><name><surname>Zlotogorski</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Generalized verrucosis and abnormal T cell activation due to homozygous TAOK2 mutation</article-title><source>Journal of Dermatological Science</source><volume>87</volume><fpage>123</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2017.03.018</pub-id><pub-id pub-id-type="pmid">28385331</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moya-Quiles</surname><given-names>MR</given-names></name><name><surname>Bernardo-Pisa</surname><given-names>MV</given-names></name><name><surname>Menasalvas</surname><given-names>A</given-names></name><name><surname>Alfayate</surname><given-names>S</given-names></name><name><surname>Fuster</surname><given-names>JL</given-names></name><name><surname>Boix</surname><given-names>F</given-names></name><name><surname>Salgado</surname><given-names>G</given-names></name><name><surname>Muro</surname><given-names>M</given-names></name><name><surname>Minguela</surname><given-names>A</given-names></name><name><surname>Alvarez-López</surname><given-names>MR</given-names></name><name><surname>García-Alonso</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Severe combined immunodeficiency: first report of a <italic>de novo</italic> mutation in the IL2RG gene in a boy conceived by in vitro fertilization</article-title><source>Clinical Genetics</source><volume>85</volume><fpage>500</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1111/cge.12208</pub-id><pub-id pub-id-type="pmid">23790094</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neitzel</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>A routine method for the establishment of permanent growing lymphoblastoid cell lines</article-title><source>Human Genetics</source><volume>73</volume><fpage>320</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1007/BF00279094</pub-id><pub-id pub-id-type="pmid">3017841</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oosting</surname><given-names>M</given-names></name><name><surname>Kerstholt</surname><given-names>M</given-names></name><name><surname>Ter Horst</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Deelen</surname><given-names>P</given-names></name><name><surname>Smeekens</surname><given-names>S</given-names></name><name><surname>Jaeger</surname><given-names>M</given-names></name><name><surname>Lachmandas</surname><given-names>E</given-names></name><name><surname>Vrijmoeth</surname><given-names>H</given-names></name><name><surname>Lupse</surname><given-names>M</given-names></name><name><surname>Flonta</surname><given-names>M</given-names></name><name><surname>Cramer</surname><given-names>RA</given-names></name><name><surname>Kullberg</surname><given-names>BJ</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Xavier</surname><given-names>R</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Functional and genomic architecture of borrelia burgdorferi-induced cytokine responses in humans</article-title><source>Cell Host &amp; Microbe</source><volume>20</volume><fpage>822</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.10.006</pub-id><pub-id pub-id-type="pmid">27818078</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintana-Murci</surname><given-names>L</given-names></name><name><surname>Clark</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Population genetic tools for dissecting innate immunity in humans</article-title><source>Nature Reviews. Immunology</source><volume>13</volume><fpage>280</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1038/nri3421</pub-id><pub-id pub-id-type="pmid">23470320</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabenhorst</surname><given-names>U</given-names></name><name><surname>Thalheimer</surname><given-names>FB</given-names></name><name><surname>Gerlach</surname><given-names>K</given-names></name><name><surname>Kijonka</surname><given-names>M</given-names></name><name><surname>Böhm</surname><given-names>S</given-names></name><name><surname>Krause</surname><given-names>DS</given-names></name><name><surname>Vauti</surname><given-names>F</given-names></name><name><surname>Arnold</surname><given-names>HH</given-names></name><name><surname>Schroeder</surname><given-names>T</given-names></name><name><surname>Schnütgen</surname><given-names>F</given-names></name><name><surname>von Melchner</surname><given-names>H</given-names></name><name><surname>Rieger</surname><given-names>MA</given-names></name><name><surname>Zörnig</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Single-stranded DNA-binding transcriptional regulator FUBP1 is essential for fetal and adult hematopoietic stem cell self-renewal</article-title><source>Cell Reports</source><volume>11</volume><fpage>1847</fpage><lpage>1855</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.05.038</pub-id><pub-id pub-id-type="pmid">26095368</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Radboudumc</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Primary Immunodeficiency Gene Panel DG 3.1.0 (456 genes)</article-title><ext-link ext-link-type="uri" xlink:href="https://www.radboudumc.nl/getmedia/9f3c2425-6875-4887-9c32-3a1dae08f627/PRIMARYIMMUNODEFICIENCY_DG310.aspx">https://www.radboudumc.nl/getmedia/9f3c2425-6875-4887-9c32-3a1dae08f627/PRIMARYIMMUNODEFICIENCY_DG310.aspx</ext-link><date-in-citation iso-8601-date="2021-03-23">March 23, 2021</date-in-citation></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>S</given-names></name><name><surname>Aziz</surname><given-names>N</given-names></name><name><surname>Bale</surname><given-names>S</given-names></name><name><surname>Bick</surname><given-names>D</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Gastier-Foster</surname><given-names>J</given-names></name><name><surname>Grody</surname><given-names>WW</given-names></name><name><surname>Hegde</surname><given-names>M</given-names></name><name><surname>Lyon</surname><given-names>E</given-names></name><name><surname>Spector</surname><given-names>E</given-names></name><name><surname>Voelkerding</surname><given-names>K</given-names></name><name><surname>Rehm</surname><given-names>HL</given-names></name><name><surname>Committee</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the american college of medical genetics and genomics and the association for molecular pathology</article-title><source>Genetics in Medicine</source><volume>17</volume><fpage>405</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1038/gim.2015.30</pub-id><pub-id pub-id-type="pmid">25741868</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudilla</surname><given-names>F</given-names></name><name><surname>Franco-Jarava</surname><given-names>C</given-names></name><name><surname>Martínez-Gallo</surname><given-names>M</given-names></name><name><surname>Garcia-Prat</surname><given-names>M</given-names></name><name><surname>Martín-Nalda</surname><given-names>A</given-names></name><name><surname>Rivière</surname><given-names>J</given-names></name><name><surname>Aguiló-Cucurull</surname><given-names>A</given-names></name><name><surname>Mongay</surname><given-names>L</given-names></name><name><surname>Vidal</surname><given-names>F</given-names></name><name><surname>Solanich</surname><given-names>X</given-names></name><name><surname>Irastorza</surname><given-names>I</given-names></name><name><surname>Santos-Pérez</surname><given-names>JL</given-names></name><name><surname>Tercedor Sánchez</surname><given-names>J</given-names></name><name><surname>Cuscó</surname><given-names>I</given-names></name><name><surname>Serra</surname><given-names>C</given-names></name><name><surname>Baz-Redón</surname><given-names>N</given-names></name><name><surname>Fernández-Cancio</surname><given-names>M</given-names></name><name><surname>Carreras</surname><given-names>C</given-names></name><name><surname>Vagace</surname><given-names>JM</given-names></name><name><surname>Garcia-Patos</surname><given-names>V</given-names></name><name><surname>Pujol-Borrell</surname><given-names>R</given-names></name><name><surname>Soler-Palacín</surname><given-names>P</given-names></name><name><surname>Colobran</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Expanding the clinical and genetic spectra of primary immunodeficiency-related disorders with clinical exome sequencing: expected and unexpected findings</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>2325</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.02325</pub-id><pub-id pub-id-type="pmid">31681265</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarrabay</surname><given-names>G</given-names></name><name><surname>Méchin</surname><given-names>D</given-names></name><name><surname>Salhi</surname><given-names>A</given-names></name><name><surname>Boursier</surname><given-names>G</given-names></name><name><surname>Rittore</surname><given-names>C</given-names></name><name><surname>Crow</surname><given-names>Y</given-names></name><name><surname>Rice</surname><given-names>G</given-names></name><name><surname>Tran</surname><given-names>TA</given-names></name><name><surname>Cezar</surname><given-names>R</given-names></name><name><surname>Duffy</surname><given-names>D</given-names></name><name><surname>Bondet</surname><given-names>V</given-names></name><name><surname>Boudhane</surname><given-names>L</given-names></name><name><surname>Broca</surname><given-names>C</given-names></name><name><surname>Kant</surname><given-names>BP</given-names></name><name><surname>VanGijn</surname><given-names>M</given-names></name><name><surname>Grandemange</surname><given-names>S</given-names></name><name><surname>Richard</surname><given-names>E</given-names></name><name><surname>Apparailly</surname><given-names>F</given-names></name><name><surname>Touitou</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>PSMB10, the last immunoproteasome gene missing for PRAAS</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>145</volume><fpage>1015</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2019.11.024</pub-id><pub-id pub-id-type="pmid">31783057</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherry</surname><given-names>ST</given-names></name><name><surname>Ward</surname><given-names>M</given-names></name><name><surname>Sirotkin</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>DbSNP—database for single nucleotide polymorphisms and other classes of minor genetic variation</article-title><source>Genome Research</source><volume>9</volume><fpage>677</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1101/gr.9.8.677</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>AJ</given-names></name><name><surname>Golan</surname><given-names>AC</given-names></name><name><surname>Lev</surname><given-names>A</given-names></name><name><surname>Stauber</surname><given-names>T</given-names></name><name><surname>Barel</surname><given-names>O</given-names></name><name><surname>Somekh</surname><given-names>I</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>AbuZaitun</surname><given-names>O</given-names></name><name><surname>Eyal</surname><given-names>E</given-names></name><name><surname>Kol</surname><given-names>N</given-names></name><name><surname>Unal</surname><given-names>E</given-names></name><name><surname>Amariglio</surname><given-names>N</given-names></name><name><surname>Rechavi</surname><given-names>G</given-names></name><name><surname>Somech</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Whole exome sequencing (WES) approach for diagnosing primary immunodeficiencies (pids) in a highly consanguineous community</article-title><source>Clinical Immunology</source><volume>214</volume><elocation-id>108376</elocation-id><pub-id pub-id-type="doi">10.1016/j.clim.2020.108376</pub-id><pub-id pub-id-type="pmid">32135276</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skaar</surname><given-names>JR</given-names></name><name><surname>Pagan</surname><given-names>JK</given-names></name><name><surname>Pagano</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mechanisms and function of substrate recruitment by F-box proteins</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>14</volume><fpage>369</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1038/nrm3582</pub-id><pub-id pub-id-type="pmid">23657496</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobreira</surname><given-names>N</given-names></name><name><surname>Schiettecatte</surname><given-names>F</given-names></name><name><surname>Valle</surname><given-names>D</given-names></name><name><surname>Hamosh</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>GeneMatcher: a matching tool for connecting investigators with an interest in the same gene</article-title><source>Human Mutation</source><volume>36</volume><fpage>928</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1002/humu.22844</pub-id><pub-id pub-id-type="pmid">26220891</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephenson</surname><given-names>JD</given-names></name><name><surname>Laskowski</surname><given-names>RA</given-names></name><name><surname>Nightingale</surname><given-names>A</given-names></name><name><surname>Hurles</surname><given-names>ME</given-names></name><name><surname>Thornton</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>VarMap: a web tool for mapping genomic coordinates to protein sequence and structure and retrieving protein structural annotations</article-title><source>Bioinformatics</source><volume>35</volume><fpage>4854</fpage><lpage>4856</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btz482</pub-id><pub-id pub-id-type="pmid">31192369</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stray-Pedersen</surname><given-names>A</given-names></name><name><surname>Sorte</surname><given-names>HS</given-names></name><name><surname>Samarakoon</surname><given-names>P</given-names></name><name><surname>Gambin</surname><given-names>T</given-names></name><name><surname>Chinn</surname><given-names>IK</given-names></name><name><surname>Coban Akdemir</surname><given-names>ZH</given-names></name><name><surname>Erichsen</surname><given-names>HC</given-names></name><name><surname>Forbes</surname><given-names>LR</given-names></name><name><surname>Gu</surname><given-names>S</given-names></name><name><surname>Yuan</surname><given-names>B</given-names></name><name><surname>Jhangiani</surname><given-names>SN</given-names></name><name><surname>Muzny</surname><given-names>DM</given-names></name><name><surname>Rødningen</surname><given-names>OK</given-names></name><name><surname>Sheng</surname><given-names>Y</given-names></name><name><surname>Nicholas</surname><given-names>SK</given-names></name><name><surname>Noroski</surname><given-names>LM</given-names></name><name><surname>Seeborg</surname><given-names>FO</given-names></name><name><surname>Davis</surname><given-names>CM</given-names></name><name><surname>Canter</surname><given-names>DL</given-names></name><name><surname>Mace</surname><given-names>EM</given-names></name><name><surname>Vece</surname><given-names>TJ</given-names></name><name><surname>Allen</surname><given-names>CE</given-names></name><name><surname>Abhyankar</surname><given-names>HA</given-names></name><name><surname>Boone</surname><given-names>PM</given-names></name><name><surname>Beck</surname><given-names>CR</given-names></name><name><surname>Wiszniewski</surname><given-names>W</given-names></name><name><surname>Fevang</surname><given-names>B</given-names></name><name><surname>Aukrust</surname><given-names>P</given-names></name><name><surname>Tjønnfjord</surname><given-names>GE</given-names></name><name><surname>Gedde-Dahl</surname><given-names>T</given-names></name><name><surname>Hjorth-Hansen</surname><given-names>H</given-names></name><name><surname>Dybedal</surname><given-names>I</given-names></name><name><surname>Nordøy</surname><given-names>I</given-names></name><name><surname>Jørgensen</surname><given-names>SF</given-names></name><name><surname>Abrahamsen</surname><given-names>TG</given-names></name><name><surname>Øverland</surname><given-names>T</given-names></name><name><surname>Bechensteen</surname><given-names>AG</given-names></name><name><surname>Skogen</surname><given-names>V</given-names></name><name><surname>Osnes</surname><given-names>LTN</given-names></name><name><surname>Kulseth</surname><given-names>MA</given-names></name><name><surname>Prescott</surname><given-names>TE</given-names></name><name><surname>Rustad</surname><given-names>CF</given-names></name><name><surname>Heimdal</surname><given-names>KR</given-names></name><name><surname>Belmont</surname><given-names>JW</given-names></name><name><surname>Rider</surname><given-names>NL</given-names></name><name><surname>Chinen</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>TN</given-names></name><name><surname>Smith</surname><given-names>EA</given-names></name><name><surname>Caldirola</surname><given-names>MS</given-names></name><name><surname>Bezrodnik</surname><given-names>L</given-names></name><name><surname>Lugo Reyes</surname><given-names>SO</given-names></name><name><surname>Espinosa Rosales</surname><given-names>FJ</given-names></name><name><surname>Guerrero-Cursaru</surname><given-names>ND</given-names></name><name><surname>Pedroza</surname><given-names>LA</given-names></name><name><surname>Poli</surname><given-names>CM</given-names></name><name><surname>Franco</surname><given-names>JL</given-names></name><name><surname>Trujillo Vargas</surname><given-names>CM</given-names></name><name><surname>Aldave Becerra</surname><given-names>JC</given-names></name><name><surname>Wright</surname><given-names>N</given-names></name><name><surname>Issekutz</surname><given-names>TB</given-names></name><name><surname>Issekutz</surname><given-names>AC</given-names></name><name><surname>Abbott</surname><given-names>J</given-names></name><name><surname>Caldwell</surname><given-names>JW</given-names></name><name><surname>Bayer</surname><given-names>DK</given-names></name><name><surname>Chan</surname><given-names>AY</given-names></name><name><surname>Aiuti</surname><given-names>A</given-names></name><name><surname>Cancrini</surname><given-names>C</given-names></name><name><surname>Holmberg</surname><given-names>E</given-names></name><name><surname>West</surname><given-names>C</given-names></name><name><surname>Burstedt</surname><given-names>M</given-names></name><name><surname>Karaca</surname><given-names>E</given-names></name><name><surname>Yesil</surname><given-names>G</given-names></name><name><surname>Artac</surname><given-names>H</given-names></name><name><surname>Bayram</surname><given-names>Y</given-names></name><name><surname>Atik</surname><given-names>MM</given-names></name><name><surname>Eldomery</surname><given-names>MK</given-names></name><name><surname>Ehlayel</surname><given-names>MS</given-names></name><name><surname>Jolles</surname><given-names>S</given-names></name><name><surname>Flatø</surname><given-names>B</given-names></name><name><surname>Bertuch</surname><given-names>AA</given-names></name><name><surname>Hanson</surname><given-names>IC</given-names></name><name><surname>Zhang</surname><given-names>VW</given-names></name><name><surname>Wong</surname><given-names>LJ</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Walkiewicz</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Eng</surname><given-names>CM</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Gibbs</surname><given-names>RA</given-names></name><name><surname>Shearer</surname><given-names>WT</given-names></name><name><surname>Lyle</surname><given-names>R</given-names></name><name><surname>Orange</surname><given-names>JS</given-names></name><name><surname>Lupski</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Primary immunodeficiency diseases: genomic approaches delineate heterogeneous mendelian disorders</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>139</volume><fpage>232</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2016.05.042</pub-id><pub-id pub-id-type="pmid">27577878</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tangye</surname><given-names>SG</given-names></name><name><surname>Al-Herz</surname><given-names>W</given-names></name><name><surname>Bousfiha</surname><given-names>A</given-names></name><name><surname>Chatila</surname><given-names>T</given-names></name><name><surname>Cunningham-Rundles</surname><given-names>C</given-names></name><name><surname>Etzioni</surname><given-names>A</given-names></name><name><surname>Franco</surname><given-names>JL</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>Morio</surname><given-names>T</given-names></name><name><surname>Ochs</surname><given-names>HD</given-names></name><name><surname>Oksenhendler</surname><given-names>E</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Puck</surname><given-names>J</given-names></name><name><surname>Torgerson</surname><given-names>TR</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name><name><surname>Sullivan</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Human inborn errors of immunity: 2019 update on the classification from the international union of immunological societies expert committee</article-title><source>Journal of Clinical Immunology</source><volume>40</volume><fpage>24</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1007/s10875-019-00737-x</pub-id><pub-id pub-id-type="pmid">31953710</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treise</surname><given-names>I</given-names></name><name><surname>Huber</surname><given-names>EM</given-names></name><name><surname>Klein-Rodewald</surname><given-names>T</given-names></name><name><surname>Heinemeyer</surname><given-names>W</given-names></name><name><surname>Grassmann</surname><given-names>SA</given-names></name><name><surname>Basler</surname><given-names>M</given-names></name><name><surname>Adler</surname><given-names>T</given-names></name><name><surname>Rathkolb</surname><given-names>B</given-names></name><name><surname>Helming</surname><given-names>L</given-names></name><name><surname>Andres</surname><given-names>C</given-names></name><name><surname>Klaften</surname><given-names>M</given-names></name><name><surname>Landbrecht</surname><given-names>C</given-names></name><name><surname>Wieland</surname><given-names>T</given-names></name><name><surname>Strom</surname><given-names>TM</given-names></name><name><surname>McCoy</surname><given-names>KD</given-names></name><name><surname>Macpherson</surname><given-names>AJ</given-names></name><name><surname>Wolf</surname><given-names>E</given-names></name><name><surname>Groettrup</surname><given-names>M</given-names></name><name><surname>Ollert</surname><given-names>M</given-names></name><name><surname>Neff</surname><given-names>F</given-names></name><name><surname>Gailus-Durner</surname><given-names>V</given-names></name><name><surname>Fuchs</surname><given-names>H</given-names></name><name><surname>Hrabě de Angelis</surname><given-names>M</given-names></name><name><surname>Groll</surname><given-names>M</given-names></name><name><surname>Busch</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Defective immuno- and thymoproteasome assembly causes severe immunodeficiency</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>5975</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-24199-0</pub-id><pub-id pub-id-type="pmid">29654304</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>TN</given-names></name><name><surname>Yi</surname><given-names>Q</given-names></name><name><surname>Krumm</surname><given-names>N</given-names></name><name><surname>Huddleston</surname><given-names>J</given-names></name><name><surname>Hoekzema</surname><given-names>K</given-names></name><name><surname>F Stessman</surname><given-names>HA</given-names></name><name><surname>Doebley</surname><given-names>AL</given-names></name><name><surname>Bernier</surname><given-names>RA</given-names></name><name><surname>Nickerson</surname><given-names>DA</given-names></name><name><surname>Eichler</surname><given-names>EE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Denovo-db: a compendium of human <italic>de novo</italic> variants</article-title><source>Nucleic Acids Research</source><volume>45</volume><fpage>D804</fpage><lpage>D811</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw865</pub-id><pub-id pub-id-type="pmid">27907889</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Made</surname><given-names>CI</given-names></name><name><surname>Hoischen</surname><given-names>A</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>van de Veerdonk</surname><given-names>FL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Primary immunodeficiencies in cytosolic pattern-recognition receptor pathways: toward host-directed treatment strategies</article-title><source>Immunol Rev</source><volume>297</volume><fpage>247</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1111/imr.12898</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Made</surname><given-names>CI</given-names></name><name><surname>Potjewijd</surname><given-names>J</given-names></name><name><surname>Hoogstins</surname><given-names>A</given-names></name><name><surname>Willems</surname><given-names>HPJ</given-names></name><name><surname>Kwakernaak</surname><given-names>AJ</given-names></name><name><surname>de Sevaux</surname><given-names>RGL</given-names></name><name><surname>van Daele</surname><given-names>PLA</given-names></name><name><surname>Simons</surname><given-names>A</given-names></name><name><surname>Heijstek</surname><given-names>M</given-names></name><name><surname>Beck</surname><given-names>DB</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>van Paassen</surname><given-names>P</given-names></name><name><surname>Elizabeth Hak</surname><given-names>A</given-names></name><name><surname>van der Veken</surname><given-names>LT</given-names></name><name><surname>van Gijn</surname><given-names>ME</given-names></name><name><surname>Hoischen</surname><given-names>A</given-names></name><name><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name><surname>Leavis</surname><given-names>HL</given-names></name><name><surname>Rutgers</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Adult-onset autoinflammation caused by somatic mutations in UBA1: a dutch case series of patients with VEXAS</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>149</volume><fpage>432</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2021.05.014</pub-id><pub-id pub-id-type="pmid">34048852</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veltman</surname><given-names>JA</given-names></name><name><surname>Brunner</surname><given-names>HG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title><italic>De novo</italic> mutations in human genetic disease</article-title><source>Nature Reviews. Genetics</source><volume>13</volume><fpage>565</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1038/nrg3241</pub-id><pub-id pub-id-type="pmid">22805709</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vissers</surname><given-names>L</given-names></name><name><surname>de Ligt</surname><given-names>J</given-names></name><name><surname>Gilissen</surname><given-names>C</given-names></name><name><surname>Janssen</surname><given-names>I</given-names></name><name><surname>Steehouwer</surname><given-names>M</given-names></name><name><surname>de Vries</surname><given-names>P</given-names></name><name><surname>van Lier</surname><given-names>B</given-names></name><name><surname>Arts</surname><given-names>P</given-names></name><name><surname>Wieskamp</surname><given-names>N</given-names></name><name><surname>del Rosario</surname><given-names>M</given-names></name><name><surname>van Bon</surname><given-names>BWM</given-names></name><name><surname>Hoischen</surname><given-names>A</given-names></name><name><surname>de Vries</surname><given-names>BBA</given-names></name><name><surname>Brunner</surname><given-names>HG</given-names></name><name><surname>Veltman</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A <italic>de novo</italic> paradigm for mental retardation</article-title><source>Nature Genetics</source><volume>42</volume><fpage>1109</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1038/ng.712</pub-id><pub-id pub-id-type="pmid">21076407</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vorsteveld</surname><given-names>EE</given-names></name><name><surname>Hoischen</surname><given-names>A</given-names></name><name><surname>van der Made</surname><given-names>CI</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Next-generation sequencing in the field of primary immunodeficiencies: current yield, challenges, and future perspectives</article-title><source>Clinical Reviews in Allergy &amp; Immunology</source><volume>61</volume><fpage>212</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1007/s12016-021-08838-5</pub-id><pub-id pub-id-type="pmid">33666867</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Wallis</surname><given-names>Y</given-names></name><name><surname>Payne</surname><given-names>S</given-names></name><name><surname>McAnulty</surname><given-names>C</given-names></name><name><surname>Bodmer</surname><given-names>D</given-names></name><name><surname>Sistermans</surname><given-names>E</given-names></name><name><surname>Robertson</surname><given-names>K</given-names></name><name><surname>Moore</surname><given-names>D</given-names></name><name><surname>Abbs</surname><given-names>S</given-names></name><name><surname>Deans</surname><given-names>Z</given-names></name><name><surname>Devereau</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Practice Guidelines for the Evaluation of Pathogenicity and the Reporting of Sequence Variants in Clinical Molecular Genetics</article-title><ext-link ext-link-type="uri" xlink:href="https://www.acgs.uk.com/media/10791/evaluation_and_reporting_of_sequence_variants_bpgs_june_2013_-_finalpdf.pdf">https://www.acgs.uk.com/media/10791/evaluation_and_reporting_of_sequence_variants_bpgs_june_2013_-_finalpdf.pdf</ext-link><date-in-citation iso-8601-date="2013-06-03">June 3, 2013</date-in-citation></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Ren</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Fbxw11 promotes the proliferation of lymphocytic leukemia cells through the concomitant activation of NF-κB and β-catenin/TCF signaling pathways</article-title><source>Cell Death &amp; Disease</source><volume>9</volume><elocation-id>427</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-018-0440-1</pub-id><pub-id pub-id-type="pmid">29555946</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>G</given-names></name><name><surname>Ding</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>CY</given-names></name><name><surname>Gou</surname><given-names>F</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>P</given-names></name><name><surname>Hao</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A comprehensive RNA editome reveals that edited azin1 partners with DDX1 to enable hematopoietic stem cell differentiation</article-title><source>Blood</source><volume>138</volume><fpage>1939</fpage><lpage>1952</lpage><pub-id pub-id-type="doi">10.1182/blood.2021011314</pub-id><pub-id pub-id-type="pmid">34388251</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiel</surname><given-names>L</given-names></name><name><surname>Baakman</surname><given-names>C</given-names></name><name><surname>Gilissen</surname><given-names>D</given-names></name><name><surname>Veltman</surname><given-names>JA</given-names></name><name><surname>Vriend</surname><given-names>G</given-names></name><name><surname>Gilissen</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>MetaDome: pathogenicity analysis of genetic variants through aggregation of homologous human protein domains</article-title><source>Human Mutation</source><volume>40</volume><fpage>1030</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1002/humu.23798</pub-id><pub-id pub-id-type="pmid">31116477</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolach</surname><given-names>B</given-names></name><name><surname>Scharf</surname><given-names>Y</given-names></name><name><surname>Gavrieli</surname><given-names>R</given-names></name><name><surname>de Boer</surname><given-names>M</given-names></name><name><surname>Roos</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Unusual late presentation of X-linked chronic granulomatous disease in an adult female with a somatic mosaic for a novel mutation in CYBB</article-title><source>Blood</source><volume>105</volume><fpage>61</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-02-0675</pub-id><pub-id pub-id-type="pmid">15308575</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>World Medical</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>World medical association declaration of helsinki: ethical principles for medical research involving human subjects</article-title><source>JAMA</source><volume>310</volume><fpage>2191</fpage><lpage>2194</lpage><pub-id pub-id-type="doi">10.1001/jama.2013.281053</pub-id><pub-id pub-id-type="pmid">24141714</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaron</surname><given-names>A</given-names></name><name><surname>Hatzubai</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>M</given-names></name><name><surname>Lavon</surname><given-names>I</given-names></name><name><surname>Amit</surname><given-names>S</given-names></name><name><surname>Manning</surname><given-names>AM</given-names></name><name><surname>Andersen</surname><given-names>JS</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name><name><surname>Mercurio</surname><given-names>F</given-names></name><name><surname>Ben-Neriah</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Identification of the receptor component of the ikappabalpha-ubiquitin ligase</article-title><source>Nature</source><volume>396</volume><fpage>590</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1038/25159</pub-id><pub-id pub-id-type="pmid">9859996</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Bao</surname><given-names>M</given-names></name><name><surname>Facchinetti</surname><given-names>V</given-names></name><name><surname>Jung</surname><given-names>SY</given-names></name><name><surname>Ghaffari</surname><given-names>AA</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>YJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>DDX1, DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsrna in dendritic cells</article-title><source>Immunity</source><volume>34</volume><fpage>866</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.03.027</pub-id><pub-id pub-id-type="pmid">21703541</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Lee</surname><given-names>GS</given-names></name><name><surname>Brady</surname><given-names>J</given-names></name><name><surname>Datta</surname><given-names>S</given-names></name><name><surname>Katan</surname><given-names>M</given-names></name><name><surname>Sheikh</surname><given-names>A</given-names></name><name><surname>Martins</surname><given-names>MS</given-names></name><name><surname>Bunney</surname><given-names>TD</given-names></name><name><surname>Santich</surname><given-names>BH</given-names></name><name><surname>Moir</surname><given-names>S</given-names></name><name><surname>Kuhns</surname><given-names>DB</given-names></name><name><surname>Long Priel</surname><given-names>DA</given-names></name><name><surname>Ombrello</surname><given-names>A</given-names></name><name><surname>Stone</surname><given-names>D</given-names></name><name><surname>Ombrello</surname><given-names>MJ</given-names></name><name><surname>Khan</surname><given-names>J</given-names></name><name><surname>Milner</surname><given-names>JD</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name><name><surname>Aksentijevich</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes A dominantly inherited autoinflammatory disease with immunodeficiency</article-title><source>American Journal of Human Genetics</source><volume>91</volume><fpage>713</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2012.08.006</pub-id><pub-id pub-id-type="pmid">23000145</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Chung</surname><given-names>YJ</given-names></name><name><surname>Parrilla Castellar</surname><given-names>ER</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Chung</surname><given-names>HJ</given-names></name><name><surname>Bandle</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Tessarollo</surname><given-names>L</given-names></name><name><surname>Batchelor</surname><given-names>E</given-names></name><name><surname>Aplan</surname><given-names>PD</given-names></name><name><surname>Levens</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Far upstream element binding protein plays a crucial role in embryonic development, hematopoiesis, and stabilizing myc expression levels</article-title><source>The American Journal of Pathology</source><volume>186</volume><fpage>701</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2015.10.028</pub-id><pub-id pub-id-type="pmid">26774856</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78469.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yuen</surname><given-names>Tony</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.03.30.22272929" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.03.30.22272929"/></front-stub><body><p>This is an important paper that reports on the diagnostic utility of TRIO-based whole-exome sequencing (WES) for patients with suspected monogenic inborn errors of immunity, which is supported by solid data. This manuscript will be of particular interest to medical geneticists, immunologists, and physicians working with patients with primary immunodeficiencies.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78469.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Yuen</surname><given-names>Tony</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.03.30.22272929">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2022.03.30.22272929v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Trio-based whole exome sequencing in patients with suspected sporadic inborn errors of immunity: a retrospective cohort study&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Mone Zaidi as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) As commented by Reviewer 1, please check the filtering strategy for DNV calls to filter false positives.</p><p>2) The novel identified candidate variants should be confirmed by Sanger sequencing or some other methods/tools (CNVs). This will give a sense of any false variant calls in this type of analysis.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Genomics analysis of rare diseases, including IEI, is valuable to the field despite the limited sample size. However, the current manuscript seems to focus on describing affected genes (though a functional experiment on one candidate). I think the paper will be more suitable for readers in clinical immunology or medical genetics.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. Page 5, line 28, &quot;&lt;20% variant allele frequency&quot;. Do the authors mean Variant Allele Fraction? The filtering pipeline excluded somatic variation below 20% VAF, which is understandable as decreasing the VAF cutoff introduces a lot of noise; nevertheless, in some diseases, somatic variations are found at 5-20% VAF. This could be commented on in the Discussion.</p><p>2. Page 11, line 13: the wording in this sentence is too strong. Finding a heterozygous pathogenic or a likely pathogenic variant in recessively inherited disease-associated genes does not constitute &quot; a likely molecular diagnosis.&quot; Unless there is evidence that at least some of these pathogenic and LP variants affect the same pathway and have a synergistic effect.</p><p>3. What is the percentage of patients with a confirmed molecular diagnosis? I can count only 6 patients in the table 3 (10,12, 59,91,105,122). Please correct me if I am wrong.</p><p>4. Finding small CNV's (for example 1-2 exon deletions) is hard due to a high false-positive rate. If only one tool was used (i.e., CoNIFER), did the authors use any additional method to confirm these de novo CNVs in patients 21, 69, and 115? It is unclear to me whether any of these CNVs have been previously identified/reported in some databases.</p><p>5. During the variant filtering step, only de novo nonsynonymous coding and splice region variants were kept. The authors mentioned analyzing splice-site DNVs specifically using the Alamut software, which provides a few prediction tools. The authors may consider using other algorithms, such as SpliceAI, which appears to be highly reliable for prioritizing variants. (PMID: 30661751)</p><p>6. Table 4, I question the pathogenicity predictions regarding the KMT2C frameshift variant. The CADD score is only 14.7, and according to UCSC as well as polyphen-2, this residue is not conserved between species (Serine to Histidine between human and mouse).</p><p>7. Page 17, line 9: although most proteasome-associate diseases are recessively inherited, there are examples of a dominantly inherited mutation in PSMB9. (PMID 33727065 and 34819510)</p><p>8. Page 21, line 13: are there different isoforms of FBXW11? Cell-specific expression of various isoforms can potentially explain how LoF variants in this gene can be associated with a neurodevelopmental phenotype in some patients and an immunological disease in other patients. (e.g., CDC42-associated diseases, UBA1-associated diseases).</p><p>9. Page 24, line 10: there is a typo in this sentence &quot; soma&quot;, it should be &quot;somatic&quot;.</p><p>10. The authors may discuss other possible explanations for the lower-than-expected diagnostic rate in this cohort and similar cohorts of patients with suspected monogenic immunological diseases. Possible explanations are uneven coverage of coding regions (especially exon 1 tends to be poorly covered), the fact that only protein-coding regions are captured by WES, somatic mutations in the early post-zygotic stage (PMID: 32750333), or some other explanations. Reduced penetrance is another factor, which is not pertinent to this study, as this study focuses on the identification of de novo variants. Expectedly, the diagnostic rate will be higher when working with patients with recessively inherited PID and from founder populations and this may explain the diagnostic rate of 75% in some studies.</p><p>11. Some sentences are repetitive in the Result section and Discussion e.g., the discussion on the PSMB10, RELA, and NLRP3 variants.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78469.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) As commented by Reviewer 1, please check the filtering strategy for DNV calls to filter false positives.</p></disp-quote><p>We agree with Reviewer 1 that filtering for rare variants, even more so for DNVs, is prone to falsepositive findings. Our filtering strategy is in accordance with other DNV filtering strategies in literature [1-3]. While this filtering strategy minimizes the likelihood for false-positive findings, it ensures that only a fraction of true positives are missed. A very low variant allele frequency should be permitted, especially for variants in genes known to cause inborn errors of immunity. DNVs in these genes that are found in presumed healthy individuals in population databases might still be pathogenic due to decreased penetrance, adult-onset development of the disease or postzygotic occurrence. Apart from standard filters on variant allele frequency and quality, we have applied several approaches to minimize the risk of false-positive DNVs:</p><list list-type="bullet"><list-item><p>To minimize the contribution of local genetic variation and sequencing artefacts to potential false-positive variant calls, we have filtered variants both on the Dutch population database (GoNL) and our in-house database (containing &gt;60,000 exomes) variant allele frequencies.</p></list-item><list-item><p>Additionally, the automated DNV calling is based on &gt;2% alternate allele reads in either parent, meaning that the DNVs are high confidence calls.</p></list-item><list-item><p>Variants were further filtered based on an annotated function in the immune system, which increased the likelihood of finding true-positive DNVs.</p></list-item><list-item><p>The final 14 candidate DNVs and variants reported by the diagnostic department were inspected visually with the Integrative Genomics Viewer (IGV) and/or Alamut Visual software to exclude false-positive variants. We have added <xref ref-type="fig" rid="sa2fig1">Author response images 1</xref>–<xref ref-type="fig" rid="sa2fig17">17</xref> , our final 14 candidate DNVs, for the inspection by the Editors and reviewers, and could add this information to the manuscript supplement if judged to be helpful.</p></list-item></list><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>Patient 1: PSMB10 Chr16(GRCh37):g.67968809C&gt;T NM_002801.3:c.601G&gt;A p.(Gly201Arg).</title><p>Score &lt;500, but validated by an independent test (Sanger sequencing).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-sa2-fig1-v2.tif"/></fig><fig id="sa2fig2" position="float"><label>Author response image 2.</label><caption><title>Patient 9: RPL27A Chr11(GRCh37):g.8707228T&gt;C NM_000990.4:c.322T&gt;C p.(Tyr108His).</title><p>Validated by an independent test (identified by single and trio-based WES).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-sa2-fig2-v2.tif"/></fig><fig id="sa2fig3" position="float"><label>Author response image 3.</label><caption><title>Patient 21: seq[GRCh37] del(17)(q25.3qter) NC_000017.10:g.(80544076_80544938)_qterdel.</title><p>Validated by independent test (identified by two different enrichment kits: Agilent Technologies and Twist Bioscience).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-sa2-fig3-v2.tif"/></fig><fig id="sa2fig4" position="float"><label>Author response image 4.</label><caption><title>Patient 27: TAOK2 Chr16(GRCh37):g.29997683C&gt;T NM_016151.3:c.2090C&gt;T p.(Ala697Val).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-sa2-fig4-v2.tif"/></fig><fig id="sa2fig5" position="float"><label>Author response image 5.</label><caption><title>Patient 28: KCTD9 Chr8(GRCh37):g.25292997C&gt;T NM_017634.3:c.695G&gt;A p.(Arg232His).</title><p>Score &lt;500, but validated by an independent test (Sanger sequencing).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-sa2-fig5-v2.tif"/></fig><fig id="sa2fig6" position="float"><label>Author response image 6.</label><caption><title>Patient 49: DDX1 Chr2(GRCh37):g.15769802dup NM_004939.2:c.1952dup p.(Trp652fs).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-sa2-fig6-v2.tif"/></fig><fig id="sa2fig7" position="float"><label>Author response image 7.</label><caption><title>Patient 52: SCRIB Chr8(GRCh37):g.144874432C&gt;T NM_182706.4:c.4472G&gt;A p.(Arg1491Gln).</title><p>Score &lt;500 and not validated by an independent test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-sa2-fig7-v2.tif"/></fig><fig id="sa2fig8" position="float"><label>Author response image 8.</label><caption><title>Patient 53: FBXW11 Chr5(GRCh37):g.171295802T&gt;C NM_012300.2:c.1468-2A&gt;G p.?.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-sa2-fig8-v2.tif"/></fig><fig id="sa2fig9" position="float"><label>Author response image 9.</label><caption><title>Patient 58: CTCF Chr16(GRCh37):g.67645905G&gt;T NM_006565.4:c.833G&gt;T p.(Arg278Leu).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-sa2-fig9-v2.tif"/></fig><fig id="sa2fig10" position="float"><label>Author response image 10.</label><caption><title>Patient 59: NLRP3 Chr1(GRCh37):g.247587794C&gt;T NM_001079821.2:c.1049C&gt;T p.(Thr350Met).</title><p>Score &lt;500, but validated by an independent test (identified prior to trio-based WES in a different hospital).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-sa2-fig10-v2.tif"/></fig><fig id="sa2fig11" position="float"><label>Author response image 11.</label><caption><title>Patient 59: NLRP3 Chr1(GRCh37):g.Patient 69: seq[GRCh37] dup(22)(q11.21q11.21) NC_000022.10:g.(18775421_18893960)_(21414845_21576183)dup.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-sa2-fig11-v2.tif"/></fig><fig id="sa2fig12" position="float"><label>Author response image 12.</label><caption><title>Patient 75: FUBP1 Chr1(GRCh37):g.78435621A&gt;C NM_001303433.1:c.199T&gt;G p.(Leu67Val).</title><p>Validated by an independent test (identified by single and trio-based WES).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-sa2-fig12-v2.tif"/></fig><fig id="sa2fig13" position="float"><label>Author response image 13.</label><caption><title>Patient 78: KMT2C Chr7(GRCh37):g.151860074del NM_170606.2:c.10588del p.(Ser3530Leufs*3).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-sa2-fig13-v2.tif"/></fig><fig id="sa2fig14" position="float"><label>Author response image 14.</label><caption><title>Patient 108: NSD2 Chr4(GRCh37):g.1959681_1959687delinsTTTTTCT NM_133330.2:c.2903_2909delinsTTTTTCT p.(Arg968_Arg970delinsLeuPheLeu).</title><p>Validated by independent test (WES on different tissue (skin biopsy)).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-sa2-fig14-v2.tif"/></fig><fig id="sa2fig15" position="float"><label>Author response image 15.</label><caption><title>Patient 115: seq[GRCh37] dup(X)(q13).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-sa2-fig15-v2.tif"/></fig><fig id="sa2fig16" position="float"><label>Author response image 16.</label><caption><title>Patient 118: RUNX3 Chr1(GRCh37):g.25256227C&gt;T NM_004350.2:c.133G&gt;A p.(Gly45Arg).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-sa2-fig16-v2.tif"/></fig><fig id="sa2fig17" position="float"><label>Author response image 17.</label><caption><title>Patient 119: RELA Chr11(GRCh37):g.65423234C&gt;T NM_021975.3:c.959-1G&gt;A p.?.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-78469-sa2-fig17-v2.tif"/></fig><p>Integrative Genomics Viewer (IGV) and/or Alamut Visual software screenshots of the 14 final candidate de novo variants and 3 de novo copy number variants</p><p>In conclusion, we are convinced that the used DNV filtering strategy already minimizes the chance of false-positives; and average number of DNVs are in line with recent literature (Figure 1 – source data 3; [4]). Nevertheless, we have adjusted the filtering strategy according to the reviewer’s suggestion by increasing the variation reads from 5 to 10, as this stricter cut-off is also mentioned by some studies in literature [3, 5, 6]. This reduced the total amount of rare DNVs to 172 (previously 187). In addition, we have clarified in the text that our analysis includes 24 variants that were present at very low allele frequencies in population databases (page 13 line 4). We have updated the text (page 5 line 7-8 and 30, page 6 lines 6-8, page 13 lines 3-5 and 8, page 15 line 1, page 23 line 12), and Figure 1 with corresponding table supplement 2 and 3 as well as figure supplement 1.</p><disp-quote content-type="editor-comment"><p>2) The novel identified candidate variants should be confirmed by Sanger sequencing or some other methods/tools (CNVs). This will give a sense of any false variant calls in this type of analysis.</p></disp-quote><p>We agree that for this type of analysis it is very important to keep the possibility of false-positive variant calls as limited as possible. However, the use of Sanger sequencing to confirm SNV candidate variants is no longer standard of practice – in our nor other laboratories as large validation studies preceded the current effort. SNVs called in next-generation sequencing techniques such as whole exome sequencing have been shown to reach a concordance of 99.965% with Sanger sequencing, indicating a very limited chance on false-positives [7]. To further support the absence of any type of bias that would give rise to false-positive DNVs (low quality base calls, read end artifacts, strand bias artifacts, erroneous alignment to low complexity regions, and paralogous alignment of reads) [8], we have added IGV and/or Alamut screenshots of the 14 final 14 DNVs, remaining as the most promising variants, at the end of this rebuttal. Furthermore, our diagnostics department follows standard practice guidelines (ISO15189) that dictate the performance of validations using other techniques if quality scores are &lt;500, as the chances of a false-positive variant call is very low if this score exceeds 500. According to these guidelines, the DNVs identified in patient 1, 28, 52 and 59 would require validation for diagnostic reporting. For three of these patients (1, 28 and 59) as well as patients 9, 75 and 108 independent tests such as re-sequencing, sequencing of other tissue samples or Sanger sequencing were performed and confirmed the presence of the identified DNVs. All other DNVs fulfil diagnostic quality criteria and would be shared in diagnostic reports without any further validation.</p><p>Finally, the de novo copy number variants (CNVs) of patient 21, 69 and 115, were also reported as high confident calls by the diagnostic division of our department according to standard operating procedures, please refer to the attached IGV and/or Alamut screenshots. The high quality scores were most importantly based on the large CNV sizes: patient 21 del17q 500kb, patient 69 dup22q 2.5MB and patient 115 dupXq 400-500kb. Moreover, the CNV in patient 21 was identified by two different enrichment kits, increasing the likelihood that this CNV is a true-positive. Lastly, the CNV in patient 69 is involved in a recurrent microduplication syndrome (Chromosome 22q11.2 micro-duplication syndrome, OMIM #608363) with well-established breakpoints in low-copy repeat elements mediated by nonallelic homologous recombination, which makes true nature of this CNV very likely.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Genomics analysis of rare diseases, including IEI, is valuable to the field despite the limited sample size. However, the current manuscript seems to focus on describing affected genes (though a functional experiment on one candidate). I think the paper will be more suitable for readers in clinical immunology or medical genetics.</p></disp-quote><p>We thank the reviewer for the overall positive assessment of our work. We leave it up to the expertise of the Editor to choose the most appropriate research area within <italic>eLife</italic> that would reach this readership.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. Page 5, line 28, &quot;&lt;20% variant allele frequency&quot;. Do the authors mean Variant Allele Fraction? The filtering pipeline excluded somatic variation below 20% VAF, which is understandable as decreasing the VAF cutoff introduces a lot of noise; nevertheless, in some diseases, somatic variations are found at 5-20% VAF. This could be commented on in the Discussion.</p></disp-quote><p>We indeed meant to express “variant allele fraction”, which has now been corrected in the revised manuscript. Moreover, the reviewer is right in pointing out that somatic variants could be missed with a VAF cut-off of 20%. However, we have checked that no filtered DNVs with a VAF below 20% were missed in established inborn errors of immunity genes. We have added a sentence specifying this in the Materials and methods (page 5 line 31 – page 6 line 1) and Discussion section (page 24 lines 20-21).</p><disp-quote content-type="editor-comment"><p>2. Page 11, line 13: the wording in this sentence is too strong. Finding a heterozygous pathogenic or a likely pathogenic variant in recessively inherited disease-associated genes does not constitute &quot; a likely molecular diagnosis.&quot; Unless there is evidence that at least some of these pathogenic and LP variants affect the same pathway and have a synergistic effect.</p></disp-quote><p>We think this might be based on a misunderstanding, as we do not suggest that the finding of a heterozygous pathogenic or likely pathogenic variant in a recessive disease gene would constitute a diagnosis, but merely carriership. We have updated Table 2 to make it more comprehensible.</p><disp-quote content-type="editor-comment"><p>3. What is the percentage of patients with a confirmed molecular diagnosis? I can count only 6 patients in the table 3 (10,12, 59,91,105,122). Please correct me if I am wrong.</p></disp-quote><p>This too might be based on a misunderstanding. We have rephrased the corresponding sentence in the revised manuscript to increase comprehensibility (page 12 lines 19-21) and we have additionally updated Table 2.</p><disp-quote content-type="editor-comment"><p>4. Finding small CNV's (for example 1-2 exon deletions) is hard due to a high false-positive rate. If only one tool was used (i.e., CoNIFER), did the authors use any additional method to confirm these de novo CNVs in patients 21, 69, and 115? It is unclear to me whether any of these CNVs have been previously identified/reported in some databases.</p></disp-quote><p>As elaborated in our response on page 2, recommendation 2, the de novo CNVs in patients 21, 69 and 115 were all based on high-confidence calls. Due to the high quality scores, the CNVs were not validated by additional sequencing approaches. The CNVs were also manually inspected, please refer to the attached IGV and/or Alamut screenshots. Moreover, the CNV in patient 69 had been previously reported as a cause for 22q11.2 microduplication syndrome (page 12 lines 8-10, Table 2 – source data 1). The CNV identified in patient 21 was encountered in DECIPHER, a reference to which has been added to the revised manuscript (page 12 lines 7-8, Table 2 – source data 1). The CNV of patient 115 was not identified in any database (page 12 lines 10-12). However, it was previously described in another case of our hospital, although the phenotypic overlap was unclear.</p><disp-quote content-type="editor-comment"><p>5. During the variant filtering step, only de novo nonsynonymous coding and splice region variants were kept. The authors mentioned analyzing splice-site DNVs specifically using the Alamut software, which provides a few prediction tools. The authors may consider using other algorithms, such as SpliceAI, which appears to be highly reliable for prioritizing variants. (PMID: 30661751)</p></disp-quote><p>We thank the reviewer for this useful comment. We have added the SpliceAI scores to Table 3 and now mention its use in the Materials and methods section (page 6 line 9).</p><disp-quote content-type="editor-comment"><p>6. Table 4, I question the pathogenicity predictions regarding the KMT2C frameshift variant. The CADD score is only 14.7, and according to UCSC as well as polyphen-2, this residue is not conserved between species (Serine to Histidine between human and mouse).</p></disp-quote><p>Since variant-specific metrics are not useful to assess the functional impact of predicted loss-offunction variants, we have removed these metrics from Table 4 for the predicted loss-of-function variants. In contrast, gene-specific metrics are much more informative. As stated in Table 4, the LOEUF score of KMT2C is 0.12, which indicates a strong constraint against loss-of-function mutations.</p><disp-quote content-type="editor-comment"><p>7. Page 17, line 9: although most proteasome-associate diseases are recessively inherited, there are examples of a dominantly inherited mutation in PSMB9. (PMID 33727065 and 34819510)</p></disp-quote><p>We thank the reviewer and have adapted the suggestion by adding a section on the dominantly inherited <italic>PSMB9</italic> mutation: “PRAAS is … in mice.” (page 22 lines 10-16).</p><disp-quote content-type="editor-comment"><p>8. Page 21, line 13: are there different isoforms of FBXW11? Cell-specific expression of various isoforms can potentially explain how LoF variants in this gene can be associated with a neurodevelopmental phenotype in some patients and an immunological disease in other patients. (e.g., CDC42-associated diseases, UBA1-associated diseases).</p></disp-quote><p>FBXW11 indeed has multiple isoforms, as can be observed in Figure 2 —figure supplement 1. It has three high quality protein-coding transcripts that produce the most abundant isoforms, and all are affected by the splice-acceptor DNV. The cell-type or tissue-specific expression does not seem to differ greatly among the isoforms (GTEx Portal, v8), but it could be that the specific functions of the SCF complex in which FBXW11 participates are cell-type specific. We have now also stated this in the discussion: “However, the exact mutational mechanism … most abundant isoforms.” (page 21 lines 19-24).</p><disp-quote content-type="editor-comment"><p>9. Page 24, line 10: there is a typo in this sentence &quot; soma&quot;, it should be &quot;somatic&quot;.</p></disp-quote><p>We have not corrected this as we actually meant to express the noun, which is ‘soma’.</p><disp-quote content-type="editor-comment"><p>10. The authors may discuss other possible explanations for the lower-than-expected diagnostic rate in this cohort and similar cohorts of patients with suspected monogenic immunological diseases. Possible explanations are uneven coverage of coding regions (especially exon 1 tends to be poorly covered), the fact that only protein-coding regions are captured by WES, somatic mutations in the early post-zygotic stage (PMID: 32750333), or some other explanations. Reduced penetrance is another factor, which is not pertinent to this study, as this study focuses on the identification of de novo variants. Expectedly, the diagnostic rate will be higher when working with patients with recessively inherited PID and from founder populations and this may explain the diagnostic rate of 75% in some studies.</p></disp-quote><p>We would like to thank Reviewer 2 for these suggestions. We have integrated some of these ideas into the Discussion section (page 26 lines 12-15).</p><disp-quote content-type="editor-comment"><p>11. Some sentences are repetitive in the Result section and Discussion e.g., the discussion on the PSMB10, RELA, and NLRP3 variants.</p></disp-quote><p>We have addressed this by reducing the respective sections in the Results section and by re-writing parts of the paragraphs in the Discussion section. Please refer to the revised manuscript.</p><p>References</p><p>1. Olfson, E., et al., Whole-exome DNA sequencing in childhood anxiety disorders identifies rare de novo damaging coding variants. Depress Anxiety, 2022. 39(6): p. 474-484.</p><p>2. Pedersen, B.S., et al., Effective variant filtering and expected candidate variant yield in studies of rare human disease. NPJ Genom Med, 2021. 6(1): p. 60.</p><p>3. Oud, M.S., et al., <italic>A</italic> de novo <italic>paradigm for male infertility.</italic> Nat Commun, 2022. 13(1): p. 154.</p><p>4. Kaplanis, J., et al., Evidence for 28 genetic disorders discovered by combining healthcare and research data. Nature, 2020. 586(7831): p. 757-762.</p><p>5. Dong, W., et al., Exome Sequencing Implicates Impaired GABA Signaling and Neuronal Ion Transport in Trigeminal Neuralgia. iScience, 2020. 23(10): p. 101552.</p><p>6. Homsy, J., et al., de novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. Science, 2015. 350(6265): p. 1262-6.</p><p>7. Beck, T.F., et al., Systematic Evaluation of Sanger Validation of Next-Generation Sequencing Variants. Clin Chem, 2016. 62(4): p. 647-54.</p><p>8. Koboldt, D.C., Best practices for variant calling in clinical sequencing. Genome Med, 2020. 12(1): p. 91.</p><p>9. Wang, T., et al., Integrated gene analyses of de novo mutations from 46,612 trios with autism and developmental disorders. BioRxiv, 2021.</p><p>10. Hoischen, A., N. Krumm, and E.E. Eichler, Prioritization of neurodevelopmental disease genes by discovery of new mutations. Nat Neurosci, 2014. 17(6): p. 764-72.</p></body></sub-article></article>